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1.1. The prevalence and incidence of cervical cancer 
 
1.1.1. Worldwide 
 
Cervical cancer (CC) is a major health problem worldwide [1]. It is the third most frequent 
cancer in women. In 2008 about 530.000 new cases and about 275.000 deaths caused by 
cervical cancer have been reported [2,3]. It has been estimated that about 1.4 million women 
worldwide have cervical cancer and that two to five more have precancerous lesions [2,4]. The 
numbers differ enormously between countries (see Fig. 1.1 and 1.2); about 80 % of new cases 
occur in low-income countries [5]. The risk of women to get cervical cancer in their life 
amounts to 4 % in developing countries; it is lower than 1 % in developed countries [6]. In the 
developed countries the mortality of cancer in general, and of cervical cancer in particular, has 
constantly decreased over the last fifty years. The positive evolution for cervical cancer has 
been caused by intensive screening programs based on early detection by cytological 
examination of cervical smears.  
 
1.1.2. The European Union 
 
In the European Union cancer is responsible for 20 % of deaths; it is second cause of death 
after cardiovascular diseases. Cervical cancer figures at the 9th place in the list of cancer in 
women with 3.8 % of all cancers.  The International Agency for Research on Cancer (IARC) 
estimated that in 2004, about 30.400 new cases and 16.300 deaths (on the 12th place) caused by 
cervical cancer would occur in the 27 countries of the European Union [5]. In 2008, 60.000 
new cases have been reported, with 30.000 deaths. The numbers on incidence and mortality are 
not equally distributed (see http://www.euro.who.int/fr; see Fig.1.3). The number of fatal 
outcome is decreasing from 6.35/100.000 women in 1980 to 4.47/100.000 women in 2009.  
 
1.1.3.  Africa 
 
Cervical cancer is the most frequent cancer of African women. It takes the second place on the 
list of death caused by cancer in developing countries in contrast to the 8th-9th place in 
developed countries.  The mortality in relation to the incidence is especially high in Africa (see  
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Figure 1.1: Geographical distribution of the incidence (ASIR, age-standardised incidence rate) of 
cervical cancer, estimated for 2008 (per 100.000 women-years). The numbers within brackets in the 
legend refers to the number of countries included in the each class of ASIR. 
 
 
 
 
Figure 1.2: Geographical distribution of the mortality (ASMR, age-standardised mortality rate) caused 
by cervical cancer, estimated for 2008 (per 100.000 women-years). The number in brackets refers to the 
number of countries included in each class of ASMR.  
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Fig.1.5). The age-standardized levels of the incidence and mortality are 18/100.000 women and 
10/100.000 respectively in the developing countries; in the developed countries the numbers 
are respectively 9 and 3/100.000 women.  In Africa about 70.000 new cases of invasive 
cervical cancer are diagnosed each year; it causes about one quarter of all cancer deaths [7,8] 
(Parkin et al. 2008a, Parkin et al. 2008b). The incidence is above 30/100.000 women and 
markedly differs between the African countries: 42.7 in East Africa, 38.2 in Southern Africa, 
29.3 in Central and Western Africa [9]. In Northern Africa the incidence is markedly lower 
[8,10].  
A marked increase in the number of new cases and deaths caused by cancer are expected in the 
next year already because of demographical reasons [2,11]. 
 
Organized screening programs for the early detection of cervical cancer and preventive 
treatment of precancerous lesions are nearly completely absent in most African countries. This 
is one of the main factors explaining the high mortality in comparison to the developed 
countries.   
.  
 
Figure 1.3: Age-standardized level of the incidence and mortality caused by cervical cancer (per 
100.000 women-years) in the 27 countries of the European Union. Estimates are based on data of 2004 
[12]. 
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The high mortality rates have an important economical impact on African families that highly 
depend on the daily activities of women. This becomes even more important as cervical cancer 
occurs in the poorest part of the population 
 
 
Figure 1.4: The incidence and mortality 
caused by cancer in Africa ; projections 
until 2020 and 2030 [11]. 
 
 
 
 
 
 
 
 
Because of the high impact of infectious diseases on mortality and disability in Africa, health 
care was traditionally focused on infection control.  It is rather recently that chronic non-
communicable diseases, as malignant neoplasms, are receiving growing interest. Because 
cervical cancer is associated with human papillomavirus infection and is the most frequent 
cancer in African women, governments of low- and middle-income countries are increasingly 
interested to support initiatives for screening and preventive treatment of cervical cancer.   
The knowledge of data about the incidence and mortality of cervical cancer are mostly limited 
to the urban population; practically nothing is known about the rural population, and this is a 
general observation for all Sub-Saharan countries [8,13,14]. 
1.1.4. The Democratic Republic of the Congo (DRC) 
Because of the absence of a national registration system little information is available on the 
incidence and mortality of cervical cancer in the RDC. Numbers are mostly obtained by 
extrapolation from other countries. The age-standardized level of mortality is estimated to be 
around 15-20 per 100.000 women-years (see Fig. 1.5 for comparison). According to the 
estimates of the WHO the estimated deaths caused by cervical cancer in the DRC in 2012 was 
4.700 (population of women: 33.067.000).  A few pilote projects on screening and HPV typing 
in the DRC have been published [15-20]. 
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1.2.  Cyto-histological aspects of the uterine cervix 
1.2.1.  The anatomy of the cervix 
The cervix of the uterus is about 2.5 – 3  cm long and has a diameter of 2.5 – 3 cm in the adult 
nulliparous. It connects the uterus to the vagina. It projects about 2 centimeters into the upper 
 
 
 
Figure 1.5: The incidence and the mortality caused by cervical cancer in different African countries. 
Data of 2008  [2]. 
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vaginal cavity; this part is the exo- or ectocervix. The ectocervix’s orifice into the vagina is 
called the external os. The size and shape of the external os and the ectocervix varies with age, 
hormonal state and vaginal births. The external os is circular and punctiform in a nulliparous, 
and rather slit-like in multiparous women. The channel that connects the uterus to the vagina is 
the endocervical channel; it is flattened anterior to posterior and measures 8 mm in its greatest 
diameter. It contains longitudinal ridges. The internal os is the opening of the channel facing 
the uterus. The endocervical canal transports sperm into the uterine cavity and allows the 
escape of blood during menstruation. The endocervical channel is covered with a secretory 
epithelium. These cells supply mucus to the endocervical channel and to the vagina.  
The innervation of the cervix is predominantly limited to the endocervix. The sparse 
distribution of pain fibres in the exocervix is responsible for the relative insensitivity of the 
exocervix. The cervical nerves are derived from the superior, middle and inferior hypogastric 
plexuses. 
 
1.2.2.  Histology 
 
The cervix is composed of a mixture of fibrous, muscular and elastic tissue. The ectocervix is 
covered with a non-keratinized squamous epithelium, the endocervix with a columnar or 
cylindrical epithelium (for details see [21]). Fibrous tissue is the predominant component. 
Smooth muscle is located mainly at the endocervix. The exocervix is nearly devoided of 
smooth muscle.  
 
The area adjacent to the junction between endo- and ectocervix is known as the 
squamocolumnar junction. The location of this junction shifts during a woman’s lifetime. The 
zone involved in this shift is the transformation zone, and the process is called metaplasia. It is 
mainly the acid pH environment of the vagina that determines which type of epithelium will be 
present. When the columnar epithelium is exposed to the acid environment of the vagina the 
epithelium changes to a metaplastic squamous epithelium.  The changes between different 
types of epithelia is a physiological process. Nevertheless, it is at the transformation zone that 
precancerous and cancerous cells originate after infection with the human papillomavirus 
(HPV).  
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Figure 1.6      Figure 1.7  
 
 
Figure 1.6: Histology of the uterine cervix at the junction between squamous and columnar epithelium. 
The mature squamous  epithelium shows a gradually ascending maturation from basal cells on the basal 
lamina to flat superficial cells at the top. At the stromal-epithelial junction finger-like protrusions 
penetrate the lower portion of the epithelium. The columnar epithelium is heavily folded. S-C J: 
squamous-columnar junction; B cells: basal cells; S cells: superficial cells; E glands: endocervical 
glands. 
Figure 1.7: Zone of severe dysplasia (CIN3) with high expression of Ki-67 (black dots) in the squamous 
layer indicating a high proliferative activity of the marked cells.  
 
 
Figure 1.8: Illustration of the shift of the squamocolumnar junction during the woman’s lifetime. Left: 
the position of the juntion at birth. The junction is at the external os. The exocervix is completely 
covered with native squamous epithelium. Middle: cervical ectopy; the squamocolumnar junction is 
now located at the exocervix below the external os. Right: some areas of the columnar cells are  
covered with squamous epithelium. The area in red is the transformation zone. Adapted from [21]. 
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1.2.2.1. The ectocervix: malpighian epithelium 
 
This epithelium consists of a malpighian coating composed by about thirty layers of regularly 
stratified cells with a clear cytoplasm. This epithelium is subdivised in three layers: 
- the basal and parabasal layer (germ cell layer; stratum germinativum): this layer is 
reponsible for the regeneration of cells. The basal cells have a diameter of about 10 µm 
with an ovular nucleus oriented perpendicularly to the underlying basal lamina; they 
contain a small amount of cytoplasm. The parabasal cells are slighty larger than the 
basal ones and have more cytoplasm. Parabasal cells form a layer that is one-to-two 
cells thick.  Different receptors mediating growth and differentiation are located in the 
membrane and in the cytoplasm of these cells, e.g. epidermal growth factor receptor 
(EGFR), human epidermal growth factor Receptor 2/neuroglioblastoma line (Her2/neu), 
oestrogen and progesteron receptors. Basal cells function as stem cells, while the 
parabasal cells are the most activily replicating layer. 
- Proliferation markers as the nuclear proteins Ki-67 (protein encoded by the MKI67 gene 
and identified by the monoclonal antibody Ki-67), PCNA (proliferating cell nuclear 
antigen) and cyclines are most densily present in the basal cells Human epidermal 
growth factor Receptor 2” (Her2/neu), oestrogen and progesteron receptors. Basal cells 
function as stem cells, while the parabasal cells are the most activily replicating layer. 
Proliferation markers as the nuclear proteins Ki-67, PCNA (proliferating cell nuclear 
antigen) and cyclines are most densily present in the basal cells. 
- the intermediate layer: consists of cells that differentiate from the preceding layer and 
contains an increasing amount of cytoplasm without obvious change of the nucleus. 
These cells stopped division. They are intensively stained with Periodic Acid Schiff 
(PAS) as they contain glycogen. 
- the superficial layer: contains the major part of mature cells. It consists of flat cells with 
a diameter of about 50 m, with a pycnotic nucleus and an eosinophil cytoplasm rich in 
microfilaments. 
In postmenopausal women the squamous epithelium is atrophic with little intracytoplasmic 
glycogen. Estrogens stimulate proliferation, maturation and desquamation. Progesterone 
inhibits maturation at the upper intermediate layer. The glycogen content decreases when 
maturation is inhibited.   
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1.2.2.2.  The endocervix: columnar epithelium 
The endocervical epithelium consists of one single layer of cylindrical cells with a basal 
nucleus and a granular cytoplasm. They contain mucus. These cells have a high affinity for 
Alcian blue.  Ciliar nonsecreting cells are present mainly in the upper part of the endocervical 
channel close to the junction with the uterine cavity. Also argentafine and argyrophile 
neuroendocrine cells can be discovered in this layer. Mitoses occur rather rarely. The 
epithelium has complex foldings that resemble glands. The invaginations augment the surface 
of mucus-producing cells. The endocervical mucus protects the uterus against bacterial 
invasion.  It is also a lubricator of the vagina during sexual intercourse. The composition and 
physical characteristics of this mucus varies during the menstrual cycle. When the 
progesterone/oestrogen ratio increases the mucus it is sticky and acid, and contains an 
increasing amount of leucocytes; it functions now as a barrier or a plug. In the ovulatory period 
under influcence of estrogens the mucus facilitates the transport of spermatozoa into the uterus. 
In this case the mucus is less acidic, has a higher water content and has a higher concentration 
of electrolytes. Also electrolytes, trace elements, organic molecules and enzymes change in 
function of the hormonal status. 
1.2.2.3.  Langerhans cells and lymphoid-derived cells 
Various subsets of lymphocytes as the helper cells CD4 (cluster of differentiation 4), cytotoxic 
cells CD8 and dendritic macrophages are present in the epithelium of the endo-and exocervix 
and in the subepithelial stroma. They are responsible for antigen recognition and the early stage 
of immune response.   
1.2.2.4.  The squamocolumnar junction and the transformation zone 
 
At the squamocolumnar junction the squamous epithelium of the ectocervix joins the columnar 
epithelium of the endocervical channel. Its location in relation to the external os changes with a 
variety of factors over a woman’s lifetime. It depends upon factors as age, hormonal status, 
birth trauma, oral contraceptives and pregnancy. The process that underlies the migration of the 
junction is called metaplasia. During metaplasia one fully differentiated type of epithelium 
changes into another. Local factors in contact with the epithelium as the acidity of cervical and 
vaginal secretions determines the type of epithelium. It is a reversible process and transformed 
epithelium may change to its original form when the stimulus that caused the metaplastic 
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process is gone. The transformation zone is the name given to the area of the cervix where 
endocervical columnar epithelium has been transformed to squamous epithelium and vice 
versa.  
At birth the squamocolumnar junction is at, or just above the external orifice with the squamous 
epithelium outside and the endocervical columnar epithelium on the inside; this is the so-called 
original squamocolumnar junction. Starting at puberty and throughout reproductive life, the 
junction moves outwardly and is situated at variable distances below the external os. The 
columnar zone migrates towards the ectocervix creating an endocervical ectropion, visible as a 
reddish-looking ectocervix. The red endocervical tissue resembles an eroded tissue and is so 
often misnamed as ‘cervical erosion’.  Ectropion becomes more pronounced during pregnancy. 
Over time, the cervical ectopy consisting of a columnar epithelium is remodeled and replaced 
by metaplastic squamous epithelium covering the areas of ectopy; now a new, functional 
squamocolumnar junction is formed. The new junction is more internal to the original junction 
on the cervix. The area between the original and new junction is the transformation zone.  
After the menopause the process of ectropion reverses and the new transformation zone lies at 
or above the external orifice, often out of direct visual observation from the vagina.  
 
Metaplasia in the cervix starts with the accumulation of reserve cells in the endocervical 
epithelium, forming a mulilayer of undifferentiated cells at the start. This multilayer is often 
covered with a superficial layer of mucus-secreting columnar cells. Finally, the undifferentiated 
cells differentiate into a mature squamous epithelium which is nearly indistinguishable from the 
original squamous epithelium. The metaplastic process starts initially in the crypts and at the 
tips and finally ends with a complete squamous epithelium. Another possibility than the reserve 
cell hypothesis (squamous metaplasia) is direct ingrowth from the squamous epithelium border 
into the columnar epithelium (squamous epithelialization).  
The concept of the transformation zone is very important for understanding the pathogenesis of 
squamous cell carcinoma of the uterine cervix: virtually all cancers start at the new 
squamocolumnar junction.  
 
1.2.3.  Immunity of the cervix 
 
The local immunity of the mucosa constitutes an important mechanism against pathogenic 
bacteria and viruses. That is the reason why a HPV infection strongly depends on the host’s 
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immune status. Women who fail clearance are at high risk for developing cervical carcinoma 
[22].  
 
Both, innate and adaptive immunity play a key role in HPV clearance and persistence. On  
average, genital HPV infections persist for 12-18 month prior to being cleared by the immune 
system [23). Immune cells as lymphocytes, plasmocytes, dendritic cells and Langerhans cells 
are present in the endo- and ectocervix and in the subepithelial stroma, and intervene in the 
immune response [24,25,26]. In HPV-infected keratinocytes, the innate immunity is stimulated 
to eliminate the invading HPV pathogen through sensitization to HPV-related proteins by 
Langerhans cells and dendritic cells [27]. The antigen-presenting properties of Langerhans cells 
are important for the protection against HPV.  Langerhans cells have the capacity to destruct 
epithelial cells presenting the proteins E6 and E7 of HPV 16. Therefore, a decrease in the 
number of Langerhans cells may contribute to a weak local immune response [29]. 
Because of the long delay between infection and clearance, and the small percentage of women 
who fail to clear HPV infection, the virus seems to possess various mechanisms to shortcircuit 
the host immune response and to create immune tolerance. The mechanisms involved depend 
on the amount and type of immunogenic proteins produced by the virus and their detection by 
the immune system, and on the interference with stimulatory signals on the host cells.  
 
The immunogenicity of HPV proteins is weakened by the low level of viral protein production 
and by a mechanism known as molecular mimicry [30]. When the protein production is low the 
exposure to the host immune system is low too. Because the virus does not lyse the infected 
cells the presentation of antigens and pro-inflammatory signals to immuneresponsive cells is 
limited. The virus is efficiently hidden in the keratinocytes. The production of immunogenic 
capsid proteins is limited to the superficial differentiated layer, which is shed off from the 
epithelium, without making contact with immunoresponsive cells in the stroma.  Molecular 
mimicry is the process in which proteins imitate molecules of the host so that the host system 
cannot discriminate between self and non-self. If viral antigens are liberated, even in small 
amounts, HPV may escape antigen-specific immune recognition by this mechanism. Another 
mechanism used by the virus is down-regulation of molecules of the major histocompatibility 
complex (MHC) [31-33]. Normally, infected cells may be destroyed after presentation of viral 
antigens on the surface of infected cells by MHC molecules. Downregulation of MHC protects 
the cell from immune attack. HPV proteins may interfere with reactions of the innate immune 
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system, e.g. with the production of interferon alpha and beta secreted by virally infected cells. 
These cytokines are involved in growth inhibition and they have anti-viral effects [34,35]. The 
E6 and E7 proteins may interact with interferon-mediated signaling. In addition, interferon-
inducible genes are downregulated. In summary, mechanisms have evolved in HPV infection to 
delay a quick response of immune cells in the cervical mucosa by limiting immunogenic 
signals and interfering with anti-viral effects of host cells [32,36].  
But fortunately, despite the escaping mechanism used by HPV, the majority of women infected 
by the virus are able to clear the virus.  
 
The importance of microbiota in the female, as well as in the gastrointestinal tract, is a rapidly 
growing field of interest. Epidemiological studies have shown that the normal vaginal 
microbiota plays a protective role against acquisition of HIV and other sexually transmitted 
diseases, including HPV.  A long series of diseases has been associated with microbial 
imbalance (bacterial dysbiosis). In particular, bacterial vaginosis is characterized by an 
overgrowth of anaerobic bacteria and a loss of indigenous Lactobacillus species [37-39]. In 
both HIV and HPV infection the prevalence of Lactobacillus microbiota was significantly 
reduced [38]. Compared with HPV-negative women, the bacterial diversity of HPV-positive 
women has been found to be more complex with a different composition of the vaginal 
microbiota [37]. Therefore, bacterial vaginosis has been suggested as a co-factor in the 
development of cervical cancer [37,40-44]. Bacterial vaginosis is associated with an increased 
risk for prevalent and incident HPV as well as delayed clearance of the virus [42,45]. Because 
of this association microbiota has been considered as the explanation why high-risk HPV 
infection is cancerous in some women but not in others [37]. And differences in the 
composition  and function of the vaginal microbiota have been used to explain why the risk of 
HIV infection per heterosexual act is higher in low-income countries than in high-income 
countries [44] with the highest prevalence in black population [39,44].  
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1.2.4.  Pathology of the uterine cervix 
 
1.2.4.1.  Inflammation 
 
Inflammation of the uterine cervix may have a non-infectious and infectious origin.  
 
Non-infectious inflammation  
Non-infectious inflammaton may be produced by irritating substances resulting in an acute or 
chronic cervicitis. In case of an acute cervicitis the ulcerated cervix is edematous and liberates 
sometimes a purulent fluid of degenerated epithelial cells and mucus of the endocervical cells.  
A biopsy shows an edematous stroma with vascular congestion and many polynuclear 
neutrophiles. In case of a chronic cervicitis the stroma is rather fibrous and it harbours 
lymphocytes, plasmocytes and histiocytes. Tissue granulation may be present. Exceptionally, 
lymphoid follicles may be observed (follicular cervicitis). 
 
Infectious inflammation  
The origin of infectious inflammation may bacterial, viral, parasitic and mycotic. They may 
play a role in chronic pelvic pain, endometritis and exocervicitis and may be responsible for 
spontaneous abortion, premature childbirth, chorioamnionitis and contamination of the foetus. 
The most important infectious causes are (for details see [21]):  
-Candida albicans  
It may infect each part of the female pelvis. At the level of the cervix it induces an infection 
characterized by the presence of polymorph leucocytes and the filamentous extensions (hyphes) 
typical for mycotic infections on the superficial layers of the epithelium of the ectocervix. 
- Trichomonas vaginalis 
The presence of Trichomonas causes an intense inflammatory reaction and an acute cervicitis. 
It elicites phenomena of repair and exfoliation of the cervical epithelium. 
- Chlamydia trachomatis 
Is a typical infection of the young women under 25 years. It causes a diffuse exsudative 
inflammatory reaction.  
- Human Papilloma Virus (HPV) 
Different types of the HPV cause condylomatous lesions. Mainly the subtypes 6 and 11 are 
implicated.  
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The infection occurs through microerosion exposing the basal cell layers. After infection, a 
hyperplastic  reaction is induced evolving into a condylomatous lesion.  
Some types of HPV are the conditio sine qua non for developing cervical cancer. 
 
1.2.4.2.  (Pre)neoplasia of the cervix: the Bethesda classification 
 
Precancerous lesions, called dysplasia or, more recently, cervical intraepithelial neoplasia 
(CIN), are a neoplastic transformation of the squamous epithelium. CIN is characterized by 
architectorial and cytological anomalies (see [21]) for details). From the point of architecture, 
the epithelium looses its differentiation. It contains many young cells without glycogen, with 
mitotic, sometimes atypical structures. It is sometimes difficult to differentiate the low grade 
lesions (light dysplasia, CIN1) from non-specific modifications caused by inflammation. The 
high grade lesions (moderate or severe dysplasia, carcinoma in situ) resemble sometimes an 
immature metaplasia of the squamous epithelium. Therefore, to differentiate these different 
grades immunohistochemistry may be helpful, e.g. the detection of protein p16 which is heavily 
expressed in case of infection by oncogenic HPV inducing deregulation of cell cycle and Ki-67 
reflecting the proliferation activity in the dysplastic epithelium.  
 
One of the most characteristic cytological signs of an HPV infection is koilocytosis in the 
intermediate and superficial layer of the epithelium. Koilocytosis is a process by which 
squamous epithelial cells undergo a number of structural changes caused by infection of the 
cell by HPV. Most typical are the nuclear changes: the nucleus is enlarged to two to three times 
the normal size, the nuclear membrane contour is irregular, the staining pattern of the nucleus is 
darker, nearly apoptotic with a more clear halo around the nucleus, known as the perinuclear 
halo. The degree of koilocytosis helps in differentiating potentially precancerous lesions in 
ASC-US (atypical squamous cells – undetermined significance) and LSIL (low-grade 
squamous intraepithelial lesion). 
 
Cervical cytology screening has been responsible for a significant decrease in mortality form 
cervical cancer in all countries that have installed an organized screening program. The 
formation of a cervical cancer is a longstanding process in which the Human Papillomavirus 
(HPV) plays a crucial role. Before arriving at the stage of cancer, precursor lesions have 
evolved during a long period making preventive interventions applicable. The classification has 
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been regularly adapted starting with the generally applied Papanicolaou (Pap) classification 
arriving at the current Bethesda classification.  
 
Since the introduction of cytology by Papanicolaou (Pap smear test) in 1943 as the base for 
cervical cancer screening, Liquid Based Cytology has markedly improved Pap-testing since its 
introduction and breakthrough in 2000. With LBC cells are fixed in an alcohol-based fixative 
and concentrated via density gradients and centrifugation. LBC has the advantage of delivering 
a smear of better quality with less red blood cells, less mucus, and with a monolayer of well-
stained and well preserved cells. In addition, it offers the opportunity of automatic reading and 
it can be used for HPV detection. With LBC it was possible to differentiate precursor lesions in 
better detail. Because of the better quality of slides with LBC new precancerous categories 
were introduced since the original Pap method. The currently followed cytological 
classification of precancerous lesions is based on the Bethesda classification, introduced in 
1988, and adapted in 2001.  
The classification of Bethesda differentiates two groups of precancerous lesions: the squamous 
intraepithelial lesion of low grade (regrouping HPV infection and CIN1) and the high grade 
lesion corresponding to CIN2 and CIN3.  
The glandular lesions are less common than the squamous lesions. It is difficult to find 
abnormal glandular cells with cytology. About 90-95 % of cervical cancers are squamous 
cancers, 5-10% are adenocarcinoma’s. 
 
 
Histologically cervical abnormalities are classified as CIN with three CIN categories: mild 
dysplasia CIN1, moderate dysplasia CIN2 and severe dysplasia CIN3. The CIN grading is 
based on the percentage of epithelium replaced by abnormally appearing, immature, 
proliferating cells. If abnormal basal cells occupy half or two thirds of the epithelial layer, the 
lesion is classified as moderate dysplasia. The upper third illustrates mostly a koilocytosis. If 
the whole thickness of the epithelium is concerned, the dysplasia is classified as severe or a 
carcinoma in situ. In this case koilocytosis is mostly absent.  
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Table 1.1: Comparison between the cytological (conventional Pap and Bethesda) and the histological 
classification.  
 
Cytological classification 
(used for screening) 
Histological classification 
(used for diagnosis) 
Pap Bethesda system CIN WHO descriptive  
classifications 
Class I Normal Normal Normal 
Class II ASC-US ASC-H Atypia Atypia 
Class III LSIL CIN1 including  
Condyloma  
Koilocytosis 
Class III HSIL CIN2 Moderate dysplasia 
Class III HSIL CIN3 Severe dysplasia 
Class IV HSIL CIN3 Carcinoma in situ 
Class V Invasive carcinoma Invasive carcinoma Invasive carcinoma 
 
 
 
1.3.  The Human Papillomavirus (HPV) 
 
1.3.1.  Epidemiology 
 
HPV types have been classified according to the genomic sequence, tropism and the oncogenic 
potential. More than 100 papillomaviruses have been genetically classified according the 
sequence of the capsid protein L1 [46]. The different types of viruses are numbered and 
grouped in genera designated with greek characters (alpha-, beta-, gamma…).  Some of these 
viruses prefer the squamous epithelium of the skin, others of the mucosa.  Some are rather 
harmless, others may induce cancer. HPV DNA has been associated with ano-genital cancers 
(cervix, vulva, vagina, anus and penis) and has been identified in head and neck cancers (oral 
cavity, the oropharynx, and the larynx) [47,48] and in cancers of the skin and conjunctiva 
[49,50].  
 
A large amount of evidence has been accumulated in the last fifteen years making Human 
Papilomaviruses as the condition sine qua non to develop a cervical cancer [51-53].   
Human papillomaviruses (HPVs) are small double-stranded DNA viruses that infect cutaneous 
and mucosal epithelia and induce proliferative lesions. HPV preferentially infects epithelial 
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cells that undergo terminal differentiation and the virus uses the differentiating host cell to 
produce virions [54,55].  
HPV viruses are classified in low-risk (LR) and high-risk (HR) categories based on the 
potential for induction of malignant transformation. LR HPVs are rarely associated with 
malignancy [53,54]. LR HPV viruses cause benign warts: these are the HPV types 6 and 11. 
The LR HPV types 6 and 11 are responsible for more than 85% of the anogenital infections 
[56]. 
 
At least 12 to 15 types of HPV have been associated with cervical cancer and were classified as 
high-risk types [46,57-59]. The 15 most common types are: 16, 18, 31, 33, 35, 39, 45, 51, 52, 
56, 58, 59, 68, 73, 82. Since the early work on the categorization of alpha-HPV types into 
different risk categories the  classification has been regularly adapted (for details see [60]). 
Mainly the weak carcinogenic and rare HPV types have been frequently moved from one risk 
category to another. According to the recent review of the International Agency for Research 
on Cancer (IARC) the following 12 HPV types are considered to be carcinogenic: 16, 18, 31, 
33, 35, 39, 45, 51, 52, 56, 58, and 59, and belong to the high-risk HPV group [61,62]. HPV 
types 26, 53, 66, 67, 70, 73 and 82 have been classified als “possibly carcinogenic”, HPV68 as 
“probably carcinogenic” (see table 1.3). Ninety six percent of cervical cancers are attributable 
to one of the 13 most common HPV types (groups 1 and 2A; [60]). Including group 2B adds 
2.6%, to reach a total of 98.7% of all HPV-positive cervical cancers. HPV-16/18 is estimated to 
account for 70% of all cervical cancers worldwide, although the estimated HPV-16/18 fraction 
is slightly higher in hig-income (72-77%) than in low-income countries (65-72%) [51,57,58,63-
66]. Higher than average proportions of type 16 were found in northern Africa, of type 18 in 
south Asia, of type 45 in Sub-Saharan Africa and of 31 in Central/South America [59]. 
About 41-67% of HSIL, 16-32% of LSIL and 6-27% of ASC-US are also estimated to be HPV-
16/18 positive underlining the increasing relative frequency of HPV-16/18 with increasing 
lesion severity [58,63,64,67,68]. These data illustrate that HPV-16 and HPV-18 have a 
biological advantage for transmission, persistency and transformation [47,67-71].  
HPV-18 is responsible for 20% of cervical adenocarcinomas [70].  
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Table 1.3: Classification of human HPV types according to tropism and oncogenic risk [46,57,58,60-
62]. 
 
HPVs of the skin 1, 4, 5, 7, 8, 9, 12, 14, 15, 19, 20, 21, 25, 41, 47, 49, 55, 63 
HPVs of the mucosa, low risk 2, 3, 6, 7, 10, 11, 13, 32, 40, 42, 43, 44, 57 
HPVs of the mucosa, high risk, 
carcinogenic (IARC group 1) 
16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 
 
HPV “probably carcinogenic” (group 2A) 68 
HPVs “possibly carcinogenic” (group 2B) 26, 53, 66, 67, 70, 73, 82 
  
A meta-analysis on the prevalence of HPV DNA in women with normal cytology indicated that 
10.4% of women were infected with HPV [66]. Corresponding estimates by region were Africa 
22.1%, Central America and Mexico 20.4%, northern America 11.3%, Europe 8.1% and Asia 
8%. In all world regions, HPV prevalence was highest in women younger than 35 years of age, 
decreasing in women of older age. In Africa, the Americas, and Europe, a second peak of HPV 
prevalence was observed in women aged 45 years or older. New sex partnerships and HPV 
reactivation have been proposed as explanations for the bimodal age-specific prevalence 
observed in some populations. HPV reactivation at older age may be explained by loss of 
immunologic control of latent HPV infection.  
On the basis of these estimates around 291 million women are carriers of HPV DNA, of which 
32% are infected with HPV 16 or HPV 18, or both. The HPV types most commonly detected 
are similar to those most commonly described in pre-neoplastic and cancer cases, although the 
relative contribution of HPV 16 and HPV 18 is substantially lower in cytologically normal 
women. In CIN1/LSIL all types of HPV can be present (LR HPV as well as HR HPV). In the 
large majority of CIN3 exclusively HR HPV are present. In general if only LR-HPV is present 
in LSIL, the lesion is not progressive.   
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Table 1.2: According to the Bethesda 2001 classification cervical abnormalities are cytologically  
classified as [72].  
 
 
Adequacy of the specimen 
  Satisfactory for evaluation 
  Unsatisfactory for evaluation 
Categories 
  Negative for intraepithelial lesion of malignancy (NILM) 
  Squamous cell abnormalities 
    Atypical squamous cells (ASC) 
          Atypical squamous cells-undetermined significance (ASC- US) 
          Atypical squamous cells -  cannot exclude HSIL (ASC- H) 
   Low-grade squamous intraepithelial lesion (LSIL) including cellular changes of HPV (koilocytosis  
          and condylomatous atypia) and mild dysplasia/cervical intraepithelial neoplasia (CIN1)  
   High-grade squamous intraepithelial lesion (HSIL) including moderate and severe dysplasia,  
         carcinoma in situ (CIS), /CIN2 and CIN3 
  Squamous cell carcinoma 
Glandular cell abnormalities 
  Atypical glandular cells (AGC) 
      Atypical glandular cells (unqualified) 
      Atypical endocervical cells (unqualified) 
      Atypical endometrial cells (unqualified) 
      Atypical glandular cells, favor neoplastic 
      Atypical endocervical cells, favor neoplastic 
  Adenocarcinoma in situ (AIS) 
  Endocervical carcinoma 
  Endometrial carcinoma 
  Adenocarcinoma, nonspecific 
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The first infection mostly occurs at young age [132]. The risk to be infected during life-time is 
80-85 %.  The prevalence of ano-genital infection decreases with age [73]: the highest 
prevalence of HR HPV in a large study on women who received routine cervical screening was 
found in the age 14 to 19 years (35%) and lowest among women age 50 to 65 years (6%). 
About all LR HPVs and the majority of HR HPVs are spontaneously eliminated.  In the group 
with persisting HPV infection lesions may evolve to intra-epithelial neoplasia. The higher the 
grade of lesion the more likely it is to persist. In CIN1 57% of lesions spontaneously regress in 
the absence of any therapy, in CIN2 43% and in CIN3 32% [74]. About the same estimates for 
regression to normal were reported for LSIL  (47%) and HSIL (35%) [75]. Even higher 
percentages of regression were reported for LSIL that increased with the duration of follow-up: 
61% had regressed after 12  months and by 36 months of follow-up 91% had regressed [76,77]. 
At 10 years, 88% of mild untreated dysplasia and 83% of moderate untreated dysplasia had 
regressed [78].  
 
Table 1.4: Evolution of precancerous lesions [21]   
 
Lesion regression persistence progression to CIN3 Progression to squamous carcinoma 
CIN1 60% 30% 10% 1% 
CIN2 40% 40% 20% 5% 
CIN3 33%   12-22% 
 
What these studies show is that the vast majority of LSIL and even HSIL spontaneously regress 
in the absence of treatment, and that it generally takes many years for a HSIL to progress to an 
invasive carcinoma.  
 
Regression is also HPV type dependent: CIN2 caused by HPV 16 is less likely to regress than 
CIN2 caused by other HR HPV genotypes [79]. Of the incident infection in a young student 
population, HPV 16 was the most persistent (18.3 months), followed by HPV 31 and HPV 53 
[80]. Twenty-six percentage of CIN2/CIN3 lesions associated with HPV 16 underwent 
regression. CIN1 lesions disappeared in 60% of infected women [36,81,82]. The transition 
from a transient to a persistent infection is caused by a lack of an efficient local immune 
response and has been associated with the integration of viral DNA in the genome of the host.  
Integration results in an increased production of the viral oncogenes E6 and E7. One of the 
main effects is that cells loose the capacity for repairing damaged DNA and are incapable to 
control growth. The final result is cancer.  
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There are four major steps in cervical cancer development: 
1/ infection of the metaplastic epithelium in the transformation zone with a HR HPV 
2/ persistence of the infection because of the inability of the immune system to clear the virus 
3/ integration of HPV DNA into the host genome and progression to cervical precancerous 
lesions 
4/ invasion through the basement membrane 
 
Invasive cancer arises over many years, even decades, with a peak at risk at about 35 and 55 
years.  
 
1.3.2.  The genomic structure of HPV and viral proteins 
 
The HPV is a DNA virus with a double-stranded circular genome of approximately 8000 base 
pairs with a diameter of about 45-55 nm. A complete virus particle, called a virion, consists of 
nucleic acid surrounded by a protective coat of protein called the capsid. The capsid is a protein 
shell composed of protein subunits, the capsomers which are composed of two types of ‘late’ 
proteins, the L1 and L2 proteins. The virus uses multiple copies of these proteins to get an 
icosahedral structure. The protein shell consists of 72 capsomeres.  A lipid envelope derived 
from the host cell membrane is missing in HPV.  L1 is the most important protein of the viral 
coat and represents 80% of the viral proteins. L1 is important because it is used as viral antigen 
in the HPV vaccines [59]. 
 
In addition to these late proteins the genome codes for at least six other proteins, the ‘early’ 
proteins.  
The division in early and late proteins is related to the time of expression during the viral life 
cycle [55,65]. The early proteins are necessary for the replication of the viral DNA and for the 
assembly of newly produced virus particles within the infected cells [54]. 
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Figure 1.9: HPV-mediated progression to cervical cancer.  Basal cells in the cervical epithelium rest on 
the basement membrane, which is supported by the dermis. Human Papillomavirus (HPV) is thought to 
access the basal cells through micro-abrasions in the cervical epithelium. Following infection, the early 
HPV genes E1, E2, E4, E6 and E7 are expressed and the viral DNA replicates from episomal DNA 
(purple nuclei). In the upper layers of epithelium (the midzone and the superficial zone) the viral 
genome is replicated further, and the late genes L1 and L2, and E4 are expressed. L1 and L2 encapsidate 
the viral genomes to form progeny virions in the nucleus. The shed virus can then initiate a new 
infection. Low-grade intraepithelial lesions support productive viral replication. An unknown number of 
HR  HPV infections progress to high-grade cervical intraepithelial neoplasia (HGCIN). The progression 
of untreated lesions to microinvasive and invasive cancer is associated with the integration of the HPV 
genome into the host chromosomes (red nuclei), with associated loss or disruption of E2, and 
subsequent upregulation of E6 and E7 oncogene expression. LCR, long control region (from [83]). 
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Figure 1.10: Genomic structure of HPV DNA [54]. (L1 
and L2 are the « late » genes that code for the capsid 
proteins that are necessary to form the virion in the host 
nucleus. E1, E2, E4, E5, E6 et E7 are the « early genes » 
that intervene in the replication of the viral DNA and the 
multiplication of epithelal cells. The upstream regulatory 
region (URR) proximal to the p97 promotor is involved in 
the regulation of early gene expression. Early in infection, 
transcipts primarily encoding E6, E7, E1 and E2 are 
transcribed from the HPV early promotor, P97. During 
the productive phase  of the viral life cycle, the late 
differentiation-dependent promotor  P742, is activated 
resulting in high level transcription of E1, E2, E4 , E5 and 
the capsid proteins L1 and L2 [84,85]. 
 
 
The non-coding URR region contains binding sites for a variety of cellular transcriptional 
factors that regulate HPV transcription. HPV early transcription is activated by a keratinocyte-
specific enhancer region that binds only cellular factors and contributes to viral tropism [86].  
Two small zinc-binding viral proteins, E6 and E7, alter cell cycle control and are the main 
arbitrators of HPV-induced oncogenesis. Recent data suggest that E6 and E7 also play a major 
role in the inhibition of the host cell innate immune response to HPV. The E1 and E2 proteins, 
in combination with various cellular factors, mediate viral replication. In addition, E2 has been 
implicated in both viral and cellular transcriptional control.  
 
1.3.3.  The life cycle of the virus 
 
The HPV life cycle is directly linked to epithelial cell differentiation. Normal epithelia grow as 
stratified layers with  only cells in the basal layer actively dividing. After division of basal 
cells, only one of the daughter cells moves upward and begins to differentiate while the other 
remain in the basal layer.  When daughter cells leave the basal layer and move upwards the 
cells stop the normal cell cycle and initiate differentiation. At that moment they start 
synthesizing high-molecular-weight keratins. Keratins accumulate within the cell; the nuclear 
envelope breaks down and cells ends up as keratin-filled sacs. 
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Mode of infection 
The initial site of infection is thought to be either basal cells or primitive ‘basal-like’ cells of 
the immature squamous epithelium. Most likely the HPV virions infect the basal cells through 
micro-traumata in the epithelium, and enter the basal cells whereby the virion associates with 
putative receptors such as alpha integrins and laminins. Subsequently, the virion enters the cell 
through clathrin-mediated endocytosis; after uptake the virus is firstly trafficked to the 
endoplasmic reticulum via the caveolin-1 mediated transport [87].  
 
Prior to the infection of the basal cells, the virus must first bind via its L1 major capsid protein 
to the basement membrane that has been exposed after epithelial microtrauma. After binding of 
L1 a partial cleavage of L2 proteins occur. L2 proteolysis exposes a previously occluded 
surface of L1 that binds on as yet undetermined cell surface receptor on keratinocytes. Once 
internalized they are transported into endosomes and traficked as an L2-genome complex into 
the nucleus.  The infectious process takes about 12-24 h for initiation of transcription. The 
processes of binding to the basement membrane and subsequently to the cell surface are 
facilitated at the transformation zone [88]. It is at the transformation zone that stem cells cause 
reversible epithelial replacements that are assocated with chronic inflammation and deregulated 
expression of soluble and cell-membrane factors important for antiviral immune response. This 
metaplastic environment increases the susceptibility to human papillomavirus and human 
immunodeficiency virus infections.  
 
Effects of HPV infection 
Viral proteins are able to override the normal cell cycle exit that normally occurs in 
differentiated cells [89] so that cells continue to divide. Following migration into the nucleus 
the virus can exist in two different states: there is the vegetative state in which the virus resides 
in the basal cells but virions are not produced. In the vegetative state the early promotor is 
activated, and a small number of copies (50-100) of viral DNA is formed in the nucleus where 
it remains in the free circular form, called the episome. Replication of the episome is coupled 
now to the replication of the DNA of the cell. HPV episomes are replicated as basal cells 
divide. Following cell division, infected daughter cells migrate to the suprabasal layer. In 
contrast to normal cells that stop dividing once detached from the basal membrane, HPV-
infected cells keep the cell cycle activated. As HPV-infected cells differentiate, the late 
27 
 
promotor is activated and late gene products are produced. The  cycle enters now in the 
productive state.  
 
Table 1.5 summarizes the functions of the E and L proteins. From this table it is clear that the main 
proteins for inducing cancer are E6 and E7 because of their function in cell immortalization and 
interferences with tumor suppressor factors [52,54,90,91]. For E-proteins see [92,93,94]. 
 
 
E1 essential for viral replication/repression, and control of gene transcription 
E2 essential for viral replication/repression, and control of gene transcription [95]  
E3 no known product or function 
E4 interaction with cytoskeleton, viral assembly [92]  
E5 growth stimulation by interaction with growth factor receptors, down-regulation of surface  
             MHC class molecules [96,97]  
E6 cell immortalization, p53-degradation, telomerase activation, anti-apoptotic effect, induction  
             of genomic instability [54,98]   
E7 cell immortalization, interaction with pRb and pRb-associated pocket proteins,  
             transactivation of E2F-dependent promotors, induction of genomic instability [54,98] 
L1 major capsid protein 
L2 minor capsid protein, role in encapsidation of viral DNA, involved in nuclear transport of  
             viral DNA [99]  
 
In the productive state the virus multiplies independently of the epithelial cell cycle. Large 
numbers of viral DNA are synthetized, L1 and L2 genes are expressed, and complete virions 
are formed. The cell may contain now more than 1000 copies. Viral replication takes place 
predominantly in the intermediate and superficial cell layers. Differentiation-specific 
transcription factors produced by the epithelium stimulate the production of capsid proteins. In 
contrast to the latent state where no morphological changes can be detected, the presence of a 
large amount of virions in the cell in the productive state is accompanied by cytoplasmic 
vacuolization, koilocytosis, multinucleation and nuclear atypia [21] (Kurman et al.2011). The 
release of infectious virions is facilitated by disintegration of the epithelial cells as a result of 
their natural turnover [65]. Thus, HPV infection does not lyse epithelial cells. Release of viral 
particles is the result of desquamation of terminally differentiated squamous cells.  
In infected cells, low levels of viral DNA synthesis occur resulting in approximately 50 to 100 
copies per cell.  After this initial amplification for which E1 in combination with E2 is required, 
episomes are replicated at each cell division leaving the copy number/cell unchanged. 
Following cell division, infected daughter cells migrate towards the suprabasal layer. In 
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contrast to uninfected cells, which exit the cell cycle as soon as they detach from the basal 
membrane, HPV-infected cells keep the cell cycle activated. In terminally differentiated cells 
the number copies/cell seems to be lost, and DNA is amplifying again. As HPV infected cells 
differentiate, the late promotor is activated and late gene products are produced. This leads to 
high-level amplification of the viral genome to at least 1000 copies per cell. Following 
amplification viral genomes are packaged as chromatin into viral capsids composed of L1 and 
L2 and released as mature virions from the cell. Capsid proteins are synthetized in the 
cytoplasm and then transferred into the nucleus in order to package the viral chromatin. 
 
 
Figure 1.11: Schematic presentation of the differentiation program in normal epithelium (left) and viral 
activities in HPV-infected epithelium (right). Virions infect the dividing cells of the basal layer. Unlike 
normal epithelium where cells exit the cell cycle upon initiation of differentation, HPV-infected cells 
maintain cell division to allow genome amplification and virion production [54]. 
 
Although E4 is considered as an early gene product it is expressed rather late in large quantities 
in the superficial layer of the epithelium. It plays a role in the amplification of the HPV genome 
at the moment that also the late proteins are synthetized.  
Finally, the release of infectious virions is facilitated by disintegration of the epithelial cells as 
a result of their natural turnover [65].  
Because HPV replication partly depends on the host cell machinery, DNA sysnthesis must 
remain intact in the superficial layer. Therefore, the HPV-infected cells do not exit the cell 
cycle. And this is mainly due to the E6 and E7 proteins. These proteins inactivate the products 
of two important tumour suppressor genes, p53 and the retinoblastoma gene product, pRb. P53 
and pRb proteins are involved in regulation of cell cycle checkpoints.  
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E6 facilitate the rapid turnover of p53 resulting in a reduction of the steady state levels of p53, 
thereby reducing restriction on cellular DNA synthesis and allowing viral replication. In 
addtion, E6 can downregulate p53-mediated transcription. E6 may further play a role via 
suppression of other, less well known tumour suppressing mechanisms. Another important 
function of E6 is the activation of telomerase in infected cells inhibiting shortening of 
telomeres and thereby cellular senescence [100]. E6 acts as a repressor of apoptosis and 
mediates survival of severely damaged cells. The side-effect of extending the life of epithelial 
cells for production of viral progeny is the HPV-induced carcinogenesis.  
 
One of the main functions of the E7 oncoprotein is the binding and degradation of the Rb 
family of proteins. The Rb proteins are major regulators of the cell cycle.  The degradation of 
Rb is a characteristic primarily of HR E7 proteins, suggesting that it may contribute to cervical 
carcinogenesis. E7 increase cyclins in epithelial cells that are known to phosphorylate Rb, 
thereby alleviating Rb-associated transcriptional suppression. In addition, E7 interacts with 
other suppressor factors influencing progression into the S phase of the cell cycle.  
    
An important difference between HR and LR HPV types is integration in the host genome in 
high-grade lesions and cancer [101]. HR HPV types show a higher tendency to integrate into 
the host’s DNA, whereas LR types are preferentially maintained as extrachromosomal circular 
episomes [102]. In general, only a segment of the HR HPV viral genome becomes integrated 
containing the URR and part of the early region, including the E6 and E7 Open Reading 
Frames (ORFs). During the normal viral life cycle, E6 and E7 expression is regulated by the E2 
protein. In cancerous lesions the viral genome is frequently found to be integrated into the 
cellular DNA [103,104] One of the consequences of integration is that the E1 and/or E2 ORFs 
are disrupted within the downstream of the E6 and E7 genes in the viral genome. Since E1 and 
E2 are involved in viral DNA replication, integration leads to disruption of viral DNA 
replication. Normally E2 binds to the early promotor and decreases the expression of E6/E7. 
Disruption  eliminates E2-mediated transcriptional control of the early promotor resulting in 
increased production of the E6 and E7 proteins. Both, E6 and E7 can independently 
immortalize human epithelials cells but their complementary and synergistic functions 
markedly increase their oncogenic activity [54].   
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But evidence is growing that besides of expression of E6 and E7, additional host genetic 
alterations are required for cancer development [105-108]. 
 
1.3.4.  Risk factors associated with HPV-related carcinogenesis 
 
Although persistent infection by HPV is an essential element in the progression from 
precancerous lesions to cancer, it is not the only condition. The local immunity plays an 
important role as well as the type of virus and a series of environmental factors that mostly 
promote HPV infection [23,109-113]. Some viruses, as the HPV 16, have characteristics that 
increase persistency [63,64,114,115]. Various conditions have been described which are related 
to the inefficiency of the immune system to eliminate the virus. 
These conditions are 
1/ related to sexual activity: early sexual intercourse  especially less than 15 years of age, 
number of sexual partners [116], sexually transmitted diseases mainly HIV [117-120].  
2/ parity [32,121-124]. 
3/ use of hormonal contraceptives [124-127].  
4/ smoking [124,126,128-131]. 
5/ immunosuppression from any cause (HIV, transplantation…). 
 
Most of these risk factors are related to facilitation of HR HPV infection. Among women 
infected with HR-types of HPV, other factors such as smoking, immunosuppression and long-
term use of hormonal contraceptives can result in a doubling or tripling of risk for HSIL and 
invasive cancer [132]. 
 
 
1.4.  Methods of screening: cytology, HPV detection, visual inspection 
 
1.4.1.  Cytology 
 
The objective of cervical screening is preventing cervical cancer to develop and to diagnose the 
disease at an early precancerous stage. Cervical screening started in 1943 with the introduction 
of the Pap test or ‘smear’ test by Papanicolaou [133,134]. With the Pap test cervical cells are 
collected with a swab brush and smeared on a glass  slide.  The glass slide is eventually 
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immersed in alcohol-ether (1/1) for fixation and stained for Papanicolaou. Since the mid-1990s, 
Liquid Based Cytology (LBC) has been increasingly used. The sample is now placed in a vial 
containing an ethanol- or methanol-based fixative. The two techniques most frequently used are 
Sure-Path (TriPat Imaging) and Thin-Prep (Cytyc Corp). The main advantage of LBC is that 
the sample is still suitable for HPV-DNA and genetic analysis and immunochemistry. The 
method allows that cells are separated from red blood cells, cellular debris and mucus reducing 
the number of unsactisfatory smears. Another advantage is that LBC makes automated reading 
possible [135]. But contrasting with these obvious advantages the sensitivity and specificity are 
not significantly different from conventional cytology for detection of CIN2 or higher [136-
138]. The sensitivity and specificity found in these reports with conventional cytology were 
respectively 72% and 94%, versus 61-66% and 82-91% with LBC. Because of the cost of 
equipment of LBC the conventional cytology is still the only method applicated in most low-
income countries without large scale screening.  
 
1.4.2.  Histopathology 
 
The golden standard for the diagnosis of precancerous lesions and cancer remains histological 
examination of a biopsy. When combined with colposcopy biopsies can be taken from suspect 
parts of the cervix after application of acetic acid. In a biopsy the relation between the 
architecture of the epithelium and the stroma can be observed and biopsies allow 
immunohistochemistry to improve the diagnosis. For comparison between cytological and 
histological classification of precancerous lesions see Table 1.1. 
 
1.4.3.  Cytology and/or determination of  HPV DNA  
 
Because of shortcomings of cytology new molecular techniques have been developed for 
testing the presence of oncogenic types of HPV (see [139] for a historical review). The 
objectives of these efforts are to develop rapid, simple and accurate tests at a low cost (see also 
[48] (Bosch et al. 2013)). This evolution towards new techniques is extremely important in 
developing countries where 85% of cervical cancer deaths occur. The use of conventional 
cytology and the requirement of multiple visits have been impractical in developing countries 
[140]. Screening in these countries are hampered by the lack of adequately trained personal for 
cytological interpretation, the high cost, and the absence of an adequate laboratory 
infrastructure. In addition, the resistence of women for gynecological examination may 
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contribute to the low coverage of screening. Cervical screening has been responsible for a 
significant decrease in mortality from cervical cancer in all countries that have an organized 
screening program. But even in the presence of national programs the coverage of screening is 
below 80 %, ranging from 10% to 79% [141]. Therefore, the introduction of self-sampling may 
solve this problem of low coverage [142].  
 
The new tests are mainly based on the determination of HR HPV DNA in the samples. HPV 
DNA testing can be used either in primary screening for cervical cancer or/and in association 
with cytology. In the USA and Europe the guidelines applied during the past 10 years recognize 
the value of HPV testing in both primary cervical screening and in the management of 
abnormal cervical cytology [143]/ The idea is that HPV DNA determination may increase the 
efficacy of cytological screening certainly for ASC-US and LSIL lesions. Most studies indicate 
that HPV DNA testing is much more sensitive than Pap testing for identifying cervical cancer 
and precancerous lesions, but with a lower specificity [144].  
 
The four major agreed indications for HPV testing in current clinical practice are [139,145- 
149]:  
1/ triage of women with equivocal cytology results in the presence of ASCUS. 
2/ follow-up of women with abnormal screening cytology results, who are negative at initial 
colposcopy/biopsy. 
3/ prediction of the therapeutic outcome after treatment of CIN2+. 
4/ primary screening of women aged 30 years and older in combination with Pap smear to 
detect cervical cancer precursors 
 
In a meta-analysis of data published between 1992 and 2002 [150]  results of virologic and 
cytologic testing followed by colposcopically directed biopsy were compared in women with 
an index smear showing atypical cells of undetermined significance (ASC-US). The published 
literature in that period indicated that the Hybrid Capture 2 (HC2) assay has improved accuracy 
(higher sensitivity, similar specificity) than the repeat Pap smear using the threshold of ASCUS 
for an outcome of CIN2+ among women with equivocal cytologic results. In other reports a 
higher sensitivity (88%), but lower specificity was found compared to thin-layer cytology for 
identifying women with CIN3 or higher ([136]. In an extensive comparative study for cervical 
cancer in Sweden in women of age 32 to 38 years the addition of a HPV test to the Pap test 
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reduced the incidence of CIN2/CIN3 or cancer detected by subsequent screening examinations. 
In general, the sensitivity of HPV tests to triage ASC-US or LSIL to detect underlying CIN2 or 
worse is better than cytology for the identification of high-grade cervical lesions, but the 
specificity is rather low. The low specificity is caused by the fact that the viral test cannot 
separate transient from persistent infections, and only the persistent infection is associated with 
an increased risk of high-grade CIN and cancer [151]. The low specificity limits the general 
application of HPV DNA testing, that is mostly restricted therefore to women aged 30-35 years, 
with the cytology used to triage HR HPV-positive women [151]. HPV tests are not 
recommended in women younger than 30 years  because most HPV found at this age will not 
cause health problems.  Most young women will clear HPV over the next years without having 
precancerous lesions. HPV is less common in women older than 30 years. HPV-positive 
women with normal or borderline cytology could be managed by repeat testing after 12 
months. This approach could potentially improve detection rates of CIN2+ without increasing 
the colposcopy referral rate. The finding of a higher sensitivity combined with a lower 
specificity in comparison with cytology have been replicated in several other studies 
[138,145,152-157]. Several studies have shown that HR HPV-DNA-positive women are 
significantly more likely to develop high-grade CIN than women with a negative HR HPV 
DNA test [154,158] and that a negative HR HPV test offers a longer period of low risk of 
developing high-grade CIN than a negative cytology result [145,159]. HR HPV testing 
identifies more cancer precursors CIN2 or worse compared to cytology alone. Implementation 
of HR HPV testing in cervical screening leads to earlier detection of clinically relevant CIN 
grade 2 or worse, which, when adequately treated, improves protection against CIN grade 3 and 
cervical cancer [160-162].  
In a recent review two follow-up procedures, one based on HR HPV testing with Hybrid 
Capure 2 method and one on repeat cytology, were evaluated for detection of underlying CIN2 
or worse (CIN2+) or CIN3 ore worse (CIN3+) in women with ASC-US or LSIL (Arbyn et al. 
2012, Arbyn et al. 2013b). The conclusion of this study was that HPV triage with HC2 can be 
recommended to triage women with ASC-US because it has a higher accuracy with a 
significantly higher sensitivity, and similar specificity. The advantage was less clear for women 
with LSIL because of the lower specificity of HPV-testing compared to repeat cytology.  
Because expression of viral oncogenes is considered as necessary for progression towards 
malignancy and maintenance of the cancerous phenotype, research for new techniques has 
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focussed on E6/E7 mRNA transcripts of genes of several HR HPVs. This might increase 
sensitivity and specificity compared to DNA testing: PreTect HPV Proofer (Norchip AS 
Klokkarastua, Norway)/NuclSENS EasyQ
®
, APTIMA
® 
(GenProbe, San Diago, CA, USA). 
Because the sensitivity of most tests is very high, it is mainly the specificity that can be 
improved.    
Other biomarkers are related to the detection of abnormal expression patterns of cell-cycle 
associated proteins disrupted by E6/E7 such as p16, Ki-67,MCM proteins. ProEx
TM
 C (Tripath 
Imaging, Burlington, NC, USA) is such a marker that detect cells with an aberrant S-phase 
induction. The CINtec p16 Cytology test (MTM Laboratories AG, Heidelberg, Germany) is an 
immunocytochemical assay for the evaluation of overexpressed p16.  
 
In a meta-analysis the accuracy of the APTIMA HPV test that identifies mRNA of 14 HR 
HPVs was found to be better in this respect than the Hybrid Capture (HC2) test that identifies 
DNA of 13 HR HPV types [148] (Arbyn et al. 2013a). Other tests that have been recently 
introduced as the Abbott RealTime, Qiagen HC2 test, Roche Linear Array and Amplicor test,  
all have a high sensitivity, but a comparable lower specificity [163]. If HPV DNA testing is to 
be used for primary cervical screening, additional tests may be desirable to increase specificity 
while retaining its very high sensitivity. Additional tests focussing on proliferation parameters 
or/and the detection HPV E6/E7 may increase  specificity. Figure 1.12 illustrates the 
sensitivities and specificities of recently introduced new tests.  
 
 
Figure 1.12: Summary of comparative 
sensitivity and specificity of viral tests 
[163-165] for cervical intraepithelial 
neoplasia grade CIN or worse 
(CIN2+).  
Hybrid Capture 2 (Qiagen), Amplicor 
(Roche Diagnostics), Linear Array 
(Roche Diagnostics), Clinical Arrays 
(Genomica), PreTest HPV-Proofer 
(NorChip), APTIMA (Gen-Probe), 
P16INK4a (mtm Laboratories). 
 
 
 
In addition, we refer here to the comprehensive inventory and critical analysis of commercial 
tests of nucleic acid tests fot the detection of HPV by [147].  In this review at least 125 distinct 
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HPV tests and at least 84 variants of the original tests were identified.  Only in a small subset of 
tests have documented clinical performance, and for more than 75% of these tests on the 
market, no single publication in peer-reviewed literature could be identified.  They expressed 
also an urgent need to develop international standards for HPV types other than HPV16 and 
HPV18.  
Therefore the critical advise presented in this review was not to use tests in clinical 
management without validation and proof of reliability, reproducibility and accuracy.  
Also in the field of cytology new tests have been developed, e.g. the CINtec PLUS cytology 
combines a conventional Pap test with a double staining of p16 and Ki-67. Simultaneous 
expression of p16- and Ki-67 proteins indicates the presence of a transforming HPV infection. 
Such a test can be used as a triage of HR-HPV-positive women with ASCUS and LSIL. The 
advantage is that all three tests (liquid-based cytology, HPV typing and p16/Ki-67 detection) 
can be performed on the same sample [166].  
 
In our study we selected three tests for determining HPV DNA: 1/ Abbott RealTime High Risk 
HPV test, 2/ INNO-Lipa HPV Genotyping Extra (Innogentics) and 3/ Full Spectrum PCR HPV 
Amplification and Detection/Genotyping System by Lab2Lab Diagnostic Service (GenoID).  
Samples were routinely tested for HPV if they showed evidence for the Bethesda 200 category 
ASCUS according to the European guidelines for quality assurance in cervical cancer screening 
[167]. 
 
1.4.4.  Screening by visual inspection, the “see and treat” method 
This method consists of observing the cervix by visual inspection after it has been stained with 
acetic acid 3-5% (VIA, visual inspection with acetic acid) and Lugol’s Iodine (VILI: visual 
inspection with Lugol’s iodine). The cervix can be examined by eye or by use of a colposcope. 
This is a low cost screening method that has the advantage that suspect lesions can be treated 
immediately with cryotherapy or LEEP. Therefore it has been applied on a large scale in low-
resource settings as a useful alternative [168-170].  
The sensitivity and specificity of VIA in eleven cross-sectional studies performed in four 
African countries and India was 56.1-93.9% and 74.2-93.8%, respectively; for VILI  the ranges 
of the sensitivity and specificity were 76.0-97.0 % and 73.0-91.3%, respectively. VILI had a 
significantly higher sensitivity than VIA in detecting HSIL, but specificity was similar. VILI 
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was found to be a more accurate visual test for use in screening and treatment programs in low-
resource settings [171]. 
 
Visual inspection and cryotherapy can be performed by medical doctors and trained nurses. 
Cryotherapy applied by midwives has been found to be safe, effective and acceptable by the 
women [172]. The disavantage of this technique is that there is no histological proof of the 
lesion. 
 
 
1.5. Prevention by vaccination 
 
The strong correlation between HPV and cervical cancer not only stimulated to search for new 
HPV-based screening techniques but it made primary prevention possible by the development 
of prophylactic vaccines against HR HPV infections. Prophylactic vaccines are based on the 
HPV capsid protein L1 that induce capsid-specific antibodies.  
Today, two commercially available vaccines are used wordwide: 1/ Gardasil
®
: is a quadrivalent 
HPV 16/18/6/11 vaccine developed by Merck Sharp & Dome (Merck and Co, Inc., West Point, 
Pennsylvania, USA) and was the first to be approved by the US Food and Drug Administration 
(FDA) in 2006 2/ Cervarix
®
: is a bivalent HPV 16/18 vaccine developed by GlaxoSmithKline 
(GlaxoSmithKline Biologicals, Rixensart, Belgium)  and was approved 3 years later 3/ 
Gardasil
®
9: a nonavalent vaccine wich includes L1 capsids from 
HPV16/18/31/33/45/52/59/6/11 was approved by the FDA in 2014. Gardasil
® 
and Cervarix
® 
were developed with the idea to prevent about 70 % of cervical, vulvar, vaginal and anal 
cancers caused by HPV 16 and HPV 18, while Gardasil 9 was designed to prevent 90% of these 
cancers. The low oncogenic risk types HPV 6 and  HPV 11 were included in the quadrivalent 
vaccine because these HPV types are responsible for anogenital warts. These three vaccines are 
prophylactic and not effective once HPV infection has been  established.  
The bivalent and quadrivalent vaccines have been proved to prevent more than 99% of 
persistent infections and high-grade lesions caused by HPV 16/18 [173-176]. Because HR HPV 
types are also associated with anogenital cancers (vulvar, vaginal, anal, penile) and head and 
neck cancers also these cancers are targeted by prophylactic vaccines.  
In addition to the beneficial effects on HPV16/18-related cancers, clinical trials have shown  
the existence of vaccine cross-protection against non-vaccine HPV types [174,177-178] mainly 
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HPV 31, 33, and 45. Cross-protection of both vaccines is expected to increase the prophylactic 
efficacy to 80-90% of HPV-related cancers. The first results with the nonavalent vaccine are 
very promising to further decrease the prevalence of precancerous lesions and cervical cancer. 
It showed significant increased efficacy compared to the quadrivalent vaccine for LSIL, 
CIN2/3 and cancer. It has been estimated that with a high coverage about 90% of cervical and 
anal cancers could be prevented [179,180]. 
Long-term monitoring of vaccinated populations will be needed to fully ascertain the impact 
and public health significance of these vaccines. 
Therapeutic vaccines are underway to counteract already established HPV infections and 
precancerous lesions. These vaccines target the early HPV E6/E7 proteins.  As HPV 16 is the 
most commonly found type worldwide, most versions of HPV therapeutic vaccines contain 
HPV 16, and some also contain HPV 18. Cross-protection  against other, non-vaccine HR HPV 
types has also been described for therapeutic vaccines ([181] for review).  
Once the mechanism of adherence of the virus to the basal cells and endocytosis are better 
known even more effective vaccines may be developed that interfere with the uptake of the 
virus and  block the entry of all HR HPVs.  
Although at least 110 countries have licensed Cervarix
®
 and over 120 countries Gardasil
®
 [182] 
there is a significant lag in the introduction of these vaccines in low- and middle-income 
countries. In 2012, of the 51 countries implementing national vaccination programmes, only six 
were low- and middle-income countries [182]. Between 2009-2013 twenty-one [183] to 
twenty-six  [182] small-scale or demonstration projects have been started in low- and middle-
income countries to test and to prepare the introduction of HPV vaccines. Part of this 
preparation consists of the application of cost-effectiveness models [182-185] to guide political 
decision making concerning screening (HPV DNA assays versus cytology) and prevention 
(which vaccine and which procedures to follow for implementation and follow-up?). 
Unfortunately, the DRC does not belong to these initiatives.  
In conclusion: better knowledge of the viral cycle of HPV and the association between HPV 
and cervical cancer has opened new perspectives for better diagnosis of precancerous lesions 
and early prevention of cervical cancer. Prophylactic vaccination will further reduce the 
prevalence of precancerous lesions and cancer.  It is one of the success stories of how research 
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on basic mechanism of viral reproduction finally results in prevention of one of the most 
frequent cancers in women worldwide.   
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Enormous progress has been made in cervical cancer research over the last 15 years: the 
association between HPV infection and cancer is well established now giving rise to new viral 
diagnostics and prophylactic vaccination. Better knowledge of the viral cycle and oncogenic 
substances produced by HR HPVs interfering with the host cell cycle even open new 
perspectives for therapeutic vaccination. It is expected that the prevalence of cervical cancer 
will be further reduced  after it has been successfully decreased by the introduction of cytology 
by Papanicolaou in 1943. The coverage of screening, however, remains low in many European 
countries indicating that education and awareness has to go hand in hand by the progress on the 
molecular diagnostic level. 
Low-income countries as the DRC are largely excluded from this progress. Priority is given to 
acute transmissible diseases as malaria, tuberculosis and HIV infection. Cancer screening is not 
on the priority list. There is no national registration system and the knowledge about cervical 
cancer is low or not-existing.  
Therefore, in order to reduce cervical cancer deaths in the future, it is mandatory to take action 
at different levels:  there is a need for an increased awareness in the population, a low cost 
screening has to be organized by the government, and precancerous lesions have to 
preventively treated. With this policy of prevention, vaccination is crucial to decrease the 
mortality. As other types of HR HPVs than types 16 and 18 are implicated in Sub-Saharan 
countries, a polyvalent vaccine with a wider spectrum will be more efficacious than those that 
are currently applied worldwide.  
With this study we wanted to extend our knowledge on several aspects of cervical cancer with 
the purpose to install an efficient screening and preventive treatment program for women in the 
DRC in the future. 
The work covers awareness about cervical cancer, its epidemiology and its relation to the 
presence of HPV subtypes in the population of Kinshasa, and a comparision of  methods to 
screen it.  
Objective 1 
A successful campaign for improving screening and prevention of cervical cancer can only be 
achieved if the awareness of women is sufficiently high.  The first objective focussed on the 
knowledge, attitudes and practices of women of Kinshasa about cervical cancer (paper 1).  
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Objective 2 
The prevalence of precancerous lesions and co-factors influencing it are incompletely known 
among Congolese women. The second objective was to investigate the type of lesions found in 
women of Kinshasa (Papers 2, 3).  
Objective 3 
In Sub-Saharan countries other types of HPV may be more important than those found in 
Europe and the USA. The third objective focusses on the HPV types associated with 
precancerous and cancerous lesions in Kinshasa (Papers 2, 5).  
Objective 4 
In most African countries the cytological method of screening is based on the conventional Pap 
smear test. In high-income countries the conventional Pap test has been replaced by Liquid 
Based Cytology. The fourth objective was to compare both tests in the setting of Kinshasa 
(Paper 3). 
Objective 5 
New molecular techniques are currently used to detect high-risk HPV. The impact of these 
detection methods in the clinical diagnostic laboratory is very important. There is a lot of 
discussion about the accuracy of these tests. The fifth objective was to compare concordance 
between several tests for determination of HR HPV DNA (Paper 4).  
 
Papers related to the objectives and presented in the next chapters 
1. Ali-Risasi C, Mulumba P, Verdonck K, Vanden Broeck D, Praet M. Knowledge, attitude 
and practice about cancer of the uterine cervix among women living in Kinshasa, the 
Democratic Republic of Congo. BMC Women’s Health 2014;14:30   
2. Ali-Risasi C, Verdonck K, Padalko E, Vanden Broeck D, Praet M. Prevalence  and risk 
factors for cancer of the uterine cervix among women living in Kinshasa, the Democratic 
Republic of the Congo: a cross-sectional study. Infect Agent Cancer 2015;10:20 
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The study population  
Our study concerned 1.542 women of Kinshasa who participated freely after the objectives of 
the study were clearly explained to them. Five hundred twenty four of them participated in an 
awareness study about cervical cancer. This was performed by an interview at home by trained 
interviewers who presented a questionnaire about the socio-demographic background of the 
women. They received a sufficient or insufficient score on three parameters related to 
awareness on cervical cancer: knowledge, attitude and practice. The participants lived in 
different districts of Kinshasa. Details on the methodology of this study are summarized in 
Chapter 4.   
Thousand eighteen women agreed with a smear test. All participants responded to a 
questionnaire with a series of details on their socio-demographic and medical background. The 
study was performed in different medical centers and hospitals of Kinshasa: the General 
Reference Hospital of Kinshasa, the Ngaliema Hospital (group 3, n: 539), the AMO-CONGO 
center (group 1, n:131 and group 2, n:128), and three smaller medical centers in the periphery 
of Kinshasa (group 4, n:220)).  Smears were taken with a Cervex Brush (Rovers) and prepared 
according to the conventional Pap method and Liquid Based Cytology (LBC). For the LBC 
method the brush was rinced in a ThinPrep solution containing methanol. The ThinPrep vials 
were stored in a refrigerator at 4°C before they were sent to the Laboratory of Pathology of the 
University Hospital of the University of Ghent for thin layer preparation, for reading and 
classification of lesions according to the Bethesda system.   
Cytological classification 
Reading was independently performed by two pathologists. In case of discordancy between 
both, a third reading was performed before a definite conclusion was made. 
HIV serology 
Group 1 consisted of HIV-positive women who were screened and followed in the AMO-
CONGO center of Kinshasa. Group 2 were women with a HIV-negative serology who visited 
the same center. The groups 3 and 4  consisted of women with unkown HIV serology.  
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Typing of HPV 
Typing of the Human Papillomavirus (HPV) was performed in the Laboratory of Virology of 
the University Hospital of the University of Ghent.  For those smears that were classified as 
ASC-US, LSIL, HSIL, CIS and Ca a HR HPV DNA test was performed. Three HPV DNA 
testing methods were applied: INNO-Lipa HPV Genotyping Extra (Innogenetics, Zwijnaarde, 
Belgium), Full Spectrum PCR HPV Amplification and Detection/Genotyping System by 
Lab2Lab Diagnostic Service (GenoID Molecular Diagnostics Laboratory, Budapest, Hungary) 
and Abbott RealTime HR HPV test (Abbott, Madison, USA). 
Statistics 
The association between socio-demographic and medical factors and the presence of 
precancerous and cancerous lesions was analyzed with bivariate and multivariable analysis. 
More details about the methods used are presented in Chapters 4, 5 and 6.  
Ethics 
The study has been approved by the ethical committee of the School of Public Health of the 
University of Kinshasa.  
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Abstract  
Background 
Cervical cancer is the most frequent cancer of women in the Democratic Republic of Congo 
(DRC). Nevertheless, the level of women’s awareness about cervical cancer is unknown. 
Knowledge, attitude and practice (KAP) are important elements for designing and monitoring 
screening programs. The study purpose was to estimate KAP on cervical cancer and to identify 
associated factors.  
Methods 
A cross-sectional study was conducted in Kinshasa, DRC, including 524 women aged 16-78 
years (median age 28; interquartile range 22-35). The women were interviewed at home by 
trained field workers using a standardized questionnaire. The women’s score on knowledge, 
attitude and practice were dichotomized as sufficient or insufficient. We used binary and 
multiple logistic regression to assess associations between obtaining sufficient scores and a 
series of socio-demographic factors: age, residence, marital status, education, occupation, 
religion, and parity.  
Results 
The women’s score on knowledge was not significantly correlated with their score on practice 
(Spearman’s rho=0.08; P>0.05). Obtaining a sufficient score on knowledge was positively 
associated with higher education (adjusted odds ratio (OR) 7.65; 95% confidence interval 
(95%CI) 3.31-17.66) and formal employment (adjusted OR 3.35; 95%CI 1.85-6.09); it was 
negatively associated with being single (adjusted OR 0.44; 95%CI 0.24-0.81) and living in the 
eastern, western and northern zone of Kinshasa compared to the city centre. The attitude score 
was associated with place of residence (adjusted OR for east Kinshasa: 0.49; 95%CI 0.27-0.86 
and for south Kinshasa: 0.48; 95%CI 0.27-0.85) and with religion (adjusted OR 0.55; 95%CI 
0.35-0.86 for women with a religion other than Catholicism or Protestantism compared to 
Catholics). Regarding practice, there were negative associations between a sufficient score on 
practice and being single (adjusted OR 0.24; 95%CI 0.13-0.41) and living in the eastern zone of 
the city (adjusted OR 0.39; 95%CI 0.22-0.70). Although 84% of women had heard about 
cervical cancer, only 9% had ever had a Papanicolaou (Pap) smear test.  
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Conclusions 
This study shows a low level of knowledge, attitude and practice on cervical cancer among 
women in Kinshasa. Increasing women’s awareness would be a first step in the long chain of 
conditions to attain a lower incidence and mortality.  
Background 
Cervical cancer is after breast cancer the second most common cancer in women worldwide, 
with a global estimation of about 530,000 new cases and 275,000 deaths each year [1-3]. The 
highest incidence is estimated to occur in developing countries including those in Sub-Saharan 
Africa [3-7]. In contrast to high-income countries where mortality caused by cervical cancer is 
on the 8-9
th
 place, it is the most frequent fatal cancer in women in Sub-Saharan Africa 
[reviewed in 2,8,9]. The incidence and mortality are expected to increase over the next 20 years 
[10]. The high mortality has been linked to inadequate screening for precancerous lesions. 
Unlike many other cancers, cervical cancer can be prevented either by focusing on primary 
prevention of human papilloma virus (HPV) infection and/or secondary prevention based on 
the early detection and treatment of precancerous lesions before they progress to invasive 
cancer.  
Multiple factors contribute to inefficient screening of cervical cancer in low-income countries, 
such as the inadequacy or inexistence of a national screening system, poorly developed health 
services, the low access of the impoverished population to health care, the lack of technical and 
laboratory expertise, and, in general, the lack of public awareness [11,12]. All these factors 
contribute to inefficient testing, late diagnosis and late treatment [12,13]. In low-income 
countries, access to correct information is additionally prevented by illiteracy, some religious 
beliefs, beliefs in witchcraft, and social inequities. In Sub-Saharan Africa, only a small 
percentage of women regularly participate in cervical cancer screening [14]. Most women only 
seek treatment and care in an advanced stage of cervical cancer, too late to stop the lethal 
progression of the disease, although cervical cancer can be easily detected at an early 
precancerous stage. In contrast to developing countries, the mortality in high-income countries 
has been declining constantly over the past three decades. This decline has been related to the 
implementation of national screening programs, most frequently based on cytology [15,16]. 
The few papers [17,18] that exist on cervical cancer in the Democratic Republic of Congo 
(DRC) indicate that cervical cancer is the most frequent gynaecological cancer. A national 
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program for early detection and treatment of high-grade lesions does not exist. Estimations of 
the prevalence and incidence have to rely therefore on extrapolation of data from other African 
countries [2]. Extrapolation of mortality rates of cervical cancer in Sub-Saharan Africa [2] to 
the context of Kinshasa with 9 million habitants means that each year about 800 women will 
die of cervical cancer in Congo’s capital. The level of awareness on cervical cancer of the 
female population of Kinshasa is unknown. Nevertheless, it is an important parameter for the 
development and monitoring of a screening program and for the follow-up of an eventual 
vaccination against HPV in the future. Awareness studies in Sub-Saharan Africa have been 
performed mostly in health care workers living in an urban environment and in the perspective 
of a future vaccination program 19-30. 
This paper aims to assess knowledge, attitude and practice (KAP) concerning cervical cancer in 
women of the general population of Kinshasa, and to investigate socio-demographic factors 
that might influence it.   
Methods 
Participants 
The target population consisted of adult women living in Kinshasa. We grouped the 24 
municipalities of Kinshasa in five zones: centre, east, west, south and north (figure 1). We then 
took a sample of the target population in three steps: we randomly selected 7 out of the 24 
municipalities (3 in the centre and 1 in each of the other 4 zones); in each selected municipality, 
we randomly selected one district; and in each selected district, we randomly selected three 
streets. Within the selected streets, the study interviewers systematically visited one out of ten 
lots (“parcelles”) and approached all the women who were present in these lots. The women 
were included if they were at least 16 years old, if they had been living in Kinshasa for six 
months, and if they were willing to participate in the study. Women who were not at home 
during the visit were not included.  
The selected municipalities were Kimbanseke (eastern zone), Mont-Ngafula (southern zone), 
Ngaliema (western zone), Gombe (northern zone), and Kalamu, Kasa-Vubu and Lemba (city 
centre). Kimbanseke (eastern zone) is a relatively recent settlement in the hills. It is thought to 
be the most extended and the most populated municipality  of the capital. Mont Ngafula 
(southern zone) is also a rather recent settlement in a hilly area. Mont Ngafula is a rapidly 
growing municipality. The municipality of Ngaliema accommodates several important 
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compounds such as the residence of two former presidents, a military zone, and an exclusive 
quarter (Mont Fleury). Gombe (northern zone) is a smaller, residential and business area. 
 
 
Figure 1  - Map of the city and the province of Kinshasa (source Wikipedia).The figure illustrates the 
seven municipalities that were selected for the study. In the centre: Kalamu, Kasa-Vubu, and Lemba; in 
the east: Kimbanseke; in the west: Ngaliema; in the south: Mont-Ngafula; and in the north: Gombe 
 
The number of participants from each of the five zones of Kinshasa was proportional to the 
demographic weight of that zone. Because of the descriptive nature of this study and because of 
the unavailability of previous information about the topic, we did not formally calculate a 
sample size. We aimed for a study size of 524 participants and expected that this would allow 
us to improve our understanding of the knowledge, attitude and practice of the women in 
Kinshasa. The recruitment period was from November to December 2008.  
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Data collection and management  
The outcome of interest was the level of knowledge, attitude and practice (dependent 
variables). The independent variables were: age, place of residence, marital status, education 
level, occupation, religion, and parity. KAP was assessed through a series of questions (table 2 
A, B, C and additional files 1 and 2).  
To standardize the application of the questionnaires, we organized three workshops in which 
candidate interviewers could familiarize with the questionnaire and its translation in Lingala, 
the most commonly used language in Kinshasa. Five interviewers were finally selected. Two 
independent data clerks entered all data in a Microsoft Excel file. A third person checked and 
corrected the discordances. 
Statistical analysis 
Twenty items on the questionnaire were used to define the levels of knowledge, attitude and 
practice. For each item, a participant’s answer was considered to be correct if she gave at least 
one of the expected answers. This gave her one to three points. Detailed information on the 
scoring system is given in table 2 and in additional files 1 and 2. The maximum score for the 
questions on knowledge was 11, for attitude 5 and for practice 6.  
The first analysis explored the correlations between the women’s scores on knowledge, attitude 
and practice. We calculated Spearman's rank correlation coefficient (rho) and the 
corresponding P values for the correlation between the score on knowledge and the score on 
attitude, between knowledge and practice, and between attitude and practice.  
The second analysis focused on the association between socio-demographic variables and the 
women’s scores. To facilitate this evaluation, the women’s scores (on an ordinal scale) were 
converted to binary variables (sufficient/insufficient score). The definition of a “sufficient” 
score was based on the participants’ median score. Women with a score of 6 or more on 
knowledge were categorized as having “sufficient” knowledge; the others had “insufficient” 
knowledge. For attitude and practice, the cut-off point was 4. In that way, approximately half of 
the women were grouped in the “sufficient” categories.  
Binary logistic regression was used to explore the bivariate associations between the socio-
demographic variables on the one hand and sufficient levels of knowledge, attitude and practice 
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on the other hand. The women’s age was first described in five-year groups and then included 
in the logistic regression analyses in ten-year groups. 
Multiple logistic regression models were developed separately for knowledge, attitude and 
practice. In a first step, all independent variables with a P-value of <0.2 on bivariate analysis 
were included in the logistic regression models . Next, we assessed if the remaining variables 
(with a P-value of  ≥0.2 on bivariate analysis) could have a relevant effect on the models by 
including them one by one. Effect measure modification was evaluated by including the 
following interaction terms: place of residence x education, place of residence x occupation, 
and education x religion. Because the information on parity was not complete, we evaluated all 
multivariable analyses with and without this variable. Where more than one multiple logistic 
regression model was evaluated, we presented the model that best fitted the data.   
The results of all logistic regression analyses are reported as odds ratios (OR) with 95% 
confidence intervals (95% CI). Excel and Stata/IC 10.1 were used for data analysis.  
Ethical considerations 
The study protocol was approved by the Ethics Committee of the School of Health at Kinshasa 
University. All study participants gave oral informed consent. 
 
Results  
Participants  
Five hundred twenty-four women participated in the study. Their median age was 28 years 
(interquartile range 22 to 35 years). The majority of women were single (54.2%), had a level of 
education of secondary school (58.2%), had no formal employment (57.5%), and adhered to 
religions other than Catholicism and Protestantism (58.8 %), (table 1). These other religions 
included several different groups of “églises de réveil”, the Kibanguist Church, and the Islam 
among other groups. About one third of the participants (37.3%) had given birth to three or 
more children.    
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Scores 
The participants’ median score on knowledge was 5 on a scale with a maximum of 11 
(interquartile range 4-7); the median attitude score was 4 on a scale of 5 (interquartile range 3-
4); and the median practice score was 4 on a scale of 6 (interquartile range 3-4). We found a 
weak but significant correlation between the women’s score on knowledge and attitude  
(r=0.27, p<0.001), and between attitudes and practice (r= 0.15, p<0.001). No significant 
correlation was found between knowledge and practice (r=0.08, p=0.08). We used a cut-off of 
≥6 to define a “sufficient” score on knowledge, ≥4 for attitude, and ≥4 for practice. In that way, 
43% of the women obtained a sufficient score on knowledge, 52% on attitude, and 60% on 
practice. 
Knowledge 
The women were first asked which diseases of the female genital organs they knew. The 
diseases that were reported most frequently were infections (mentioned by 83.6% of the 
women), myoma (mentioned by 47.9%), dysmenorrhea (43.1%) and cysts of the ovaries 
(37.2%). Cervical cancer came on the seventh place of this list; it was mentioned spontaneously 
by 64 women (12.2%). When the interviewer then specifically enquired about cervical cancer, 
the majority of the women (81.9%) told that they had heard about it, mostly through 
conversations with other people (73.4%) and less frequently through the media (30.3%). Only 
3.7% got the information from a physician, a medical centre or a hospital. A minority of 
women (15.1%) knew a person in their neighbourhood who became victim to the disease. 
Fifteen percent of the women considered that having multiple sexual partners is an underlying 
cause of cervical cancer. Only 16.8% had ever heard of cervical smears. Table 2A lists the 
questions on knowledge, the expected answers, and the proportion of the participants who gave 
the expected answer. 
On bivariate analysis, seven socio-demographic characteristics were significantly associated 
with having a sufficient level of knowledge: age, place of residence, marital status, education, 
occupation, religion and parity (table 3A). Women of 30–59 years old were more likely to get a 
sufficient score than the youngest group, with the best score in the age group of 50-59 years 
(OR 3.77; 95% CI: 1.38-10.34). Women from the eastern and the western parts of the city 
scored worse than the women from the city centre (OR east: 0.33; 95% CI: 0.18-0.60; OR west: 
0.29; 95% CI: 0.16–0.53). Single women were less likely than married women to obtain a 
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sufficient score (OR: 0.60; 95% CI: 0.42-0.87). There was a strong association with the level of 
education: highly educated women scored notably better than those who never went to school 
or only went to primary school (OR 4.41; 95% CI: 2.49-7.81). Also the women with a formal 
income scored well (OR: 3.18; 95% CI: 1.98-5.11) compared to the women without formal 
income. The women adhering to religions other than Catholicism and Protestantism were less 
likely to obtain a sufficient score compared to those who declared that they were Catholic (OR: 
0.54; 95% CI: 0.37-0.81). Finally, women who had given birth to three or more children scored 
better than the nulliparous women (OR: 1.77; 95% CI: 1.09-2.87). 
On multivariable analysis, the positive associations of higher education (adjusted OR 7.65; 
95% CI 3.31-17.66) and a regularly paid job (adjusted OR 3.35; 95% CI 1.85-6.09) with 
sufficient knowledge remained significant. Also the negative associations of being single 
(adjusted OR 0.44; 95% CI 0.24-0.81) or living in the eastern or western part of Kinshasa with 
sufficient knowledge remained significant (OR east: 0.47; 95% CI: 0.24-0.90; OR west: 0.27; 
95% CI: 0.13-0.55, compared to the centre of the city). In addition, the women from the  north 
were less likely to obtain a sufficient score (OR: 0.51; 95% CI: 0.27-0.96). 
The product terms residence x education, residence x occupation, and education x religion were 
not significant and were not included in the final model. The inclusion of the variable parity in 
the multivariable logistic regression model did not change the findings: there was no significant 
association between a sufficient knowledge score and parity (OR: 0.95; 95% CI: 0.46-1.89) for 
three or more compared to zero births), and the other associations (with place of residence, 
marital status, education, and occupation) remained significant.  
Attitude 
Table 2B lists the five questions we used to assess the women’s attitude. Most of the 
respondents (80.0 %) were willing to consult a medical doctor in case of abnormal bleeding 
between menstruations. In addition, 56.7% told the interviewers that they were willing to 
regularly consult a physician for screening of cervical cancer. Eighty percent were willing to 
have a smear test and 95% were in favour of the installation of a national screening program. 
Although the majority wanted to be screened, only 31.7% was prepared to pay for it. 
On bivariate analysis, four factors were significantly associated with a sufficient score on 
attitude: age, place of residence, education and religion.  As for knowledge, the age group of 
50-59 years scored best. Women from the eastern, western and southern part of the city scored 
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worse than those from the centre (OR east: 0.36; 95% CI: 0.21-0.63; OR west: 0.54; 95% CI: 
0.32-0.91; OR south: 0.48; 95% CI: 0.28-0.82). Among those with a sufficient attitude score, 
there were more women with higher education (OR 1.83; 95% CI 1.07-3.16) and fewer women 
of a religion other than Catholicism or Protestantism (OR 0.49; 95% CI 0.33-0.73),  
On multivariable analysis, the place of residence and religion remained significant. Women 
from the eastern and southern zone of the city were less likely to have a sufficient score on 
attitude than those from the centre (adjusted OR east: 0.49; 95% CI 0.27-0.86; adjusted OR 
south 0.48; 95% CI:  0.27-0.85). Those women who declared to have a religion other than 
Catholicism or Protestantism were also less likely to get a sufficient attitude score (adjusted OR 
0.55; 95% CI 0.35–0.86 compared to adherents of the Catholic Church).  
The inclusion of product terms (residence x education, residence x occupation, and education x 
religion) and of additional variables (parity and marital status) in the multiple logistic 
regression model did not change the findings. On multivariable analysis, there was no 
significant association between parity and having a sufficient attitude score (OR: 1.66; 95% CI: 
0.84-3.28 for three or more compared to zero births).  
Practice 
Concerning practice (table 2C), 67.9% of the participants had undergone a gynaecological 
examination during the last two years. The majority (71.0%) declared not to use plants or 
chemicals for their intimate care, and not to smoke (96.8%). Most women (87.0%) declared to 
have had sexual contacts with maximum one partner during the last year, and 37.2% were 
convinced that their partner had no other sexual contacts. Only 8.6% had already had a Pap test. 
On bivariate analysis, four socio-demographic factors were significantly associated with a 
sufficient score on practice: place of residence, marital status, occupation and parity. The 
women who lived in the eastern and northern part of the city scored worse than those from the 
centre (OR east: 0.48; 95% CI: 0.28-0.82; OR north: 0.57; 95% CI: 0.33-0.96). In addition, 
single women were less likely to obtain a sufficient score than married women (OR: 0.31; 95% 
CI: 0.21-0.46). Finally, the women who had given birth to three or more children scored better 
than the nulliparous women (OR: 2.59; 95% CI: 1.57-4.28).   
The associations with place of residence and marital status remained significant on 
multivariable analysis. The women living in the east of the city were less likely than those from 
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the centre to obtain a sufficient score on practice (adjusted OR 0.39; 95% CI 0.22-0.70). There 
was also a negative association between being single (adjusted OR: 0.24; 95% CI: 0.13-0.41) or 
being widow (adjusted OR 0.22; 95% CI: 0.06–0.86) and obtaining a sufficient practice score.  
The inclusion of product terms and of additional variables (education, religion, and parity) in 
the multiple logistic regression model did not change the findings. On multivariable analysis, 
there was no significant association between parity and having a sufficient practice score (OR: 
1.61; 95% CI: 0.75-3.48 for three or more compared to zero births).  
 
Discussion 
The present study explored the knowledge, attitude, and associated behaviours of women in 
Kinshasa with regard to cancer of the uterine cervix. The results provide support for the view 
that among African women, the awareness about cervical cancer, and especially its prevention 
and treatment, is very limited. Of note, several socio-demographic parameters (place of 
residence, level of education, occupation, marital status, and religion) were found to affect the 
women’s knowledge, attitude, and/or practice (KAP).   
Several limitations of the present study should be acknowledged. Firstly, although we believe 
that the houses that were visited are fairly representative of the houses in Kinshasa, selection 
bias may still affect the internal validity of the study. The main reason for this is that our study 
population did not include women who were not at home when the interviewers visited their 
houses nor did it include women who did not want to participate. Secondly, as noted by 
Launiala [31], there are some limitations to the KAP survey method itself. These limitations 
include the difficulty of expressing concepts of western medicine in a local African language, 
the possibility of social desirability bias (i.e. the tendency of interviewees to over-report what 
they believe to be “good behaviour”), and the fact that the KAP survey is not a good method to 
obtain in-depth information about sensitive issues. In spite of the limitations, this study stands 
as a first attempt to systematically explore and document KAP about cervical cancer among 
women in the DRC. 
Our study shows that, although only 12% of the women of Kinshasa spontaneously mentioned 
cervical cancer as one of the diseases of the female genital organs, the large majority (82%) of 
these women reported to have heard about the disease. These results are similar to those 
published for Ethiopia (79%) [32], Ghana (93%) [33], and Nigeria (71%) [34]. Lower figures 
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have been published for Botswana (23%) [35] and in other reports for Nigeria (about 48%) [36-
38]. In most of these studies, the concept of “knowledge” was very elementary and limited to a 
positive answer on ‘having heard’ about cancer. With regard to the knowledge of risk factors, 
15% of the respondents related cervical cancer to sexual behaviour. This finding agrees with 
observations in Nigeria [37], Ethiopia [32] and Botswana [39]. 
Although newspapers, radio and television are easily accessible in Kinshasa, word-of-mouth 
communication was the most important source of information. This finding is consistent with a 
publication from Botswana [35], but contrasts with studies in Ethiopia [32] and Nigeria [37] 
where the media came on the first place. But in these countries too, oral communication 
remained an important way of exchange of information on health issues. In rural areas without 
electricity, it is the only way of communication.  
The population of Kinshasa (about 9 million)  is estimated to represent 12% of the total 
population (about 75 million) of the DRC.  The majority of the Congolese population live in 
rural areas where electricity is not always available and information transfer via the media is 
scarce. The results of our study are limited to the urban population of the capital which is 
favoured by easy access to information, and even within Kinshasa, we found that the place of 
residence was associated with the women’s knowledge about cervical cancer.  The relative role 
of the media in the transfer of knowledge may become more important when governments will 
use them more actively in a policy of cancer prevention. Furthermore, because of the oral 
culture, churches may play an important role in the transfer of information on health care 
matters.  
About half of the women (58%) told the interviewers that they knew that suspect lesions can be 
detected early. However, the proportion of women who had heard about cervical smear testing 
was substantially lower (17%), and only 9% of the participants had ever had a Pap test. This 
finding is consistent with the low effective coverage rates for cervical cancer screening in 
developing countries reported elsewhere: on average 19% compared to 63% in high-income 
countries [14]. The situation might even be worse, as a recent survey in 15 developing 
countries has indicated, that as few as 4% of the women aged 18 – 69 years had undergone a 
pelvic exam or a Pap smear test in the past three years [40]. Poor access to health care in 
general, and the lack of specific screening and treatment facilities in particular may explain the 
low coverage rates for cervical cancer screening in developing countries [40].  
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Concerning attitude, a large majority of women (80%) said that they agreed to participate in a 
screening program, but considerably less women (30%) would be willing to pay for a smear 
test. This suggests that financial issues should be taken into consideration when a wide-scale 
screening program is introduced in Kinshasa. Nowadays, the cost of a Pap smear in Kinshasa 
varies between 30 US$ and 50 US$. Most women in an impoverished society who gain 1 US$ 
to 2 US$ a day are unable to pay this amount. Part of this high cost is related to the lack of 
trained people to read and interpret the Pap smears, the insufficient number of tests performed, 
and the low appreciation of preventive measures as a profitable strategy at the long end. If 
screening is already an obstacle because of the high cost, it is difficult to motivate women to 
pay even more for preventive treatment such as loop electrical excision procedure or 
cryotherapy.  
The correlations between the knowledge and attitude scores and between attitude and practice 
were significant but weak, and the correlation between knowledge and practice was even not 
significant. This finding adds to the growing body of evidence showing that increased 
knowledge is not automatically translated into changes in attitude and practice. Some studies 
have even found that a high level of awareness, as encountered in medical students and 
physicians, was associated with a lower level of practice [34, 37, 41, 42]. Even in countries 
where information about cervical cancer is easily available, the effective coverage of screening 
was found to be only 63% [14].  
By multivariable analysis, we found that knowledge was associated with four socio-
demographic factors: the place of residence within Kinshasa, level of education, occupation and 
marital status. The municipality of Mont-Ngafula in south Kinshasa had a high proportion of 
women with a sufficient score on knowledge. Mont-Ngafula is semi-residential area that is 
situated near the University of Kinshasa and the Higher Institute for Medical Technology and 
Nursing.  It may be expected that women living in these places have better access to 
information than the women living elsewhere. They are also likely to have received a better 
education and to have better jobs. However, the effect of the place of residence on knowledge 
cannot be explained by education and employment alone, because these factors were included 
in the multivariable analysis. Therefore, other factors that are still unknown are likely to 
explain the association between the place of residence and the level of knowledge.  
In our study, married women scored better on knowledge than singles. Contradictory reports 
have been published on the influence of marital status on knowledge: in a Nigerian study, 
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singles scored better for the awareness on cervical cancer [37] while in an Ethiopian study, no 
effect was found [32]. Overall, the participants who were most likely to have a sufficient 
knowledge score were the married women with a degree of higher education, a regular income 
and living in the southern district of Mont-Ngafula.  
With regard to attitude, the significantly associated factors on multivariable analysis were the 
place of residence and religion. Although the women from Mont Ngafula scored well on 
knowledge, this was not reflected in their attitude scores. They were less likely to get a 
sufficient score than the women from the city centre, illustrating the poor correlation between 
knowledge and attitude. In this study, adherents to the Catholic Church scored better than the 
category ‘other religions’. The category ‘other’ included a multitude of small and diverse 
churches which were difficult to classify in one well-defined group. Most of the women in this 
group adhered to the “églises de réveil” and the Kibanguist church. Religion, however, was not 
associated with a better practice.   
Regarding practice, marital status and place of residence were independent predictors of a 
sufficient score. Married women were more likely than single women to obtain a sufficient 
score, and women from eastern Kinshasa (Kimbanseke) scored worse on practice compared to 
the women from the city centre. Kimbanseke is an extended municipality with a large, and 
relatively recent population. A high proportion (25/75) of the women from this municipality 
had insufficient scores on knowledge, attitude as well as practice.  
Information on the level of KAP and the socio-demographic factors influencing it is important 
to guide future awareness campaigns about cervical cancer. The fact that we found no 
significant associations between parity and KAP suggests that women did not learn about 
cervical cancer when they had contact with health services. Most women in the DRC give birth 
in health care centres and are assisted by skilled health personnel [43]. This could be 
considered therefore to be a missed opportunity in order to increase the awareness about 
cervical cancer through the existing health services. The fact that only 4% of the women 
mentioned doctors or health services as a source of information about cervical cancer is an 
additional illustration of this missed opportunity. In addition to health services, local churches 
appear to be a relevant stakeholder in the organization of awareness campaigns, given our 
findings on the probable influence of religious groups on attitude and on the importance of oral 
communication as a source of information. The potential of church communities in the 
promotion of healthy behaviour has been widely recognized [44].  
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Finally, our study illustrates that women are clearly willing to participate in screening 
initiatives. Nevertheless, it is important to recognize that a screening strategy can only be useful 
if it improves patient-important outcomes. This is possible only if effective treatment is 
available, if test-related adverse events or anxiety are reduced, and/or if prognostic information 
improves patients’ wellbeing [11, 45]. 
Conclusions  
Our findings underline the low level of knowledge, attitude and practice regarding cervical 
cancer among women in Kinshasa despite the high incidence of this cancer. Increasing the 
women’s awareness is an important  first step in the long chain of conditions to attain a lower 
incidence and mortality. In parallel with an increased awareness, the national health care 
system should facilitate and encourage early diagnosis and therapy.  
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Table 1  - Socio-demographic characteristics of respondents 
 Place of residence in Kinshasa 
 Centre East West South North Total 
 (N=224) (N=75) (N=75) (N=75) (N=75) (N=524) 
Characteristic   N (%) N (%) N (%) N (%) N (%) N (%) 
Age, years       
   16-19 23 (10.3) 20 (26.7) 8 (10.7) 5 (6.7) 9 (12.0) 65 (12.4) 
   20-24 53 (23.7) 12 (16.0) 24 (32.0) 15 (20.0) 14 (18.7) 118 (22.5) 
   25-29 41 (18.3) 12 (16.0) 11 (14.7) 22 (29.3) 18 (24.0) 104 (19.8) 
   30-34 40 (17.9) 16 (21.3) 12 (16.0) 16 (21.3) 10 (13.3) 94 (17.9) 
   35-39 27 (12.1) 3 (4.0) 10 (13.3) 8 (10.7) 8 (10.7) 56 (10.7) 
   40-44 9 (4.0) 7 (9.3) 3 (4.0) 4 (5.3) 7 (9.3) 30 (5.7) 
   45-49 11 (4.9) 2 (2.7) 3 (4.0) 4 (5.3) 3 (4.0) 23 (4.4) 
   50-54 6 (2.7) 3 (4.0) 1 (1.3) 1 (1.3) 1 (1.3) 12 (2.3) 
   55-59 7 (3.1) 0 (0) 0 (0) 0 (0) 3 (4.0) 10 (1.9) 
   60-64 4 (1.8) 0 (0) 0 (0) 0 (0) 2 (2.7) 6 (1.1) 
   65-69 1 (0.4) 0 (0) 0 (0) 0 (0) 0 (0) 1 (0.2) 
   70-74 0 (0) 0 (0) 2 (2.7) 0 (0) 0 (0) 2 (0.4) 
   75-79 2 (0.9) 0 (0) 1 (1.3) 0 (0) 0 (0) 3 (0.6) 
Marital status       
   married  86 (38.9) 34 (45.3) 27 (36.0) 29 (40.8) 26 (34.7) 202 (39.1) 
   single  119 (53.8) 36 (48.0) 43 (57.3) 40 (56.3) 42 (56.0) 280 (54.2) 
   widowed  8 (3.6) 2 (2.7) 3 (4.0) 1 (1.4) 3 (4.0) 17  (3.3) 
   divorced    8 (3.6) 3 (4.0) 2 (2.7) 1 (1.4) 4 (5.3) 18  (3.5) 
Level of education       
   no school & primary   39 (17.7) 23 (30.7) 18 (24.0) 17 (23.0) 8 (10.7) 105 (20.2) 
   secondary   128 (58.2) 50 (66.7) 47 (62.7) 46 (62.2) 31 (41.3) 302 (58.2) 
   higher  53 (24.1) 2 (2.7) 10 (13.3) 11 (14.9) 36 (48.0) 112 (21.6) 
Occupation       
   no formal employment  124 (56.1) 57 (76.0) 48 (64.0) 49 (66.2) 21 (28.0) 299 (57.5) 
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   student  59 (26.7) 12 (16.0) 14 (18.7) 8 (10.8) 30 (40.0) 123 (23.7) 
   formal employment  38 (17.2) 6 (8.0) 13 (17.3) 17 (23.0) 24 (32.0) 98 (18.8) 
Religion       
   catholic 70 (31.4) 8 (10.7) 15 (20.0) 24 (32.4) 32 (42.7) 149 (28.5) 
   protestant  22 (9.9) 7 (9.3) 10 (13.3) 13 (17.6) 14 (18.7) 66 (12.6) 
   other  131 (58.7) 60 (80.0) 50 (66.7) 37 (50.0) 29 (38.7) 307 (58.8) 
Parity
1
       
   0 births 42 (24.9) 16 (21.9) 27 (36.0) 5 (10.9) 32 (45.1) 122 (28.1) 
   1 to 2 births 59 (34.9) 29 (39.7) 26 (34.7) 19 (41.3) 17 (23.9) 150 (34.6) 
   3 or more births 68 (40.2) 28 (38.4) 22 (29.3) 22 (47.8) 22 (31.0) 162 (37.3) 
1 
The proportion of missing values was <2% for all variables except for parity (17% missing values) 
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Table 2 A - Survey questions, and absolute and relative (%) number of expected answers on 
knowledge  
Questions Expected answer 
N (%) with 
score=1 
1. Which diseases of the female genital 
tract do you know? 
description of at least one of the 
following diseases: leucorrhoea, 
infections, cancer of the uterine 
cervix, ovarian cysts or tumours, 
uterine myomas or tumours, 
dysmenorrhea, galactorrhoea 
503 (96.0)
 1
 
2. Have you ever heard about cervical 
cancer? 
yes 429 (81.9) 
 
3. How did you hear about it? 
oral communication, newspaper, 
television, radio, conference, 
medical doctor or at the hospital, at 
a church or a school, or through a 
non-governmental organisation 
 
434 (82.8) 
4. What are the causes of cervical cancer? 
many sexual partners, use of plants 
for intimate care, sexually 
transmitted diseases, HIV infection, 
papilloma virus, old age 
101 (19.3) 
5. In your close circle of acquaintances, 
do you know someone who has had 
cervical cancer? 
yes 79 (15.1) 
6. How can cervical cancer be treated? 
surgery, chemotherapy, 
radiotherapy 
90 (17.2) 
7. How can you prevent cervical cancer? 
avoid multiple sexual partners, 
avoid HIV infection, use condoms 
92 (17.6) 
8. Have you ever heard about cervical 
smears? 
yes 88 (16.8) 
9. Do you know that suspect lesions can 
be detected early?  
yes 303 (57.8) 
1
 241 participants (46.0%) spontaneously mentioned three or more items from the list and got 3 points; 
126 (24.0%) gave two items and got 2 points; and 136 (26.0%) gave one item and got one point. The 
remaining 21 women (4.0%) did not describe any of the listed diseases. 
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Table 2 B - Survey questions, and absolute and relative (%) number of expected answers on 
Attitude  
Questions Expected answer N (%) with score=1 
1. What would you do in case of vaginal 
bleeding between periods? 
consult a medical doctor or 
go to a health centre 
419 (80.0) 
2. Are you willing to regularly consult a 
medical doctor for screening of cervical 
cancer?   
yes 297 (56.7) 
3. Are you willing to get a smear test? 
yes 417 (79.6) 
4. Would you want that a screening national 
program would be made available in the 
future? 
yes 498 (95.0) 
5. Are you willing to pay for a smear test?  
yes 
166 (31.7) 
 
Table 2C - Survey questions, and absolute and relative (%) number of expected answers on 
Practices 
Questions Expected answer N (%) with score=1 
1. When was your last gynaecological exam? 
less than 2 years ago 356 (67.9) 
2. Do you use chemicals or plants for your 
intimate care? 
no 372 (71.0) 
3. Do you smoke? 
no, never 507 (96.8) 
4. How many sexual partners have you had 
in the last year? 
maximum one 456 (87.0) 
5. Does your partner have a partner beside 
you? 
no 195 (37.2) 
6. Have you ever got a Pap smear test? 
yes 
45 (8.6) 
Table 3 A - Association between socio-demographic characteristics and knowledge 
  
N (%) with 
score ≥61 
Crude OR 95% CI 
Adjusted 
OR
2
 
95% CI 
Age, years 10 – 19 18 (27.7)   1.00**  1.00  
 20 – 29 80 (36.0) 1.47 0.80 - 2.70 0.56 0.26 - 1.22 
 30 – 39 80 (53.3) 2.98 1.59 - 5.61 1.52 0.62 - 3.71 
 40 – 49 28 (52.8) 2.92 1.36 - 6.29 1.33 0.46 - 3.86 
 50 – 59 13 (59.1) 3.77 1.38 - 10.34 1.56 0.39 - 6.27 
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 60 – 69 4 (57.1) 3.48 0.71 - 17.11 1.19 0.17 - 8.62 
 70 – 79 2 (40.0) 1.74 0.27 - 11.29 2.53 0.22 - 28.54 
Residence centre 109 (48.7)      1.00
***
  1.00  
 east 18 (24.0) 0.33 0.18 - 0.60 0.47
**
 0.24 - 0.90 
 west 16 (21.3) 0.29 0.16 - 0.53  0.27
***
 0.13 - 0.55 
 south 45 (60.0) 1.58 0.93 - 2.69 2.13
**
 1.14 - 3.99 
 north 37 (49.3) 1.03 0.61 - 1.73 0.51
**
 0.27 - 0.96 
Marital  status married 101 (50.0)   1.00
**
  1.00  
 single 105 (37.5) 0.60 0.42 - 0.87 0.44
**
 0.24 - 0.81 
 widowed 10 (58.8) 1.43 0.52 - 3.90 1.23 0.33 - 4.50 
 divorced 6 (33.3) 0.50 0.18 - 1.38 0.50 0.15 - 1.69 
Education no school/primary 38 (36.2)    1.00
***
  1.00  
 secondary 104 (34.4) 0.93 0.58 - 1.47 1.15 0.65 - 2.01 
 higher 80 (71.4) 4.41 2.49 - 7.81    7.65
***
 3.31 - 17.66 
Occupation non-formal income 105 (35.1)    1.00
***
  1.00  
 student 57 (46.3) 1.60 1.04 - 2.44 1.60 0.79 - 3.26 
 formal income 62 (63.3) 3.18 1.98 - 5.11    3.35
***
 1.85 - 6.09 
Religion catholic 76 (51.0)   1.00
**
  1.00  
 protestant 37 (56.1) 1.23 0.68 - 2.19 1.40 0.70 - 2.81 
 other 111 (36.2) 0.54 0.37 - 0.81 0.93 0.57 - 1.51 
Parity 0 births 42 (34.4)   1.00
**
    
 1 to 2 births 54 (36.0) 1.07 0.65 - 1.77   
 3 or more births 78 (48.1) 1.77 1.09 - 2.87   
OR: odds ratio; crude OR: odds ratio by bivariate analysis 
95% CI: confidence interval at the 95% level 
*: 0.05 ≤ p < 0.2; **: 0.001 ≤ p < 0,05; ***: p < 0.001 
1
 absolute number and proportion of women belonging to a specific category who got a sufficient score 
on knowledge, e.g. out of 65 women aged 10 to 19 years, 18 (27.7%) had a score of ≥6 points 
2
Adjusted OR: odds ratio by multiple logistic regression (variables in the model: age, residence, marital 
status, education, occupation, and religion) 
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Table 3 B - Association between socio-demographic characteristics and attitude 
  
N (%) with 
score ≥41 
Crude 
OR 
95% CI 
Adjusted 
OR
2
 
95% CI 
Age, years 10 - 19 23 (35.4)  1.00
*
  1.00  
 20 - 29 116 (52.3) 2.00 1.13 - 3.54 1.50 0.78 - 2.87 
 30 - 39 82 (54.7) 2.20 1.21 - 4.02 1.74 0.84 - 3.57 
 40 - 49 30 (56.6) 2.38 1.31 - 5.01 2.00 0.85 - 4.72 
 50 - 59 15 (68.2) 3.91  1.40 - 10.97 2.57 0.80 - 8.25 
 60 - 69 4 (57.1) 2.43  0.50 - 11.83 0.87 0.15 - 5.13 
 70 -79 2 (40.0) 1.22 0.19 - 7.82 0.34 0.03 - 3.88 
Residence centre 136 (60.7)   1.00
**
  1.00  
 east 27 (36.0) 0.36 0.21 - 0.63   0.49
**
 0.27 - 0.86 
 west 34 (45.3) 0.54 0.32 - 0.91 0.64 0.37 - 1.12 
 south 32 (42.7) 0.48 0.28 - 0.82   0.48
**
 0.27 - 0.85 
 north 43 (57.3) 0.87 0.51 - 1.48 0.72 0.41 - 1.27 
Marital status married 112 (55.4) 1.00    
 single 135 (48.2) 0.75 0.52 - 1.08   
 widowed 9 (52.9) 0.9 0.34 - 2.44   
 divorced 11 (61.1) 1.26 0.47 - 3.39   
Education no school/primary 52 (49.5)   1.00
**
  1.00  
 secondary 143 (47.4) 0.92 0.59 - 1.43 1.01 0.61 - 1.65 
 higher 72 (64.3) 1.83 1.07 - 3.16 1.57 0.78 - 3.14 
Occupation non-formal income 146 (48.8) 1.00  1.00  
 student 64 (52.0) 1.14 0.75 - 1.73 0.93 0.52 - 1.68 
 formal income 59 (60.2) 1.59 1.00 - 2.52 1.30 0.78 - 2.17 
Religion catholic 95 (63.8)   1.00
**
  1.00  
 protestant 35 (53.0) 0.64 0.36 - 1.15 0.68 0.37 - 1.27 
 other 142 (46.3) 0.49 0.33 - 0.73   0.55
**
 0.35 - 0.86 
Parity 0 births 58 (47.5)  1.00
*
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 1 to 2 births 71 (47.3) 0.99 0.61 - 1.60   
 3 or more births 94 (58.0) 1.53 0.95 - 2.45   
OR: odds ratio; crude OR: odds ratio by bivariate analysis 
95% CI: confidence interval at the 95% level 
*: 0.05 ≤ p < 0.2; **: 0.001 ≤ p < 0,05; ***: p < 0.001 
1
 absolute number and proportion of women belonging to a specific category who got a sufficient score 
on attitude, e.g. out of 65 women aged 10 to 19 years, 23 (35.4%) had a score of ≥4 points 
2
Adjusted OR: odds ratio by multiple logistic regression (variables in the model: age, residence, 
education, occupation, and religion) 
Table 3 C - Association between socio-demographic characteristics and practice 
    
N (%) with 
score ≥4§ 
Crude OR 95% CI 
Adjusted 
OR 
95% CI 
Age, years 10 – 19 35 (53.8)  1.00*  1.00  
 20 – 29 124 (55.9) 1.08 0.62 - 1.89 0.74 0.40 - 1.35 
 30 – 39 93 (62.0) 1.40 0.78 - 2.52    0.41** 0.19 - 0.89 
 40 – 49 35 (66.0) 1.67 0.79 - 3.52 0.47 0.18 - 1.22 
 50 – 59 18 (81.8) 3.86 1.18 - 12.65 1.66 0.36 - 7.75 
 60 – 69 6 (85.7) 5.14 0.59 - 45.15 1.05 0.10 - 10.59 
 70 -79 4 (80.0) 3.43 0.36 - 32.36 1.54 0.11 - 21.00 
Residence centre 147 (60.7)   1.00
**
  1.00  
 east 36 (48.0) 0.48 0.28 - 0.82   0.39
**
 0.22 - 0.70 
 west 47 (62.7) 0.88 0.51 - 1.51 0.92 0.52 - 1.63 
 south 46 (61.3) 0.83 0.48 - 1.43 0.98 0.54 - 1.79 
 north 39 (52.0) 0.57 0.33 - 0.96 0.58 0.33 - 1.04 
Marital  status married 153 (75.7)    1.00
***
  1.00  
 single 138 (49.3) 0.31 0.21 - 0.46    0.24
***
 0.13 - 0.41 
 widowed 10 (58.8) 0.46 0.17 - 1.27   0.22
**
 0.06 - 0.86 
 divorced 11 (61.1) 0.50 0.19 - 1.37 0.50 0.18 - 1.42 
Education no school/primary 63 (60.0) 1.00    
 secondary 185 (61.3) 1.05 0.67 - 1.66   
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 higher 63 (56.3) 0.86 0.50 - 1.47   
Occupation non-formal income 194 (64.9)   1.00
**
  1.00  
 student 59 (48.0) 0.50 0.33 - 0.76 0.77 0.45 - 1.31 
 formal income 59 (60.2) 0.82 0.51 - 1.31 1.09 0.64 - 1.85 
Religion catholic 88 (59.1) 1.00    
 protestant 43 (65.2) 1.30 0.71 - 2.37   
 other 182 (59.3) 1.01 0.68 - 1.50   
Parity 0 births 56 (53.3)     1.00
***
    
 1 to 2 births 84 (56.0) 1.12 0.69 - 1.80   
  3 or more births 121 (74.7) 2.59 1.57 - 4.28   
OR: odds ratio; crude OR: odds ratio by bivariate analysis 
95% CI: confidence interval at the 95% level 
*: 0.05 ≤ p < 0.2; **: 0.001 ≤ p < 0,05; ***: p < 0.001 
1
 absolute number and proportion of women belonging to a specific category who got a sufficient score 
on practice, e.g. out of 65 women aged 10 to 19 years, 35 (53.8%) had a score of ≥4 points 
2
Adjusted OR: odds ratio by multiple logistic regression (variables in the model: age, residence, marital 
status, and occupation) 
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Appendix 
Questionnaire, expected answers, and scoring system 
KNOWLEDGE 
1. Which diseases of the female genital tract do you know? 
 Expected answers:   
- leucorrhoea 
- infections or sexually transmitted diseases 
- cancer of the uterine cervix 
- ovarian cysts 
- uterine tumour or myoma 
- dysmenorrhea 
- galactorrhoea 
 Scoring: 1 point for a description of 1 disease from the list, 2 points for a description of 2 
diseases and 3 for descriptions of 3 diseases from the list 
2. Have you ever heard about cancer of the uterine cervix? 
 Expected answer: yes 
 Scoring: 1 point if yes 
3. How did you hear about it? 
 Expected answers:  
- oral communication 
- newspaper 
- television 
- radio 
- conference 
- medical doctor or at the hospital 
- church 
- school 
- non-governmental organisation 
 Scoring: 1 point if at least one of the listed answers is given 
4. What are the causes of cervical cancer? 
 Expected answers:  
- many sexual partners 
- use of plants for intimate care 
- sexually transmitted diseases 
- HIV infection 
- papilloma virus 
- old age 
 Scoring: 1 point if at least one of the listed answers is given 
5. In your close circle of acquaintances, do you know someone who has had cervical cancer? 
 Expected answer: yes 
 Scoring: 1 point if yes 
6. How can cervical cancer be treated? 
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 Expected answers:  
- surgery 
- chemotherapy 
- radiotherapy 
 Scoring: 1 point if at least one of the listed answers is given 
7. How can cervical cancer be prevented? 
 Expected answers:  
- avoid multiple sexual partners 
- avoid HIV infection 
- use condoms 
- vaccination 
 Scoring: 1 point if at least one of the listed answers is given 
8. Have you ever heard about cervical smears? 
 Expected answer: yes 
 Scoring: 1 point if yes 
9. Do you know that suspect lesions can be detected early? 
 Expected answer: yes 
 Scoring: 1 point if yes 
ATTITUDE 
1. What would you do in case of vaginal bleeding between periods? 
 Expected answers:  
- consult a medical doctor 
- go to a health centre 
 Scoring: 1 point if at least one of the listed answers is given 
2. Are you willing to regularly consult a medical doctor for screening of cervical cancer? 
 Expected answer: yes 
 Scoring: 1 point if yes 
3. Are you willing to get a smear test? 
 Expected answer: yes 
 Scoring: 1 point if yes 
4. Would you want that a screening national program would be made available in the future? 
 Expected answer: yes 
 Scoring: 1 point if yes 
5. Are you willing to pay for a Pap smear test? 
 Expected answer: yes, or a concrete amount  
 Scoring: 1 point if yes or any amount >0 US$ 
PRACTICE 
1. When was your last gynaecological examination? 
 Expected answer: any moment in the past 2 years 
 Scoring: 1 point if less than 2 years ago 
2. Do you use chemicals of plants for your intimate care? 
 Expected answer: no 
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 Scoring: 1 point if no products are used 
3. Do you smoke? 
 Expected answer: no 
 Scoring: 1 point if the participant has never smoked (0 points for current or past smokers) 
4. How many sexual partners have you had in the last year? 
 Expected answer: maximum one 
 Scoring: 1 point if maximum one partner in the last year 
5. Does your partner have a partner beside you? 
 Expected answer: no 
 Scoring: 1 point if no 
6. Have you ever got a Pap smear test? 
 Expected answer: yes 
 Scoring: 1 point if a smear test had been performed in the past 
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Abstract  
Background  
Cancer of the uterine cervix is the leading cause of cancer-related death among women in Sub-
Saharan Africa, but information from the Democratic Republic of the Congo (DRC) is scarce. 
The study objectives were to: 1/ assess prevalence of (pre)cancerous cervical lesions in adult 
women of Kinshasa, 2/ identify associated socio-demographic and behavioural factors and 3/ 
describe human papillomavirus (HPV) types in cervical lesions.  
Methods  
A cross-sectional study was conducted in Kinshasa. Between 2006 and 2013, four groups of 
women were recruited. The first two groups were included at HIV screening centres. Group 1 
consisted of HIV-positive and group 2 of HIV-negative women. Group 3 was included in large 
hospitals and group  4 in primary health centres. Pap smears were studied by monolayer 
technique (Bethesda 2001classification). Low-or high-grade squamous intraepithelial lesions or 
carcinoma were classified as LSIL+. HPV types were determined by INNO-LiPA®. Bivariate 
and multivariable analyses (logistic regression and generalized estimating equations (GEE)) 
were used to assess associations between explanatory variables and LSIL+.  
Results  
LSIL+ lesions were found in 76 out of 1018 participants. The prevalence was 31.3% in group 1 
(n=131 HIV-positive women), 3.9% in group 2 (n=128 HIV-negative women), 3.9% in group 3 
(n=539) and 4.1% in group 4 (n=220). The following variables were included in the GEE 
model but did not reach statistical significance: history of abortion, ≥3 sexual partners and use 
of chemical products for vaginal care. In groups 3 and 4 where this information was available, 
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the use of plants for vaginal care was associated with LSIL+ (adjusted OR 2.70 (95% 
confidence interval 1.04 - 7.01). The most common HPV types among HIV-positive women 
with ASCUS+ cytology (ASCUS or worse) were HPV68 (12 out of 50 samples tested), HPV35 
(12/50) , HPV52 (12/50) and HPV16 (10/50). Among women with negative/unknown HIV 
status, the most common types were HPV52 (10/40), HPV35 (6/40) and HPV18 (5/40).  
Conclusion  
LSIL+ lesions are frequent among women of Kinshasa. The use of plants for vaginal care 
deserves attention as a possible risk factor for LSIL+. In this setting, HPV16 is not the most 
frequent genotype in samples of LSIL+ lesions.  
Keywords: Cervical Intraepithelial Neoplasia – Human Papillomavirus– Risk Factors – Cross-
Sectional Studies – Democratic Republic of the Congo  
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Background  
Cervical cancer constitutes a major health problem worldwide. It is responsible for 530,000 
new cases of cancer and causes 270000 deaths each year [1,2]. Up to 80-85% of cervical 
cancer-related deaths occur in low-income countries [1,3]. In African women, it is the second 
most common cancer after breast cancer with an incidence rate of about 25 per 100,000 women 
per year. In Sub-Saharan Africa the incidence rate amounts to about 30-35, and here it is the 
most frequent cancer in women (for African data see [3-6]). It is expected, even on 
demographic grounds, that the burden of cervical cancer will further increase in Africa over the 
next years [7].  In contrast, in high-income countries such as the US and Europe the age-
standardized incidence rate is about 6 to 10 per 100,000 women per year [1,2]. Also the number 
of deaths from cervical cancer is nearly ten times lower in high-income countries [8,9]. 
Differences between low- and high-income countries have been related to differences in 
exposure to risk factors and adequacy of screening. The most important risk factor is human 
papillomavirus (HPV) infection. Several  other factors have been found to increase the risk of 
cervical cancer, possibly through their relation with the risk of HPV infection: number of 
sexual partners, early sexual activity [10], parity [11], long-term use of oral contraceptives [12-
14], cigarette smoking [15] and HIV/AIDS [16-18].  
The link between cervical cancer and HPV infection has been well established [16,19-22]. 
From the more than 100 types of HPV described, about 40 are known to infect the genital tract 
and about 20 have been classified as oncogenic to humans [23-25]. Persistent infection with 
high-risk HPV has been considered as the necessary condition for malignant transformation of 
the cervical epithelium. In most studies, HPV16 and HPV18 are the predominant genotypes: 
they cause about 70% of precancerous lesions and cervical cancer [26]. In Sub-Saharan Africa 
however, other oncogenic genotypes have been reported [22,27-32].   
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In most Sub-Saharan countries, data on the prevalence and mortality of cervical cancer are 
either sparse or unavailable. Only 17% of African countries have a national programme and a 
specific budget for fighting cervical cancer. And where such a cervical cancer programme 
exists, the effective coverage may be low. In addition, those women at the highest risk of 
developing cervical cancer may have the most difficult access to care[33,34].  The prevalence 
of precancerous and cancerous lesions has been studied in a small number of women in the 
Democratic Republic of  the Congo (DRC) [35-40]. Some of these reports include the 
prevalence of HPV and/or cervical lesions in HIV-positive women  [35,40].  
Because of the importance of cervical cancer as a major health problem of women in Sub-
Saharan Africa, and presumably also in the DRC, the primary objectives of this study were to 
evaluate the prevalence of (pre)cancerous lesions, to identify associated socio-demographic and 
behavioural factors and to describe HPV types present among women of Kinshasa. 
Results  
Characteristics of study participants  
The total number of participants was 1018. One hundred thirty-one HIV-positive women were 
recruited at HIV screening centres (group 1); 128 HIV-negative women came from the same 
HIV screening centres (group 2); 539 women were recruited at large hospitals (group 3); and 
220 were referred through small health centres (group 4). The HIV status of the women of 
groups 3 and 4 was unknown. 
Table 1 shows the age and age-related characteristics of the participants. The mean age for all 
participants was 43.0 years (±12.8 standard deviation (SD). The mean age of menarche was 
14.3 years (±1.9) and the age of the first sexual intercourse was 18.5 years (±3.9).  Table 2 
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summarizes the socio-demographical characteristics of the study population. About half of the 
women were married, with the highest percentage in group 3 (61.2%) and the lowest in group 2 
(20.3%). About 1 in 5 women was widowed (18.0%), and 1 in 4 was single. Concerning 
pregnancies and parity, 44.0% of the women reported six or more pregnancies, 29.8% 
responded to have six or more children and 60.7% reported to have had an abortion (not 
specified whether spontaneously or not).  
Behaviour-related characteristics of the study population are shown in table 3. About half of the 
participants reported to have had zero to two lifetime sexual partners. In groups 1 and 2 
(recruited at HIV screening centres), more women reported to have had three or more sexual 
partners (65.4% and 61.2% respectively). One out of five women declared to have used 
hormonal contraceptives (19.2%); no information is available on the duration of its use. One 
out of four women reported alcohol consumption, including regular as well as irregular use. 
About the same percentage (26.0%) reported to use chemical products for vaginal care. The 
women in groups 3 and 4 were also asked about the use of plants for vaginal care: 11.4% of the 
women confirmed  the intravaginal application of plants or vegetable products. Although the 
structured interview did not include specific questions about the type of plants that were used, 
some interviewers took note of what some of the women reported. Terms that were mentioned 
repeatedly in the local language Lingala included: mbonzimbonzi (leaves of a tree), tangawisi 
(ginger), tomatu (tomato), lumbalumba (medicinal leaves), ngaingai (sorrel).   
Prevalence of  low-grade squamous intraepithelial lesions or worse (LSIL+)  
In total, 76 of 1018 women were diagnosed with LSIL+ lesions (i.e. low- or high-grade 
squamous intraepithelial lesions (LSIL or HSIL) or invasive cancer, table 4). Among the HIV-
positive women of group 1, the prevalence of LSIL+ was 31.3% (95% confidence interval (CI): 
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24.0% - 39.7%). Among the HIV-negative women recruited at the same clinics (group 2), the 
LSIL+ prevalence was 3.9% (95% CI: 1.7% - 8.8%). Among the participants coming from the 
large hospitals (group 3), the prevalence was 3.9% (95%  CI: 2.6% - 5.9%) and among the 
women coming via smaller health centres (group 4),  4.1% (95% CI: 2.2% - 7.6%) . Among the 
women with unknown or negative HIV status, lesions classified as ASCUS or ASC-H (atypical 
squamous cells of undetermined significance  or atypical squamous cells; cannot rule out high-
grade lesion) were more frequent than LSIL+ lesions (table 4).  
Socio-demographic factors and behaviour characteristics associated with LSIL+ lesions  
In each of the four groups, bivariate associations were assessed between all explanatory factors 
(age, socio-demographic and behaviour-related characteristics) and the presence of LSIL+ 
lesions. Crude odds ratios (ORs) are given in table 5. Explanatory factors with a P-value of 
<0.2 were included in a model of multiple logistic regression (one model per study group). The 
adjusted ORs are given in table 6. None of these associations reached statistical significance on 
multiple logistic regression.  
All participants were then analysed together using generalized estimating equations (GEE) to 
account for clustering within the study groups. Also in the GEE analysis, all factors with a P-
value <0.2 on bivariate evaluation were included in a multivariable model. The final GEE 
model (one model for all the study groups) included history of abortion (adjusted OR 1.60; 
95% CI 0.97 – 2.63), more than three sexual partners (adjusted OR 1.29; 95% CI 0.83 – 1.99) 
and use of chemical products for vaginal care (adjusted OR 0.65; 95% CI 0.37 – 1.14). Adding 
age to the model did not substantially change the ORs. None of the associations in this model 
reached statistical significance (table 6).  
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The use of plants for vaginal care could only be evaluated in groups 3 and 4 because this 
information was not available for the women of the other groups. In a multiple logistic 
regression model including the use of plants, alcohol consumption and having had more than 
three sexual partners, the adjusted OR for the association between the use of plants for vaginal 
care and the presence of LSIL+ lesions was 2.70 (95% CI 1.04 - 7.01; table 6). 
Determination of HPV DNA and HPV typing 
The following cytology results were classified as ASCUS+ and the corresponding samples 
were submitted for HPV typing: atypical squamous cells of undetermined significance 
(ASCUS); atypical squamous cells; cannot rule out high-grade lesion (ASC-H); LSIL; HSIL or 
carcinoma. In the HIV-positive group, 50 out of the 52 ASCUS+ samples contained HPV 
DNA. HPV16 was found in 10 out of 50 samples, and HPV18 in 5 (table 7). Other genotypes 
that were frequently detected were HPV35 (n=12), HPV52 (n=12), HPV68 (n=12), HPV51 
(n=10), and HPV31 (n=9). In the groups  of women with negative or unknown HIV status, 50 
samples were tested with INNO-LiPA out of which 40 contained detectable HPV DNA (table 
7). Here, the most frequently detected genotype was HPV52 (n=10), HPV35 (n=6), HPV16 
(n=3), HPV18 (n=5), HPV51(n=5), and HPV54 (n=5).  In addition to the three samples in 
which HPV16 was detected through the INNO-LiPA test, there were three samples in which 
both the Abbot Real Time and the GenoID test indicated the presence of HPV16. 
In  groups 2, 3 and 4, 55% of samples which tested positive for HPV DNA contained one single 
HPV type.  Two genotypes were found in 23% of the samples, three genotypes in 9%, four in 
7% and more than four in 7% of HPV-DNA positive samples. In the HIV-positive group (group 
1), a single HPV infection occurred only in 20.0% of the samples. Two genotypes were found 
in 38%, three in 9%, four in 16% and more than four in 18% of the samples. 
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Discussion  
The present study was performed to assess the prevalence of LSIL+ lesions and to identify 
associated factors in different groups of women of Kinshasa.. The prevalence of LSIL+ lesions 
ranged from approximately 4% in women with unknown or negative HIV status to 31% in 
HIV-positive women. We found an association between the practice of intravaginal insertion of 
plants and the presence of LSIL+. HPV types 16 and 18 which are known to cause cervical 
cancer in many countries worldwide appear to be less predominant in women of Kinshasa.  
The prevalence of LSIL+ lesions that we found in the current study in women with unknown or 
seronegative HIV status (4%) is consistent with the few studies previously performed in 
Kinshasa (3% and 5%) [35,36] and in Bukavu in the eastern part of the country (7%) [37]. 
Numbers of the same order of magnitude  have been published in other Sub-Saharan countries. 
A prevalence between 4 and 10% was found in studies in Burkina-Faso, Nigeria, Tanzania, 
South Africa, Malawi and Kenya [29, 41-44,46, 47, 49-51]. Higher prevalences (16%) were 
reported in studies in the Central African Republic and Uganda [45,48]. These reports and our 
findings highlight the high and heterogeneous frequency of (pre)cancerous lesions in different 
countries of Sub-Saharan Africa. Furthermore, in our study, lesions classified as ASCUS and 
ASC-H were also frequent (more frequent than LISL+) among women with negative or 
unknown HIV status.  
Cervical cancer is known to be more frequent among HIV-positive women. In the DRC, it is 
estimated that 1.9% of the adult women are HIV infected, with differences between women 
living in urban areas (2.4%) and rural areas (1.0%) [52]. We found a prevalence of LSIL+ 
lesions of  31% in HIV-seropositive women. This finding is consistent with  an earlier result 
(27%) described in a small group of seropositive women in Kinshasa [35]. Also in other Sub-
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Saharan countries (pre)cancerous lesions were about five times more frequent in HIV-positive 
than in HIV-negative women [41,42,45,46,48,50,51,53].  
Several demographic, economical and behavioural risk factors have been studied in relation to 
cervical cancer. Most of them may influence the risk of cancer through their effects on the risk 
of HIV and HPV infection. In the current study, we found a significant association between the 
intravaginal application of plant products and the presence of LSIL+ lesions. It is a frequent 
practice in Sub-Saharan Africa to use herbs, leaves and bark of trees to reduce vaginal 
lubrication and increase friction during sexual intercourse (dry sex) [54-59]. The perception is 
that dry sex increases sexual enjoyment. A study in the DRC revealed that one third of the 
women had used intra-vaginal substances at some time [55]. Another Congolese study looked 
into how specific plants are used and what the chemical and microbiological consequence of 
this traditional practice could be [60].  
Most of the studies about the vaginal use of plants have been done in relation to the risk of HIV 
infection. It has been hypothesized that differences in the vaginal environment may partially 
explain the different HIV transmission probabilities that are observed across populations [61]. 
Similar mechanisms may play a role in transmission and clearance of HPV [62-64]. The 
insertion of plant products and the increased friction during dry sex may alter the vaginal 
microbiota and cause traumatic microlesions in the vaginal wall facilitating the entry of HPV 
[62-64].   
The association between HPV infection and cervical cancer is well established,  but the specific 
HPV genotypes that are involved in neoplasia differ across populations..  The HPV types that 
have been most frequently linked to cervical cancer are: 16, 18, 31, 33, 45, 52 and 58  [53,65]. 
HPV16 and 18 are responsible for 70% of precancerous lesions and cervical cancer worldwide 
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and consequently, these are the HPV types on which the vaccine development has focused. 
Nevertheless, our study suggests that HPV16 and 18 are less frequent (maximally 30% of 
women with ASCUS+) and that HPV types 35,52 and 68 are more predominant than in other 
regions. Other studies in the DRC have also described specific patterns of HPV types [38,40].   
In other Sub-Saharan countries, the frequency of HPV16 and 18 varies. Some countries have 
reported patterns that resemble the situation in Europe and the United States with a high 
prevalence for HPV16 and HPV18 [22,50,66,67], whereas in other countries HPV16 and 
HPV18 appear to be less prominent [29,49,68,69].  
The DRC is a large country that is facing many complex problems at the same time. As a 
consequence, cervical cancer is not getting the attention that would be required for adequate 
disease control. Yet, the burden caused by cervical cancer in the DRC would justify a 
coordinated control strategy. This study together with a previous report illustrate that women of 
Kinshasa are willing to participate in prevention and control activities [70]. Interventions that 
could help to reduce the morbidity and mortality of cervical cancer include vaccination for 
HPV, systematic screening and early treatment. The effectiveness of such interventions may 
benefit from further research into the epidemiology of oncogenic HPV types and modifiable 
risk factors such as the use of plants for intimate care.   
Conclusion  
Our work illustrates that the prevalence of (pre)cancerous lesions in women from different 
districts in Kinshasa is approximately 4%. In HIV-positive women, the prevalence is about 8 
times higher. Traditional practices concerning vaginal hygiene may increase the risk of 
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malignant transformation. More extensive studies, including rural areas, are needed to unravel 
the contribution of different HPV types in the development of cervical cancer.  
Methods   
Study design, setting and participants  
We performed a cross-sectional study on the prevalence of precancerous and cancerous lesions 
of the uterine cervix  in four groups of women of Kinshasa. The first two groups consisted of 
women who participated in a voluntary screening programme for HIV in the ACS/AMO-
CONGO centre (Action Communautaire contre le Sida/Avenir Meilleur pour les Orphelins du 
Sida au Congo) and in the Centre Hospitalier Monkole 3. Women who visited these centres for 
HIV screening and care between September 2006 and January 2007 were invited to participate 
in free cervical cancer screening. The first group (n=131) consisted of women who were found 
to be seropositive for HIV; the second group (n= 128) consisted of HIV-seronegative women. 
The diagnosis of HIV was based on two rapid tests (Determine
®
HIV-1/2 (Abbott) and 
OraQuick
®
HIV-1/2 (OraSure Technologies)) combined with one of the following serological 
tests: Vironostika
®
 Uni-Form II Plus O (BioMérieux), Enzygnost
®
 Anti-HIV ½ Plus (Siemens), 
or Inno-Lia HIVI/II Score (Inno-LIA
®
, Innogenetics). The third group (n= 539) consisted of 
women who consulted the gynaecology department of the Provincial Reference Hospital of 
Kinshasa (Hôpital Provincial Général de Référence de Kinshasa, HPGRK) and the Ngaliema 
hospital. Both hospitals are state hospitals, are situated in the centre of the city, and are among 
the largest hospitals of the capital. Data were collected from July to August 2009. At that time, 
there was a sensitization campaign for free cervical screening on television, there were posters 
advertising cervical cancer screening at the hospitals and there was as symposium on cervical 
cancer at the HPGRK. The participants of the fourth group (n= 220) were recruited via primary 
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health care centres in the communities of Kimbanseke, Kisenso, Ndjili and Lemba, located in 
the poorer suburbs of the city. Data were collected from September 2012 to January 2013 after 
a campaign in local churches for free cervical cancer screening.  
All women of more than 17 years of age who were willing to participate in the study and for 
whom a liquid-based cytology (LBC) result was available were included in the analysis.  
Variables, data sources and measurement 
Cytology  
Cytology was the main outcome variable. Cervical smears were collected with Cervex Brush 
and conserved in ThinPrep solution for LBC and HPV typing. Samples were kept at 4°C. 
ThinPrep vials were transferred to the Pathology Laboratory of the University Hospital of 
Ghent, Belgium, for further analysis. The collected smears were independently read and 
interpreted by two pathologists. The pathologists were not aware of the HIV and HPV status at 
the time of reading the slides. In case of discrepancy, the slides were reread by both for a final 
interpretation. The cytology results were reported according to the Bethesda Classification 
2001 of cervical pathology. Women with cytology results indicating LSIL (low-grade 
squamous intraepithelial lesion), HSIL (high-grade squamous intraepithelial lesion) and 
invasive carcinoma were considered to have precancerous or cancerous lesions and classified as 
LSIL+ (according to [71]). Women with ASCUS (atypical squamous of undetermined 
significance),ASC-H (atypical squamous-cannot exclude HSIL) results or worse (ASCUS+) 
underwent HPV-DNA determination. Women with  NILM (negative for intraepithelial lesion 
of malignancy) or inflammation were considered to be free of cancer.  
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Determination of HPV DNA and HPV typing 
HPV  typing was done in participants with ASCUS+ cytology results. Samples from women 
with ASCUS and ASCUS-high were included in the HPV evaluation because the European 
guidelines recommend to determine HPV DNA in these groups. INNO-LiPA HPV Genotyping 
Extra (Innogenetics, Zwijnaarde, Belgium) was used for HPV typing. It is molecular technique 
based on the principle of reverse hybridization designed to recognize 15 high-risk HPV types 
(16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 and 82), 3 probable high-risk HPV types 
(26, 53 and 66), 7 low-risk HPV types (6, 11, 40, 43, 44, 54 and 70) and 3 non-classified HPV 
types (69, 71 and 74).) The testing strategies varied across the study groups. In groups 1 and 2, 
INNO-LiPA Genotyping was done for all ASCUS+ cases. In groups 3 and 4, due to the high 
cost of the INNO-LiPA test, it was only done if two other tests gave discordant results (Abbott 
Real Time High Risk HPV test (Abbott, Madison, USA) and Full Spectrum PCR HPV 
Amplification and Detection/Genotyping System (GenoID Molecular Diagnostics Laboratory, 
Budapest, Hungary)). We present all available INNO-LiPA results because this test detects 
many different HPV types [72]. Concordant Abbott and GenoID results for HPV16 and HPV18 
are also reported.    
 Socio-economic, gynaecological/medical and behaviour variables  
Socio-economic and behaviour characteristics that were studied in association with the 
presence or absence of LSIL+ were: age, age of menarche, age of first sexual contact, marital 
status, formal employment, life-time number of sexual partners, use of products for vaginal 
care (chemicals and products from plants), alcohol consumption (no alcohol versus any 
consumption), number of pregnancies, number of childbirths, and history of abortion (without 
discrimination between spontaneous or provoked). Concerning the practice of intravaginal 
application of plants, information was only available for groups 3 and 4.  
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The variables “age”, “age of menarche” and “age of first sexual contact” follow a relatively 
normal distribution and are presented and analysed as continuous variables. The variables 
“number of sexual partners”, “number of pregnancies” and “number of deliveries” follow a 
clearly abnormal distribution and are presented and analysed as categorical variables. 
Information about the socio-economic situation and behaviour characteristics was obtained 
through a structured interview by medical doctors. Interviewers were trained during a training 
session before the start of the study.  
Statistical analysis  
The prevalence of LSIL+ lesions with 95% confidence intervals (95% CI, Wilson score method 
without continuity correction) is reported for each of the four groups. Next, we used bivariate 
and multiple logistic regression to assess the association between socio-demographic and 
behaviour variables and the presence of LSIL+ lesions within each of the four groups. Finally, 
we analysed all participants together using generalized estimating equations (GEE) to account 
for clustering within the groups.  The results of all logistic regression and GEE analyses are 
reported as odds ratios (OR) with 95% confidence intervals (95% CI). Data was missing for 
some participants in some of the explanatory variables; for each of the analyses, the number of 
included participants is given. We used Stata/IC 10.1 for data analysis.  
Ethical considerations  
The study protocol on the collection of data and the reporting of data to participants was 
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118 
 
Competing interests 
The authors declare that they have no competing interests. 
Authors’ contributions 
CAR: is the main investigator and participated in the design of the study, data collection and 
interpretation, analysis and writing.  
KV: participated in the statistical analysis, drafting and revision of the manuscript.  
EP: participated in data collection and interpretation, and in revision of the manuscript.  
DVB: participated in data analysis and interpretation and critically revised the manuscript.  
MP: helped in the design and the interpretation and gave final approval of the version to be 
published.  
All authors read and approved the final manuscript.  
 
Acknowledgements  
Our thanks go to Belgian Cooperation for Development, the Flemish Interuniversity Council 
for Development Cooperation, and the Alumni Association of the Faculty of Medicine of the 
University of Leuven for scholarships for C. Ali-Risasi.  
119 
 
References 
1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide 
burden of cancer in 2008:GLOBOCAN 2008. Int J Cancer 2010;127:2893-917. 
2. Arbyn M, Castellsague X, De Sanjose S, Bruni L, Saraiya M, Bray F, et al. Worldwide 
burden of cervical cancer in 2008. Ann Oncol 2011;22:2675-86. 
3. Jemal A, Bray F, Forman D, O'Brien M, Ferlay J, Center M, et al. Cancer burden in 
Africa and opportunities for prevention. Cancer 2012;118:4372-84. 
4. Parkin DM, Sitas F, Chrirenje M, Stein L, Abratt R, Wabinga H. Part I: Cancer in 
Indigenous Africans-burden, distribution, and trends. Lancet Oncol 2008;9:683-92. 
5. Louie KS, de Sanjose S, Mayaud P. Epidemiology and prevention of human 
papillomavirus and cervical cancer in sub-Saharan Africa: a comprehensive review. Trop 
Med Int Health 2009;14:1287-1302. 
6. Denny L. Cervical cancer treatment in Africa. Curr Opin Oncol 2011;23:469-74. 
7. Sylla BS, Wild CP. A million africans a year dying from cancer by 2030: what can cancer 
research and control offer to the continent? Int J Cancer 2012;130:245-50. 
8. Peto J, Gilham C, Fletcher O, Mattews FE. The cervical cancer epidemic that screening 
has prevented in the UK. Lancet 2004;364:249-56. 
9. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the 
Human Development Index (2008-2030): a population-based study. Lancet Oncol 
2012;13:790-80 
10. Plummer M, Peto J, Franceschi S, the International Collaboration of Epidemiological 
Studies of Cervical Cancer. Time since first sexual intercourse and the risk of cervical 
cancer. Int J Cancer 2012;130:2638-44. 
120 
 
11. Franceschi S, Herrero R, Clifford GM, Snijders PJ, Arslan A, Anh PT, et al. Variations in 
the age-specific curves of human papillomavirus prevalence in women worldwide. Int J 
Cancer 2006;119:2677-84. 
12. Kjellberg L, Hallmans G, Ahren, AM, Johansson R, Bergman F, Wadell G, et al. 
Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intra-
epithelial neoplasia in relation to human papillomavirus infection. Br J Cancer 2000; 
82:1332-38. 
13. Castellsague X, Munoz N. Cofactors in human papillomavirus carcinogenesis--role of 
parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr 2003;31:20-
8. 
14. Applebey P, Beral V, Berrington de Gonzalez A, Colin D, Franceschi S,  Goodhill A, et 
al. Cervical cancer and hormonal contraceptives:collaborative reanalysis of individual 
data for 16, 573 women with cervical cancer and 35, 509 women without cervical cancer 
from 24 epidemiological studies. Lancet 2007;370:1609-21. 
15. Applebey P, Beral V, Berrington de Gonzalez A, Colin D, Franceschi S, Goodhill A, et al. 
Carcinoma of the cervix and tobacco smoking:collaborative reanalysis of individual data 
on 13, 541 women with carcinoma of the cervix and 23, 017 women without carcinoma of 
the cervix from 23 epidemiological studies. Int J  Cancer 2007;118:1481-95. 
16. Denny LA, Franceschi S, De Sanjose S, Heard I, Moscicki AB, Palefsky J. Human 
papillomavirus, human immunodeficiency virus and immunosuppression. Vaccine 2012; 
30 Suppl 5:168-74. 
17. De Vuyst H, Mugo NR, Chung MH, Mckenzie KP, Nyongesa-malava E, Tenet V, et al. 
Prevalence and determinants of human papillomavirus infection and cervical lesions in 
HIV-positive women in Kenya. Br J Cancer 2012;107:1624-30. 
121 
 
18. De Vuyst H, Ndirangu G, Moodley M, Tenet V, Estambale B, Meijer CJ, et al. Prevalence 
of human papillomavirus in women with invasive cervical carcinoma by HIV status in 
Kenya and South Africa. Int J Cancer 2012;131:949-55. 
19. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. 
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J 
Pathol 1999;189:12-19. 
20. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human 
papillomavirus and cervical cancer. Lancet 2007;370:890-907. 
21. Bosch FX , Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between 
human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-65. 
22. Denny L, Adewole I, Anorlu R, Dreyer G, Moodley M, Smith T, et al. Human 
papillomavirus prevalence and type distribution in invasive cervical cancer in sub-Saharan 
Africa. Int J Cancer 2014;134:1389-98. 
23. Munoz N, Bosch FX, De Sanjose S, Herrero R, Castellsague X, Shah KV, et al. IARC 
Multicenter Cervical Cancer Study Group: Epidemiologic classification of human 
papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27. 
24. Munoz N, Castellsague X, De Gonzalez AB, Gissmann L. HPV in the etiology of human 
cancer. Vaccine, 2006;24 Suppl 3:1-10. 
25. Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human papillomavirus and 
cervical cancer. Lancet 2013;382:889-99. 
26. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F. WHO IARC 
Monograph Working Group: A review of human carcinogens-Part B: biological agents. 
Lancet Oncol 2009;10:321-22. 
122 
 
27. Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, De Sanjose S. Cervical human 
papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal 
cytological findings. J Infect Dis 2010;202:1789-99. 
28. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier  JE, Lloveras, B, et al. 
Human papillomavirus genotype attribution in invasive cervical cancer:a retrospective 
cross-sectional worldwide study. Lancet Oncol 2010;11:1048-56. 
29. De Vuyst  H, Parisi MR, Karani A, Mandaliya K, Muchiri L, Vaccarella S. The 
prevalence of human papillomavirus infection in Mombasa, Kenya. Cancer Causes & 
Control  2010;21:2309-13. 
30. Ndiaye C, Alemany L, Ndiaye N, Kamate B, Diop Y, Odida M, et al. Human 
papillomavirus distribution in invasive cervical carcinoma in sub-Saharan Africa:could 
HIV explain the differences? Trop Med Int Health 2012;17:1432-40. 
31. El-Khatib Z, Tota JE,  Kaufmann AM. Progress on human papillomavirus (HPV) 
infection and cervical cancer prevention in sub-Saharan Africa: highlights of the 27th 
International Papillomavirus Conference in Berlin. J Epidemiol Glob Health 2012;2:99-
102. 
32. Maranga IO, Hampson L, Oliver AW, He X, Gichangi P, Rana F, et al. HIV Infection 
Alters the Spectrum of HPV Subtypes Found in Cervical Smears and Carcinomas from 
Kenyan Women. Open Virol J 2013;7:19-27. 
33. Gakidou E, Nordhagen S, Obermeyer Z. Coverage of cervical cancer screening in 57 
countries:low average levels and large inequalities. PLoS Med 2008;5:e132. 
34. Anorlu RI. Cervical cancer:the Sub-Saharan African perspective. Reprod Health Matters 
2008;16:41-9. 
123 
 
35. Laga M, Icenogle JP, Marsella R, Manoka  AT, Nzila N, Ryder RW, et al. Genital 
papillomavirus infection and cervical dysplasia-opportunistic complications of HIV 
infection. Int J Cancer1992;50:45-8. 
36. Sangwa-Lugoma G, Mahmud S, Nasr SH, Liaras J, Kayembe PK, Tozin RR, et al. Visual 
inspection as a cervical cancer screening method in a primary health care setting in Africa. 
Int J Cancer 2006;119:1389-95. 
37. Hovland S, Arbyn M, Lie AK, Ryd W, Borge B, Berle EJ, et al. A comprehensive 
evaluation of the accuracy of cervical pre-cancer detection methods in a high-risk area in 
East Congo. Br J Cancer 2010;102:957-65. 
38. Sangwa-Lugoma, G, Ramanakumar AV, Mahmud S, Liaras J, Kayembe PK, Tozin RR, et 
al. Prevalence and determinants of high-risk human papillomavirus infection in women 
from a sub-Saharan African community. Sex Transm Dis 2011;38:308-15. 
39. Mahmud S, Sangwa-Lugoma G, Nasr SH, Kayembe PK, Tozin RR, Drouin P, et al. 
Comparison of human papillomavirus testing and cytology for cervical cancer screening 
in a primary health care setting in the Democratic Republic of the Congo. Gynecol Oncol 
2012;124:286-91. 
40. Icenogle JP, Laga, M, Miller D, Manoka AT, Tucker RA, Reeves W. Genotypes and 
sequence variants of human papillomavirus DNAs from human immunodeficiency virus 
type 1-infected women with cervical intraepithelial neoplasia. J Inf Dis 1992;166:1210-
16. 
41. Anorlu RI, Igwilo CI, Aknamu AS, Banjo AA, Odunukwe NN, Okany CC, et al. 
Prevalence of abnormal cervical smears among patients with HIV in Lagos, Nigeria. West 
Afr J Med 2007;26:143-47. 
124 
 
42. Dim CC, Ezegwui HU, Ikeme AC, Nwagha UI, Onyedum CC. Prevalence of cervical 
squamous intraepithelial lesions among HIV-positive women in Enugu, South-eastern 
Nigeria. J Obstet Gynaecol 2011;31:759-62.  
43. Durowade KA, Osagbemi GK, Salaudeen AG, Musa OI, Akande TM, Babatunde OA. 
Prevalence and risk factors of cervical cancer among women in an urban community of 
Kwara State, north central Nigeria. J Prev Med Hyg 2012;53:213-19. 
44. Pimentel VM, Jiang X, Mandavilli S, Umenyinwana C, Schnatz PF. Prevalence of high-
risk cervical human papillomavirus and squamous intraepithelial lesion in Nigeria. J  Low 
Genit Tract Dis 2013;17:203-9. 
45.  Koffi B, Serdouma E, Mbolissa-Nguérékoudou W, Ngadjou-Kouchou-Fondjo M, 
Pengoussou-Gbatoumba V, Pengoussou-Gbatoumba V. Cervical dysplasia in women with 
human immunodeficiency virus (HIV) in areas of high prevalence of infection. Gynecol 
Obstet Fertil 2010;38:576-80. 
46. Obure J, Olala O, Swai B, Mlay P, Masenga G, Walmer D. Prevalence and severity of 
cervical squamous intraepithelial lesion in a tertiary hospital in northern Tanzania. 
Tanzania J Health Res 2009;11:163-69. 
47. Fonn S, Bloch B, Mabina M, Carpenter S, Cronje H, Maise C, et al. Prevalence of pre-
cancerous lesions and cervical cancer in South Africa--a multicentre study. S Afr Med J 
2002;92:148-56. 
48. Blossom DB, Beigi RH, Farrell JJ, Mackay W, Qadadri B, Brown DR, et al. Human 
papillomavirus genotypes associated with cervical cytologic abnormalities and HIV 
infection in Ugandan women. J Med Virol 2007;79:758-65. 
49. Didelot-Rousseau MN, Nagot N, Costes-Martineau V, Valles X, Ouedraogo A, Konate I, 
et al. Human papillomavirus genotype distribution and cervical squamous intraepithelial 
125 
 
lesions among high-risk women with and without HIV-1 infection in Burkina Faso. Br J  
Cancer 2006;95:355-62. 
50. Motti PG, Dallabetta GA, Daniel RW, Canner JK, Chiphangwi JD, Liomba GN, et al. 
Cervical abnormalities, human papillomavirus, and human immunodeficiency virus 
infections in women in Malawi. J Infect Dis 1996;173:714-17. 
51. Luchters S, Vanden Broeck D, Chesich MF, Nel A, Delva W, Mandaliya K,  et al. 
Association of HIV infection with distribution and viral load of HPV types in Kenya:a 
survey with 820 female sex workers. BMC Infect Dis 2010;10:18.  
52. USAID/GLOBAL HEALTH. HIV Prevalence Results from the Democratic Republic of 
Congo 2007. http://dhsprogram.com/pubs/pdf/HF25/HF25.pdf. Accessed 22 May 2015. 
53. Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in 
high-grade cervical lesions and cervical cancer:a meta-analysis. Br J Cancer 2003:101-5. 
54. Hilber MA, Hull TH, Preston-Whyte E, Bagnol B, Smit J, Wacharasin C. A cross 
sectional study of vaginal practices and sexuality:implications for sexual health. Social 
Science & Medicine 2010;70:392 – 400. 
55. Brown JE, Ayowa OB, Brown RC. Dry and tight: sexual practices and potential AIDS 
risk in Zaire. Social Science & Medicine 1982;37:989-94. 
56. Civic D and Wilson D. Dry sex in Zimbabwe and implications for condom use. Social 
Science & Medicine 1982;42:91-8. 
57. Beksinska ME, Rees HV, Kleinschmidt I, McIntyre J. The practice and prevalence of dry 
sex among men and women in South Africa:a risk factor for sexually transmitted 
infections? Sex Transm Infect 1999;75:178-80. 
58. Myer L, Denny L, De Souza M, Wrigth TC Jr, Kuhn L. Distinguishing the temporal 
association between women's intravaginal practices and risk of human immunodeficiency 
126 
 
virus infection: a prospective study of South African women. Am J Epidemiol 
2006;163:552-60.  
59. Scorgie F, Kunene B, Smit JA, Manzini N, Chersich MF, Preston-Whyte EM: In search of 
sexual pleasure and fidelity: vaginal practices in KwaZulu-Natal, South Africa. Cult Health Sex 
2009;11:267-83. 
60. Kabena Ngandu O, Luyeye Lukoki F, Mpiana TP, Ngombe KN, Ruphin PF, Robijaona B, 
et al. Pytochemical screening of some medicinal plants traditionally used by African 
women in Kinshasa city (DR Congo for their intimate hygiene and evaluation of the pH of 
derived recipes. J Modern Drug Discovery & Drug Delivery Res 2014;1:1–7. 
61. Buvé A, Jespers V, Crucitti T, Fichorova RN. The vaginal microbiota and susceptibility to 
HIV. AIDS 2014;28:2333–44. 
62. Gillet E, Meys JF, Verstraelen H, Bosire C, De Sutter P, Temmerman M. Bacterial 
vaginosis is associated with uterine cervical human papillomavirus infection:a meta-
analysis. BMC Inf Dis 2011;11:10 
63. King CC, Jamieson DJ, Wiener J, Cu-Uvin S, Klein RS, Rompalo AM. Bacterial 
vaginosis and the natural history of human papillomavirus. Infect Dis Obstet Gyncecol 
2011; 2011:319460. 
64. Gillet E, Meys JF, Verstraelen H, Verhelst R, De Sutter P, Temmerman M. Association 
between bacterial vaginosis and cervical intraepithelial neoplasia:systematic review and 
meta-analysis. PloS One 2012;7:e45201. 
65. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus 
types in invasive cervical cancer worldwide:a meta-analysis. Br Cancer 2003;88:63-73. 
66. Carrilho C, Cirnes L, Alberto M, Buane L, Mendes N, David L. Distribution of HPV 
infection and tumour markers in cervical intraepithelial neoplasia from cone biopsies of 
Mozambican women. J Clin Pathol 2005;58:61-8. 
127 
 
67. Dartell M, Rasch V, Munk C, Kahesa C, Mwaiselage J, Iftner T, et al. Risk Factors for 
High-Risk Human Papillomavirus Detection among HIV-Negative and HIV-Positive 
Women from Tanzania. Sex Transm Dis 2013;40:737-43. 
68. Luque AE, Hitti J, Mwachari C, Lane C, Messing S, Cohn SE. Prevalence of human 
papillomavirus genotypes in HIV-1-infected women in Seattle, USA and Nairobi, Kenya: 
results from the Women's HIV Interdisciplinary Network (WHIN). Int J  Infect Dis 2010; 
14:e810-4. 
69. Veldhuijzen NJ, Braunstein SL, Vyankandondera J, Ingabire C, Ntirushwa J, Kestelyn E, 
et al. The epidemiology of human papillomavirus infection in HIV-positive and HIV-
negative high-risk women in Kigali, Rwanda. BMC Infect Dis 2011;11:333. 
70. Ali-Risasi C, Mulumba P, Verdonck K, Vanden Broeck D, Praet M. Knowledge, attitude 
and practice about cancer of the uterine cervix among women living in Kinshasa, the 
Democratic Republic of the Congo. BMC Women’s Health 2014;14:30. 
71. Wright TC, Ronnett BM, Kurman RJ, Ferenczy A. (Pre)cancerous lesions of the cervix. In 
Kurman RJ, Ellenson HL, Ronnett BM, editors. Blaustein’s Pathology of the Female 
Genital Tract:Springer; 2011. p 193-252. 
72. Padalko E, Ali-Risasi C, Mesmaekers S, Ryckaert I, Van Renterghem L, Lambein K, et al. 
Comparative analysis of cervical cytology and HPV genotyping by three different 
methods in routine diagnostic setting. Eur J Cancer Prevention, 2014 November 3 (Epub ahead of  
 
128 
 
Table 1.  Age-related characteristics of the study population 
 Group 1 (n = 131) 
HIV screening centres 
HIV-positive women 
Group 2 (n = 128) 
HIV screening centres 
HIV-negative women 
Group 3 (n = 539) 
Hospitals 
HIV status unknown 
Group 4 (n = 220) 
Health centres 
HIV status unknown 
Total 
(n = 1018) 
Age      
   mean (years) ± SD 38.8 ± 9.1 29.4 ± 7.9 45.2 ± 11.0 48.0 ± 14.8  43.0 ± 12.8 
   range (years) 20 – 59 17 - 51 20 – 76 20 – 82  17 - 82 
   n with available data 131 128 537 216 1012 
Age of menarche      
   mean (years) ± SD 15.0 ± 1.9 14.5 ± 1.5 14.2 ± 1.9 14.5 ± 2.0  14.3 ± 1.9 
   range (years) 11 – 20 12- 17 10 – 21 10 - 20  10 - 21 
   n with available data 50 26 502 208 786 
Age of first sexual intercourse      
   mean (years) ± SD 17.2 ± 2.5  18.0  ± 3.2  18.8 ± 3.9  19.1 ± 4.5  18.5 ± 3.9  
   range (years) 12 – 25  12 – 32  10 – 36  12 – 32 10 – 36 
   n with available data 127 125 523 207 982 
n: number of participants with available data in each group; SD: standard deviation 
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Table 2. Socio-demographic characteristics of the study population 
 Group 1 (n = 131) 
HIV screening centres 
HIV-positive women 
Group 2 (n = 128) 
HIV screening centres 
HIV-negative women 
Group 3 (n = 539) 
Hospitals 
HIV status unknown 
Group 4 (n = 220) 
Health centres 
HIV status unknown 
Total 
(n = 1018) 
 n % n % n % n % n % 
Marital status 130  128  533  217  1008  
  married 43 (33.1) 26 (20.3) 326 (61.2) 120 (55.3) 515 (51.1) 
  single 39 (30.0) 95 (74.2) 76 (14.3) 33 (15.2) 243 (24.1) 
  widowed 34 (26.2) 4 (3.1) 92 (17.3) 51 (23.5) 181 (18.0) 
  divorced 14 (10.8) 3 (2.3) 39 (7.3) 13 (6.0) 69 (6.9) 
Formal employment 129  126  525  215  995  
  no 73 (56.6) 67 (53.2) 225 (42.9) 109 (50.7) 474 (47.6) 
  yes 56 (43.4) 59 (46.8) 300 (51.7) 106 (49.3) 521 (52.4) 
Number of pregnancies 128  126  517  219  990  
  0-2 29 (22.7) 87 (69.1) 131 (25.3) 53 (24.2) 300 (30.3) 
  3-5 42 (32.8) 28 (22.2) 124 (24.0) 60 (27.4) 254 (25.7) 
  6 or more 57 (44.5) 11 (8.7) 262 (50.7) 106 (48.4) 436 (44.0) 
Number of childbirths 128  126  520  218  992  
  0-2 48 (37.5) 100 (79.4) 190 (36.5) 70 (32.1) 408 (41.1) 
  3-5 41 (32.0) 20 (15.9) 161 (31.0) 66 (30.3) 288 (29.0) 
  6 or more 39 (30.5) 6 (4.8) 169 (32.5) 82 (37.6) 296 (29.8) 
Abortion 128  126  518  218  990  
  no 48 (37.5) 61 (48.4) 175 (33.8) 105 (48.2) 389 (39.3) 
  yes 80 (62.5) 65 (51.6) 343 (66.2) 113 (51.8) 601 (60.7) 
n: absolute number; %: percentage of participants in each study group and each category 
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Table 3.  Behaviour-related characteristics of the study population 
 Group 1 (n = 131) 
HIV screening centres 
HIV-positive women 
Group 2 (n = 128) 
HIV screening centres 
HIV-negative women 
Group 3 (n = 539) 
Hospitals 
HIV status unknown 
Group 4 (n = 220) 
Health centres 
HIV status unknown 
Total 
(n = 1018) 
 n % n % n % n % n % 
Number of sexual partners 129  127  529  190  975  
   zero to two 50 (38.8) 44 (34.7) 304 (57.5) 132 (69.5) 530 (54.4) 
   three or more 79 (61.2) 83 (65.4) 225 (42.5) 58 (30.5) 445 (45.6) 
Use of hormonal contraception 131 131 128  539  171  969 969 
   no 105 (80.2) 118 (92.2) 421 (78.1) 139 (81.3) 783 (80.8) 
   yes 26 (19.8) 10 (7.8) 118 (21.9) 32 (18.7) 186 (19.2) 
Alcohol consumption 131  127  529  138  925 925 
   no 123 (93.9) 99 (78.0) 378 (71.5) 87 (63.0) 687 (74.3) 
   yes 8 (6.1) 28 (22.1) 151 (28.5) 51 (37.0) 238 (25.7) 
Use of plants for vaginal care     539  212  751 751 
   no     513 (95.2) 153 (72.2) 666 (88.6) 
   yes     26 (4.8) 59 (27.8) 85 (11.4) 
Use of chemical products for 
vaginal care 
131  128  539  151  949  
   no 98 (74.8) 92 (71.9) 445 (82.6) 67 (44.4) 702 (74.0) 
   yes 33 (25.2) 36 (28.1) 94 (17.4) 84 (55.6) 247 (26.0) 
n: absolute number; %: percentage of participants in each study group and each category 
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Table 4. Numbers and proportions of different lesions according to the Bethesda 2001 classification, per study group  
 Group 1 (n = 131) 
HIV screening centres 
HIV-positive women 
Group 2 (n = 128) 
HIV screening centres 
HIV-negative women 
Group 3 (n = 539) 
Hospitals 
HIV status unknown 
Group 4 (n = 220) 
Health centres 
HIV status unknown 
Total 
(n = 1018) 
 n (%) n (%) n (%) n  (%) 1018 (%) 
NILM 80 (61.1) 117 (91.4) 449 (83.3) 188 (85.5) 834 (81.9) 
ASCUS 9  (6.9) 5  (3.9) 46  (8.5) 19  (8.6) 79  (7.8) 
ASC-H 1  (0.8) 1  (0.8) 23  (4.3) 4  (1.8) 29  (2.9) 
LSIL 2  (1.5) 0  (0.0) 0  (0.0) 0  (0.0) 2  (0.2) 
HSIL 30 (22.9) 5  (3.9) 17  (3.2) 5  (2.3) 57  (5.6) 
Ca 9  (6.9) 0  (0.0) 4  (0.7) 4  (1.8) 17  (1.7) 
Subtotal: LSIL+ 41 (31.3) 5 (3.9) 21 (3.9) 9 (4.1) 76 (7.5) 
 
 
NILM: negative for intraepithelial lesion and malignancy 
ASCUS: atypical squamous cells of undetermined significance 
ASC-H: atypical squamous cells, cannot rule out high-grade lesion 
LSIL: low-grade squamous intraepithelial lesion 
HSIL: high-grade squamous intraepithelial lesion 
Ca: Carcinoma 
LSIL+: cytology findings compatible with (pre)cancerous lesions (includes low- and high-grade squamous intraepithelial lesions and carcinoma) 
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Table 5. Bivariate associations between socio-demographic and behavioural characteristics and presence of LSIL+ lesions, per study group 
 
  Group 1 (n = 131) 
HIV screening centres 
HIV-positive women 
Group 2 (n = 128) 
HIV screening centres 
HIV-negative women 
Group 3 (n = 539) 
Hospitals 
HIV status unknown 
Group 4 (n = 220) 
Health centres 
HIV status unknown 
    Crude OR 95% CI Crude OR 95% CI Crude OR 95% CI Crude OR 95% CI 
Age (in years) ‡   0.99 0.95 - 1.03 1.11 ** 1.00 -  1.24 1.02 0.98 - 1.07 1.02 0.97 -  1.06 
Age of menarche (in years) ‡   0.94 0.67 - 1.30 2.87 0.36 - 23.07 1.03 0.82 - 1.30 0.80 0.55 - 1.15 
Age of first sexual 
intercourse 
  0.89 * 0.76 - 1.05 1.09 0.86 - 1.38 1.01 0.90 - 1.13 0.84 * 0.68 - 1.06 
Marital status married 1.00   1.00 *   1.00   1.00   
  single 0.56 0.21 - 1.48 0.82 0.08 - 8.18 2.23 0.74 - 6.71 1.23 0.24 - 6.38 
  widowed 1.16 0.45 - 2.94 8.33 0.41 - 170.67 1.44 0.44 - 4.69 §   
  divorced 0.75 0.20 - 2.79 §   1.71 0.36 - 8.10 1.58 0.18 - 14.28 
Formal employment   0.75 0.35 - 1.61 1.74 0.28 - 10.79 1.92 * 0.73 - 5.03 0.28 * 0.06 - 1.38 
Number of pregnancies 0 - 2 1.00   1.00 **   1.00   1.00   
  3 - 5 1.31 0.47 - 3.70 1.96 0.14 - 18.04 1.06 0.33 - 3.38 0.28 0.03 - 2.80 
  6 or more 1.31 0.49 - 3.51 10.01 1.18 - 75.36 0.66 0.22 - 1.93 0.83 0.19 - 3.59 
Number of childbirths 0 - 2 1.00 *   1.00 **   1.00   1.00   
  3 - 5 1.08 0.96 - 5.77 8.65 1.34 - 55.65 0.31 0.15 - 1.70 0.70 0.11 - 4.31 
  6 or more 1.18 0.45 - 3.06 §   1.00 0.38 - 2.65 1.15 0.25 - 5.30 
Abortion   1.70 * 0.77 - 3.78 1.43 0.23 - 8.85 2.09 * 0.69 - 6.35 1.17 0.31 - 4.48 
Three or more lifetime sexual 
partners 
 1.26 0.58 - 2.74 2.18 0.24 - 20.10 2.27 * 0.92 - 5.57 0.91 0.17 - 4.82 
Hormonal contraception   1.21 0.49 - 3.00 3.17 0.32 - 31.40 1.12 0.40 - 3.12 §   
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Alcohol consumption   0.30 0.04 - 2.49 2.46 0.39 - 15.51 1.57 0.64 - 3.87 4.62 * 0.86 - 24.75 
Plants for vaginal care   †   † *   3.59 * 0.99 – 13.05 2.15 0.56 – 8.31 
Chemicals for vaginal care   0.63 0.26 - 1.55 §   0.49 0.11 - 2.13 2.06 0.39 - 10.95 
 
LSIL+: cytology findings compatible with (pre)cancerous lesions (includes low- and high-grade squamous intraepithelial lesions and carcinoma) 
OR: odds ratio; 95% CI: 95% confidence interval of the odds ratio 
‡ Age was treated as a continuous variable. Interpretation, e.g.in group 2: the odds of LSIL+ lesions increased with a factor 1.11 for each one-year increase in  
age. 
** P-value of Wald, chi-squared or Fisher exact test < 0.05   
* P-value of Wald, chi-squared or Fisher exact test is not significant but is less than 0.2 
§ Odds ratio could not be calculated because there were cells without observations. 
† Data about use of plants for vaginal care were not available in groups 1 and 2. 
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Table 6. Multivariable evaluations of the association between explanatory variables and the presence of LSIL+ lesions 
Type of analysis Study groups included Number of observations * Explanatory variables included 
in the model 
Adjusted OR 95% CI 
Logistic regression 1 
(HIV screening centres 
HIV-positive women) 
124 Age of first sexual intercourse ‡ 0.86 0.72 – 1.02 
Number of pregnancies   
   0 – 2 1  
   3 – 5 0.95 0.31 – 2.86 
   6 or more 0.83 0.28 – 2.44 
Abortion 1.98 0.83 – 4.75 
Logistic regression 2 
(HIV screening centres 
HIV-negative women) 
123 Age ‡ 1.11 0.95 – 1.31 
Marital status   
   married 1  
   single 5.26 0.27 – 102.32 
   widowed 4.34 0.18 – 105.99 
   divorced §  
Number of pregnancies   
   0 – 2 1  
   3 – 5 1.15 0.07 – 18.34 
   6 or more 4.27 0.22 – 81.82 
Logistic regression 3 
(Hospitals 
HIV status unknown) 
502 Formal employment 2.08 0.74 – 5.88 
Abortion 1.65 0.53 – 5.14 
≥3 lifetime sexual partners 1.75 0.69 – 4.46 
Plants for vaginal care 2.85 0.75 – 10.82 
Logistic regression 4 
(Health centres 
HIV status unknown) 
203 Age of first sexual intercourse ‡ 0.86 0.68 – 1.07 
Formal employment 0.30 0.06 – 1.50 
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GEE 1, 2 3 and 4 886 Abortion 1.60 0.97 – 2.63 
≥3 lifetime sexual partners 1.29 0.83 – 1.99 
Chemicals for vaginal care 0.65 0.37 – 1.14 
Logistic regression 3 and 4 643 Alcohol consumption 1.76 0.80 – 3.86 
≥3  lifetime sexual partners 1.58 0.72 – 3.46 
Plants for vaginal care 2.70 1.04 – 7.01 ** 
 
LSIL+: cytology findings compatible with (pre)cancerous lesions (includes low- and high-grade squamous intraepithelial lesions and carcinoma) 
OR: odds ratio; 95% CI: 95% confidence interval of the odds ratio 
GEE: generalized estimating equations (population-averaged model; group variable: study group) 
‡ Age was treated as a continuous variable. 
§ Odds ratio could not be calculated because there were cells without observations. 
** P-value of Wald test < 0.05 
 
 
  
136 
 
 
Table 7. HPV genotyping results for women with ASCUS+ cytology 
HPV 
genotype 
Group 1 (HIV-positive women) Groups 2, 3 and 4 (women with unknown 
or negative HIV status) 
 Number of women with ASCUS+ = 52 Number of women with ASCUS+ = 133 
 Number of samples in which HPV 
DNA was detected = 50 
Number of samples in which HPV DNA 
was detected = 40 
6 3 (6%) 0 (0%) 
11 2 (4%) 1 (3%) 
16  10 (20%) 3 (8%) * 
18 5 (10%) 5 (13%) 
31 9 (18%) 2 (5%) 
33 6 (12%) 4 (10%) 
35 12 (24%) 6 (15%) 
39 6 (12%) 4 (10%) 
40 1 (2%) 1 (3%) 
43 2 (4%) 0 (0%) 
44 5 (10%) 0 (0%) 
45 7 (14%) 2 (5%) 
51 10 (20%) 5 (13%) 
52 12 (24%) 10 (25%) 
53 5 (10%) 1 (3%) 
54 3 (6%) 5 (13%) 
56 6 (12%) 3 (8%) 
58 7 (14%) 0 (0%) 
59 2 (4%) 1 (3%) 
66 7 (14%) 4 (10%) 
68 12 (24%) 3 (8%) 
69 1 (2%) 1 (3%) 
70 5 (10%) 1 (3%) 
74 4 (8%) 4 (10%) 
82 0 (0%) 1 (3%) 
 
HPV: human papillomavirus 
ASCUS+ includes: atypical squamous cells of undetermined significance (ASCUS); atypical 
squamous cells; cannot rule out high-grade lesion (ASC-H); low- grade squamous intraepithelial 
lesions (LSIL), high-grade squamous intraepithelial lesions (HSIL) and carcinoma. 
* In addition to the three samples in which HPV16 was detected through the INNO-LiPA test, there 
were three samples in which both the Abbot Real Time and the GenoID test indicated the presence of 
HPV16 
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 ABSTRACT 
In the Democratic Republic of the Congo, cervical cancer remains the most lethal cancer 
among women and the diagnosis still relies on the Papanicolaou test. This cross-sectional 
study aimed to determine the strength of the association between HIV infection and 
precancerous or cancerous lesions of the uterine cervix (LISL+) and to assess the accuracy of 
the Papanicolaou test for LSIL+ diagnosis taking liquid-based cytology as reference standard. 
We enrolled 271 participants in two HIV screening and treatment centres in Kinshasa in 
2006-2007. The adjusted odds ratio for the association between HIV and LSIL+ was 7.5 (95% 
confidence interval (95%CI) 2.7-21.4). Pap test sensitivity was 80% (95%CI 38–96) in HIV-
negative and 68% (95%CI 53–80%) in HIV-positive women. The specificity was 98% both in 
HIV-negative and HIV-positive women. In HIV-positive women in Kinshasa, the negative 
predictive value of one Pap test (87%) is too low to safely rule out LSIL+. 
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INTRODUCTION 
Globally, cancer of the uterine cervix causes more than 266,000 deaths each year
1
. About 
85% of new cases occur in low-income countries
1, 2
. Early detection and prompt treatment of 
cervical lesions can prevent more than half of the invasive cancers
3
. In high-income countries, 
control programmes have contributed to a decrease in incidence and mortality
4,5
. By contrast, 
in most African countries, systematic screening programs are nearly inexistent
6
 and cervical 
cancer remains the leading cause of cancer deaths of women
1, 2
.  
Persistent infection with high-risk types of human papilloma virus (HPV) is thought to be a 
necessary condition for malignant transformation of the cervical epithelium
7,8
. Most women 
in the world get infected with HPV after they start sexual intercourse, but usually, these HPV 
infections disappear spontaneously
9
. It is incompletely understood why a minority of women 
fail to clear HPV.  Several factors increase the risk of cervical cancer. Most of these are 
related to the risk of HPV infection, such as having multiple sexual partners, starting sexual 
activities at early age, having other sexually transmitted infections, and multiparity
9
.  
HIV aggravates the natural history of HPV infection. HIV-infected women have a high 
incidence, persistence and prevalence of HPV infections and a high risk of developing 
invasive cancer
9-11
. Unlike some other AIDS-defining cancers, the risk of cervical cancer does 
not seem to be affected by highly active antiretroviral therapy
9-11
. Therefore, as the access to 
antiretroviral therapy slowly increases, it is expected that chronic HIV-related diseases such 
as cervical cancer will increasingly come to the foreground
11
. 
The conventional Papanicolaou (Pap) test is the cytology test for the diagnosis of cervical 
lesions that is most commonly used in Sub-Saharan Africa
12
. In high-income countries, this 
Pap test is progressively replaced by liquid-based cytology in combination with HPV testing. 
The advantages of liquid-based cytology include semi-automatic reading, few indeterminate 
results and possibility of co-testing (cytology plus HPV). The introduction of liquid-based 
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cytology in low-income countries is hampered by its high cost and by the lack of screening 
programmes for large numbers of women. In places where the Pap test remains the mainstay 
of cervical cancer diagnosis, it is of public health relevance to know the accuracy of this test, 
but reports from routine settings in Sub-Saharan Africa are infrequent and divergent
12,13
.  
In most Sub-Saharan countries, cervical cancer is assumed to be frequent, although in some 
regions, this assumption is based on a small number of reports. Particularly in the Democratic 
Republic of Congo (DRC), little information is available
14-19
. In a previous paper, we 
described the frequency of LSIL+ lesions (low- or high-grade squamous intraepithelial lesions 
or carcinoma) and HPV types in women of Kinshasa and looked for associated 
sociodemographic and behavioural factors
20
. That study did not focus on HIV as a risk factor 
for LSIL+ because the HIV status of the majority of the study participants was not known.  
The purpose of the current paper is to determine, in a subgroup of the original study 
population, the strength of the association between HIV infection and LSIL+ while 
controlling for confounding factors, and to assess the accuracy of the conventional Pap test in 
the setting of Kinshasa, DRC.  
 
METHODS  
Study design and setting 
The study followed a cross-sectional design. Participants were enrolled between September 
2006 and January 2007 in two HIV screening and treatment centres in Kinshasa, DRC: 
ACS/AMO-CONGO (Action Communautaire contre le SIDA/Avenir Meilleur pour les 
Orphelins du Sida au Congo) and Centre Hospitalier Monkole. At these centres, HIV is 
diagnosed according to national guidelines. In brief, after pre-test counselling, one of two 
rapid tests is used (Determine
®
 HIV-1/2 (Abbott) or OraQuick
® 
HIV-1/2 (OraSure 
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Technologies)) in combination with one of three serological tests (Vironostika
® 
Uni-Form II 
Plus O (BioMérieux) or Enzygnost
®
 Anti-HIV-1/2 Plus or InnoLia
®
 HIV I/II Score 
(Innogenetics)).  
Participants 
All women of more than 17 years old who were willing to participate and who had started 
sexual activity were eligible. Those women for whom a liquid-based cytology result was 
available were included in the analysis. This study population is part of a larger study, the 
results of which are reported elsewhere
20
. 
Data variables and sources 
The outcome variable was the cervical cytology result. A pelvic examination was done and a 
cervix brush (Cervex-brush®) was used to collect cervical samples. A smear was made for 
conventional Pap staining and the cervix brush was then immersed in Thinprep liquid-based 
cytology medium (Hologic, Inc). The conventional Pap smears were read by one pathologist 
at the Department of Medical Biology of the University of Kinshasa. The liquid-based 
cytology smears were interpreted at the Laboratory of Pathology of the University of Ghent 
by two independent pathologists. In case of discordancy, the pathologists re-read the smear 
and came to a final diagnosis together. The pathologists interpreted the conventional Pap 
smears without knowledge of liquid-based cytology results and vice versa. When reading the 
slides, the pathologists were unaware of the participants’ HIV status.  
We reported the cytology results according to the Bethesda 2001 Classification system. The 
following diagnostic categories were considered to be precancerous or cancerous lesions
21
 
and were classified as LSIL+: low-grade squamous intraepithelial lesion (LSIL), high-grade 
squamous intraepithelial lesion (HSIL), carcinoma in situ (CIS), and carcinoma (Ca). The 
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remaining categories were defined as not precancerous: negative for intraepithelial lesion of 
malignancy (NILM), atypical squamous cells of undetermined significance (ASCUS) and 
atypical squamous cells – cannot exclude HSIL (ASC-H). 
The main exposure variable of interest was the HIV status. HIV-related information was taken 
from the patient files at the study centres. The majority of  HIV-positive participants had been 
receiving antiretroviral therapy for different periods of time. Information about time on 
treatment and adherence was not available for this study. If CD4-cell counts were mentioned 
in the patient files, the most recent value was copied to the participant’s case report form. 
In order to adjust for potential confounders and effect modifiers, we collected information 
about sociodemographic and behavioural factors that might be associated with cervical 
cancer, including age, marital status, socio-economic status, alcohol use, smoking, age at first 
sexual intercourse, number of lifetime partners, childbirths, and habit of vaginal cleansing. 
One indicator of socio-economic status was the housing condition, which was calculated as 
the average number of rooms per household member. Study doctors collected the 
sociodemographic and behavioural information using a standard questionnaire. The 
participants were interviewed in French or Lingala, the most common local language. 
Statistical analysis  
The first objective was to assess the strength of the association between HIV infection 
(primary exposure of interest) and presence of LSIL+ (outcome) after correction for 
confounding factors. For each of the potentially confounding sociodemographic and 
behavioural variables, we checked if their inclusion in a logistic regression model together 
with HIV changed the odds ratio (OR) of the association between HIV and LSIL+, i.e. if they 
really acted as confounders. We then checked if there were effect modifiers and used the 
likelihood ratio test to evaluate if a logistic regression model including an interaction term 
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fitted the data significantly better than a model without that term. A multivariable logistic 
regression model was then built, including HIV, confounders, effect modifiers, and any other 
exposure variables that significantly improved the model fit, which was evaluated using the 
likelihood ratio test. Furthermore, within the group of HIV-positive women, we used the 
Mann-Whitney U test to compare CD4 counts of women with and without LSIL+.  
The second objective was to estimate the accuracy of the conventional Pap test in HIV-
positive and HIV-negative women using liquid-based cytology as a reference standard. We 
computed sensitivity, specificity, and predictive values of the conventional Pap test in HIV-
positive and in HIV-negative women. Confidence intervals were calculated using the Wilson 
score method without continuity correction
22
.  
Microsoft Excel 2010 and Stata 10.0 (StataCorp, Texas, USA) were used for data analysis. 
Unless mentioned otherwise, the significance level set for statistical tests was 0.05.   
Ethics 
The study protocol was approved by the Ethics Committee of the School of Health of 
Kinshasa University. Participants provided written informed consent, and the results of liquid-
based cytology were reported back to the attending physicians. 
 
RESULTS 
Two hundred seventy-one women were recruited. Their mean age was 34.2 years (standard 
deviation (SD) 9.9). One hundred forty participants (52.0%) were single, 71 (26.4%) married, 
19 (7.1%) divorced, and 39 (14.5%) widowed. For 47 women (17.7%), primary school was 
the highest level of education. Six participants (2.2%) were smokers. Mean age at first sexual 
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intercourse was 17.5 years (SD 2.9). Thirty-seven women (13.9%) reported one lifetime sex 
partner; 152 (56.9%) had had two to four partners; and 78 (29.2%) had had five or more sex 
partners. One hundred twenty-eight women (47.2%) were HIV positive; one hundred thirty-
two (48.7%) were HIV negative; and for 11 (4.1%), the HIV status was unknown (table 1).  
Based on liquid-based cytology, precancerous or cancerous lesions (LSIL+) were present in 
47 participants (17.3%). Five HIV-negative women  (3.9%)  and 41 HIV-positive women 
(31.1%) had LSIL+. The association between HIV and the presence of LSIL+ was strong and 
significant: the crude OR was 11.1 (95% CI 4.2 to 29.2; table 1). 
On bivariate analysis, four independent variables other than HIV were significantly associated 
with LSIL+: age, number of childbirths, history of abortion, and marital status. Four 
additional variables had a P-value ≥0.05 but <0.2 and were also treated as potential 
confounders: age at first sexual intercourse, condom use, alcohol use, and weight (table 1). 
Two of these variables (number of childbirths and marital status) were confounders for the 
association between HIV infection and the presence of LSIL+. None of the independent 
variables was found to modify the effect of HIV on LSIL+ (there was no statistical 
interaction). The final logistic regression model included HIV infection, number of 
childbirths, marital status, number of lifetime sexual partners, and age at first sexual 
intercourse (table 2). The last two factors were no confounders but improved the fit of the 
model. HIV infection was the only independent variable for which the association with the 
presence of LSIL+ remained significant: the adjusted OR was 7.5 (95% CI 2.6 to 21.4).  
CD4 counts were available in 87 HIV-positive women (figure 1). HIV-positive women with 
LSIL+ had a lower CD4 count (median 162 cells/µL; interquartile range 93–327) than those 
without LSIL+ (336 cells/µL; interquartile range 184–475; P=0.002).  
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Using liquid-based cytology as a reference standard (table 3), the sensitivity of the 
conventional Pap test was 80% (95% CI 38–96%) in HIV-negative and 68% (95% CI 53–
80%) in HIV-positive women. The specificity of the conventional Pap test was high both in 
HIV-negative (98%; 95% CI 94–100%) and in HIV-positive women (98%; 95% CI 92–99). 
The positive predictive value was 67% (95% CI 30–90%) in HIV-negative and 93% (95% CI 
79–98%) in HIV-positive women. The negative predictive value was 99% (95% CI 96–100%) 
in HIV-negative and 87% (95% CI 79-92%) in HIV-positive women.  
Figure 1. CD4 counts according to cervical cytology result.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CD4 counts in 87 women attending HIV screening or treatment centres in Kinshasa, 
Democratic Republic of the Congo 
Horizontal lines indicate median with interquartile range.  
a
 Mann-Whitney U test 
“Suspect lesion” (LISL+ present) includes the following Bethesda categories: low-grade 
squamous intraepithelial lesion (LSIL), high-grade squamous intraepithelial lesion (HSIL), 
carcinoma in situ (CIS), and carcinoma (Ca).  
“No suspect lesion” (LSIL+ absent) includes the following Bethesda categories: negative for 
intraepithelial lesion of malignancy (NILM),  atypical squamous cells of undetermined 
significance (ASCUS), and atypical squamous cells – cannot exclude HSIL (ASC-H). 
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DISCUSSION 
In adult women in Kinshasa, the association between HIV infection and LSIL+ is strong and 
significant. After adjustment for marital status, age at first sexual intercourse, number of 
lifetime sex partners and childbirths, the OR for the association between HIV and LSIL+ is 
7.5. At the same time, the sensitivity of the conventional Pap smear test is low, particularly in 
HIV-positive women (68% when liquid-based cytology is taken as a reference standard). This 
is of concern because in the DRC, the conventional Pap smear is the most commonly used test 
to diagnose lesions of the uterine cervix.  
The strengths of this study are the multivariable analysis adjusting for confounding factors 
and the fact that the conduct of the study and the reporting of the results follow STROBE 
guidelines
23
. On the other hand, the power of our study was limited. Although the association 
with HIV was clear, none of the other sociodemographic and behavioural candidate predictors 
of LSIL+ reached significance in the multivariable analysis. The power of our study was 
insufficient to detect weak associations because the total study population was relatively 
small, known risk factors other than HIV were relatively uncommon, and LSIL+ was 
infrequent among HIV-negative women. Another limitation is the fact that information about 
the evolution of CD4 counts and antiretroviral therapy was not available. Finally, we 
evaluated the conventional Pap smear test against liquid-based cytology, which is an 
imperfect reference standard. The histopathological examination of biopsy samples could 
have been a more accurate reference standard but was not feasible in this study. In fact, if 
liquid-based cytology produced some false-negative results in our study, an observation that 
has been reported before
24
, the true sensitivity of the conventional Pap smear might be even 
lower than our estimate.  
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The strength of the association between HIV and LSIL+ in this study is in line with previous 
studies that estimated that HIV increases the risk of invasive cervical cancer with a factor of 2 
to 22
25, 26
. This high risk has been explained by the fact that HIV-positive women are more 
susceptible to HPV infection and HPV reactivation, and more likely to have persistent HPV 
infections than HIV-negative women
25
. In our study, HIV-infected women with LSIL+ had 
lower CD4 counts than HIV-infected women with normal cervical smears, suggesting that 
immunosuppression facilitates the progression to precancerous lesions. How this occurs is not 
entirely understood, but HIV does not seem to strongly affect the risk of invasion through the 
basement membrane of the epithelium, and highly active antiretroviral therapy does not seem 
to reduce the risk of cervical cancer
9, 27
.  
Taking liquid-based cytology as a reference standard, the sensitivity of the conventional Pap 
test is rather low: 80% in HIV-negative and 67% in HIV-positive women. Although the 
precision of this estimate is limited because of the infrequency of LSIL+ in our study, the 
observation is in line with previous reports
13
. The high frequency of false-negative results in 
HIV-positive women may be caused by concomitant inflammation. On the other hand, the 
Pap test gives few false-positive results in this as well as in other studies
13
. With a positive 
predictive value of 67%, one positive Pap test does not seem to be sufficient to rule in the 
diagnosis of LSIL+ in HIV-negative women of Kinshasa, and other tests will be required for 
confirmation. And with a negative predictive value of 87%, one negative Pap test does not 
adequately rule out cervical lesions in HIV-positive women of Kinshasa. In this population, 
Pap tests should be repeated regularly or combined with other screening tests.  
This study has important policy implications: first, it confirms once more that in HIV-positive 
women, LSIL+ needs to be proactively sought and treated. As the access to  highly active 
antiretroviral treatment improves, the need for cervical cancer diagnosis and treatment is 
likely to increase, because antiretroviral therapy raises life expectancy without strongly 
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lowering the risk of cervical cancer
9-11
. Second, the study highlights some limitations of the 
conventional Pap smear test. In addition to the suboptimal sensitivity particularly in HIV-
positive women, this test poses operational challenges as it depends on well-trained 
pathologists. In the DRC, about 13 pathologists are active for a population of about 70 million 
people; 10 of them work in Kinshasa. New diagnostic tests that detect high-risk HPV types, 
viral oncogenes or cellular proliferation markers are now under investigation
28
. Most of these 
tests appear to be more sensitive but less specific than conventional cytology. The availability 
of new tests, however, does not exclude the necessity of a nationally organized screening 
program, the extension of expertise and training of skilled people, investment in technical 
infrastructure, and the follow-up and treatment of patients diagnosed with precancerous 
lesions. 
In conclusion, among women of Kinshasa, HIV infection is strongly associated with lesions 
of the uterine cervix. In HIV-positive women, the sensitivity and the negative predictive value 
of the conventional Pap smear are low. It is, therefore, recommended to regularly repeat Pap 
tests or to use additional diagnostic tests in HIV-positive women, even if they receive 
antiretroviral therapy.    
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Table 1. Description of study population according to cervical cytology results; 271 women attending 
HIV screening or treatment centres in Kinshasa, Democratic Republic of the Congo 
 
Total study population 
(n = 271) 
Women without LSIL+ 
a 
(n = 224) 
Women with LSIL+ b 
(n = 47) 
crude odds ratio (95% 
confidence interval) c 
 n (%) or mean (SD) n (%) or mean (SD) n (%) or mean (SD)  
HIV infection 132 (50.2) 91 (42.5) 41 (89.1) 11.08 (4.21 – 29.15) d 
Mean age, years (SD) 34.2 (9.9) 33.4 (10.0) 37.7 (8.3) 1.04 (1.01 – 1.08) d 
Ethnic background     
     Bandundu 45 (16.6) 35 (15.6) 10 (21.3) 2.00 (0.57 – 7.06) 
     Kasai 57 (21.0) 47 (21.0) 10 (21.3) 1.49 (0.43 – 5.20) 
     Kongo 96 (35.4) 77 (34.4) 19 (40.4) 1.73 (0.54 – 5.52) 
     Ngala 21 (7.8) 18 (8.0) 3 (6.4) 1.17 (0.23 – 5.84) 
     Oriental 20 (7.4) 19 (8.5) 1 (2.1) 0.37 (0.04 – 3.56) 
     Other 32 (11.8) 28 (12.5) 4 (8.5) 1.00 
Marital status     
     Single 140 (52.0) 127 (57.2) 13 (27.7) 1.00 
     Married 71 (26.4) 55 (24.8) 16 (34.0) 2.84 (1.28 – 6.31) d 
     Divorced 19 (7.1) 15 (6.8) 4 (8.5) 2.61 (0.75 – 9.02) 
    Widowed 39 (14.5) 25 (11.3) 14 (29.8) 5.47 (2.30 – 13.03) d 
Housing condition e     
     Quartile 1 45 (24.1) 35 (23.5) 10 (26.3) 1.00 
     Quartile 2 62 (33.2) 51 (34.2) 11 (29.0) 0.75 (0.29 – 1.97) 
     Quartile 3 35 (18.7) 29 (19.5) 6 (15.8) 0.72 (0.23 – 2.23) 
     Quartile 4 45 (24.1) 34 (22.8) 11 (29.0) 1.13 (0.43 – 3.01) 
Education level higher 
than primary school 
219 (82.3) 181 (82.7) 38 (80.1) 0.89 (0.40 – 1.99) 
Formal job 43 (16.0) 38 (17.2) 5 (10.6) 0.57 (0.21 – 1.54) 
Regular alcohol use  36 (13.3) 33 (14.7) 3 (6.4) 0.39 (0.12 – 1.35) 
Smoker 6 (2.2) 6 (2.7) 0 (0.0) - f 
Mean weight, Kg (SD) 57.7 (11.7) 58.2 (12.0) 55.2 (9.6) 0.98 (0.95 – 1.00) 
Mean age at first 
sexual intercourse, 
years (SD) 
17.5 (2.9) 17.7 (3.0) 16.9 (2.3) 0.91 (0.80 – 1.03) 
Number of lifetime 
sex partners 
    
     1 37 (13.9) 35 (15.8) 2 (4.4) 1.00 
     2 to 4 152 (56.9) 123 (55.7) 29 (63.0) 4.13 (0.94 – 18.15) 
     5 or more 78 (29.2) 63 (28.5) 15 (32.6) 4.17 (0.90 – 19.28) 
Number of childbirths     
     0 78 (29.4) 73 (33.5) 5 (10.6) 1.00 
     1 or 2  77 (29.1) 67 (30.7) 10 (21.3) 2.18 (0.71 – 6.70) 
     3 or more 110 (41.5) 78 (35.8) 32 (68.1) 5.99 (2.21 – 16.20) d 
History of abortion 151 (57.0) 118 (54.1) 33 (70.2) 1.99 (1.01 – 3.94) d 
Regular condom use 103 (38.0) 90 (40.2) 13 (27.7) 0.57 (0.28 – 1.14) 
Vaginal cleansing 75 (27.7) 65 (29.0) 10 (21.3) 0.66 (0.31 – 1.41) 
 
SD: standard deviation; n: number of participants in each group; %: percentage of women in 
each group and category 
a “Without LSIL+” includes the following Bethesda categories: negative for intraepithelial 
lesion of malignancy (NILM), atypical squamous cells of undetermined significance 
(ASCUS), and atypical squamous cells – cannot exclude HSIL (ASC-H). These cytology 
results indicate the absence of precancerous or cancerous lesions.  
b “With LISL+” includes the following Bethesda categories: low-grade squamous 
intraepithelial lesion (LSIL), high-grade squamous intraepithelial lesion (HSIL), carcinoma in 
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situ (CIS), and carcinoma (Ca). These cytology results indicate the presence of precancerous 
or cancerous lesions.  
c
 The crude odds ratios indicate the strength of the association between each of the 
explanatory characteristics of the study population and the presence of LSIL+  (bivariate 
analyses) 
d
 P<0.05 
e
 Calculated as the number of rooms per resident of a household; the women in quartile 1 live 
in the most crowded conditions 
f
 An odds ratio could not be calculated because there were no smokers with LSIL+.
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Table 2. Results of a multivariable logistic regression model predicting the presence of LSIL+ in 271 
women attending HIV screening or treatment centres in Kinshasa, Democratic Republic of the Congo 
Independent variable Adjusted odds ratio 95% confidence interval 
HIV infection 7.52 2.65 – 21.35 a 
Number of childbirths   
     0 1  
     1 or 2 1.75 0.48 – 6.43 
     3 or more 2.62 0.64 – 10.68 
Marital status   
     Single 1  
     Married 1.18 0.39 – 3.60 
     Divorced 0.80 0.18 – 3.49 
     Widowed 1.58 0.47 – 5.32 
Number of lifetime sex partners   
    1 1  
    2 to 4 4.38 0.88 – 21.68 
    5 or more 3.80 0.72 – 19.95 
Age at first sexual intercourse, years 0.93 0.79 – 1.09 
 
a
 P<0.001. The P-values for the other independent variables are >0.05 
LISL+ includes the following Bethesda categories: low-grade squamous intraepithelial lesion 
(LSIL), high-grade squamous intraepithelial lesion (HSIL), carcinoma in situ (CIS) and 
carcinoma (Ca). These cytology results indicate the presence of precancerous or cancerous 
lesions.  
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Table 3. Comparison of findings on Papanicolaou test and liquid-based cytology according to HIV 
status in 271 women attending HIV screening or treatment centres in Kinshasa, Democratic Republic 
of the Congo 
   Liquid-based cytology   
Group   LSIL+ PRESENT LSIL+ ABSENT Total 
All participants Pap test 
LSIL+ PRESENT 33 4 37 
LSIL+ABSENT 14 220 234 
Total 47 224 271 
HIV-negative 
women 
Pap test 
LSIL+ PRESENT 4 2 6 
LSIL+ ABSENT 1 121 122 
Total 5 123 128 
HIV-positive 
women 
Pap test 
LSIL+ PRESENT 28 2 30 
LSIL+ ABSENT 13 89 102 
Total 41 91 132 
 
Shaded cells contain discordant results 
“LISL+ present” includes the following Bethesda categories: low-grade squamous 
intraepithelial lesion (LSIL), high-grade squamous intraepithelial lesion (HSIL), carcinoma in 
situ (CIS), and carcinoma (Ca). These cytology results indicate the presence of precancerous 
or cancerous lesions.  
“LSIL+ absent” includes the following Bethesda categories: negative for intraepithelial lesion 
of malignancy (NILM),  atypical squamous cells of undetermined significance (ASCUS), and 
atypical squamous cells – cannot exclude HSIL (ASC-H). These cytology results indicate the 
absence of precancerous or cancerous lesions.  
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Abstract 
OBJECTIVE Application of Bethesda guidelines on cervical cytology implements the HPV 
determinations on all ASC-US and ASC-H results. We compared HPV DNA results in view 
of the eventual development of a CIN lesion either determined on cytology or histology.  
METHODS A total number of 214 LBC samples were analysed. Three different HPV DNA 
methods were applied: Abbott RealTime High Risk HPV test, INNO-Lipa HPV Genotyping 
Extra (Innogenetics) and Full Spectrum PCR HPV Amplification and Detection/Genotyping 
System by Lab2Lab Diagnostic Service (GenoID).  
RESULTS The comparison of these 3 methods revealed full concordance only for 49 samples 
(23%) and 27 (13%) of samples were discordant regarding revealing presence of high risk 
HPV type. Out of 214, 88 patients were selected presenting CIN or VAIN lesion in follow-up 
cytology or histology. In this group full concordance in HPV genotyping was present only in 
19 (22%) of follow-up samples. Nine (10%) of follow-up samples showed discordant results 
for the presence of high risk genotype between 3 tested genotyping methods either by 
negativity for high risk HPV by one of the methods (n=6) or by failure to genotype HPV 
(n=2) or by combination of both (n=1). Moreover, discordance for the detection of HPV16 or 
HPV18 was observed between 3 HPV DNA genotyping methods used in 9 (10%) follow-up 
samples. Additionally, performance of genotyping methods on 20 external quality samples 
was assessed showing discordant results for HPV16 and HPV18.  
CONCLUSIONS Major differences were found in genotyping results according to the HPV 
DNA method. Our findings accentuate the importance of careful interpretation of data from 
studies using different HPV genotyping methods and underline the need for standardisation 
by method validation in clinical laboratories especially in the foresight of primary HPV 
screening. 
 
Keywords: human papillomavirus, genotyping, reverse hybridisation, cervical cytology, 
precancerous cervical lesions 
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Introduction 
Approximately 40 different HPV types can infect the mucosa of the human anogenital tract. 
Based on their oncogenicity, these anogenital HPV types have been subdivided into high-risk 
HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 and 82), low-risk HPV types 
(6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81 and CP6108) and probable high-risk HPV types (26, 
53, 66) (Muñoz et al., 2003; de Villiers et al., 2004).
 
Molecular and epidemiological studies 
have shown that a persistent infection with high-risk HPV is a necessary but not sufficient 
condition for the development of cervical cancer (reviewed by zur Hausen, 2002).
 
Detection 
of high-risk HPV has consequently become an important part in various algorithms in cervical 
cancer screening (Arbyn et al., 2006; Brink et al., 2006; Cuzick et al., 2008).
 
Nevetheless the 
introduction of evaluation of cytological abnormalities by Pap smear as a screening tool for 
cervical cancer has proved its effectiveness in organised screeening programs with 
histopathology providing the final diagnosis on the basis of which treatment is planned 
(Michalas 2000; Arbyn et al., 2010). Many currently available commercial as well as in-house 
molecular tests rely on cocktails of probes representing 13 or 14 of the most common high-
risk HPV types next to the assays that additionally include detection of low-risk HPV types 
(Poljak and Kocjan, 2010; Hwang and Lee, 2012; Venturoli et al., 2012).
 
However this 
qualitative detection of the presence of high-risk HPV type doesn’t allow the identification of 
specific genotypes, nor the existence of multiple infections.
 
Recent studies have provided 
evidence for a difference in oncogenic potential between the different high-risk HPV and as 
suggested by de Sanjose et al. the type-specific high-risk HPV screening tests should focus on 
HPV types 16, 18 and 45 as these 3 high-risk HPV genotypes were detected in 94% of 
cervical adenocarcinomas (de Sanjose et al., 2010).  The importance of HPV 16, 18 and 45 
types are also found more in the integrated state and in younger women suggesting faster 
progression to invasive cervical cancer (Vinokurova et al., 2008; Powell et al., 2013). The 
predominance of HPV 16, 18 and 45 in cervical adenocarcinomas, with more cumbersome 
diagnosis and faster natural history, strengthens once more the significance of these HPV 
types in screening programs (Seoud et al., 2011). High contributions of HPV 16, 18 and 45 in 
cervical cancer strongly suggest biological advantage for transmission, persistency and 
transformation of these HPV types (Bosch et al., 2008). International Agency for Research on 
Cancer (IARC) confirmed the predominance of HPV16 and 18 in invasive cervical cancer 
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worldwide in all regions in the presence of minor geographical variations for other HPV types 
(Li et al., 2011).  
HPV genotyping is used for the monitoring of women already treated for highgrade cervical 
intraepithelial neoplasia (CIN) or cervical cancer (Brink et al., 2007). About 20-30% of HPV 
infections involve multiple high-risk HPV types and as the prognostic value of the finding of 
coinfection has still to be investigated, the natural history studies show an increased risk of 
acquisition of new high-risk HPV type in those women who were already found positive for 
other high-risk HPV (Liaw et al., 2001; Rousseau et al., 2001; Woodman et al., 2007). 
Genotyping and its role in the epidemiology of HPV infections locally and worldwide remain 
very important, especially in detection of epidemiological changes due to the vaccination 
policies. It is in the context of effective monitoring and implementation of HPV vaccination 
programs that different HPV genotyping methods were evaluated showing good type-specific 
agreement (Else et al., 2011; Roberts et al., 2011).
 
However, in the same setting of HPV 
vaccine evaluations the international assessments of HPV genotyping have demonstrated the 
high degree of variation in performance, accentuating the need for continuous global 
proficiency studies for establishing comparable HPV genotyping results (Quint et al., 2006; 
Eklund et al., 2010; Eklund et al., 2012; Eklund et al., 2014).
 
The comparative studies 
between different diagnostic methods in clinical use are mainly focussed on the agreement in 
detection rates of high-risk HPV types and little data are currently available on the impact of 
the use of various HPV genotyping methods in clinical diagnostic laboratory (Poljak et al., 
2009; Hwang et al., 2012; Carozzi et al., 2011; Park et al., 2012).
  
The objective of the current study is to compare the performance of HPV genotyping methods 
in view of the development of CIN lesions in further follow-up. The following 3 HPV 
genotypring methods were used: Abbott RealTime High Risk HPV test (Abbott), INNO-Lipa 
HPV Genotyping Extra (Innogenetics) and Full Spectrum PCR HPV Amplification and 
Detection/Genotyping System by Lab2Lab Diagnostic Service (GenoID Molecular 
Diagnostics Laboratory). Abbott RealTime High Risk HPV test has become available in 
Europe since January 2009 and is currently frequently applied in the diagnostic laboratories as 
a result of its full automation next to consistently high clinical sensitivity and specificity 
(Cuzick et al., 2013; Poljak and Ostrbenk, 2013). Clinical validation of Abbott RealTime 
High Risk HPV test according to the guidelines for HPV DNA test requirements for cervical 
screening has been completed (Hesselink et al., 2013). INNO-Lipa HPV Genotyping Extra 
167 
 
has proven its clinical performance as compared to other commercial HPV genotyping assays 
in various studies and also because of its high sensitivity and short size of PCR fragment, this 
assay has been successfully used on more technically tough paraffine-embedded samples 
(Barbieri et al., 2012; Barzon et al., 2012; Steinau et al., 2012). Full Spectrum PCR HPV 
Amplification and Detection/Genotyping System by Lab2Lab Diagnostic Service (GenoID) 
represents a cost-effective and sensitive high throughput laboratory technique for HPV 
diagnostics providing international sample collection and testing services next to advanced 
computerized documentation (Benczik et al., 2006; Benczik et al., 2007; Takacs et al., 2008). 
This was carried out in a stepwise protocol according the applied guidelines.  
 
Methods 
A total of 214 liquid-based cytology (LBC) samples were taken during routine patient visits to 
the Gynecology Clinic of Ghent University Hospital between April 2010 till April 2011 and 
to the outpatient clinic of General Hospital and Ngaliema Hospital of Kinshasa, Democratic 
Republic of Congo (DRC) in July and August 2009. The samples were tested for HPV after 
cytological screening of the liquid-based Pap test (PreservCyt Solution; Hologic Inc. 
(Marlborough, Masschusetts, USA) if they showed evidence of Atypical Squamous Cells of 
Undetermined Significance (ASC-US) as reported according to Bethesda System 2001 for 
cervicovaginal cytology. According to the guidelines all ASC-US and ASC-H samples were 
completed by a HPV DNA analysis. If in follow-up ASC-US + high-risk HPV and ASC-H + 
high-risk HPV was found as result a colposcopy was recommended with biopsy according to 
the European guidelines for quality assurance in cervical cancer screening (Arbyn et al., 
2010). Full HPV genotyping was the final test in the stepwise protocol and was performed if 
HPV testing by Abbott RealTime High Risk HPV test (Abbott, Madison, USA) gave high-
risk-positive result but other genotype than HPV 16 or HPV 18. To avoid violation of the test-
specific DNA extraction protocol, aliquots were prepared from the LBC medium. After 
shaking the vials, adequate amounts for each test were transferred to a new reaction tube. 
Eighty eight patients presented at gynecological consultation as part of follow-up visit based 
on their initial cytological result revealing ACS-US or ASC-H where liquid-based Pap test 
was taken for follow-up cytology and HPV genotyping. Of these 88 patients,  for 34 (39%) 
cytological and histological data were available. HPV genotyping by 3 different methods used 
was performed on liquid-based Pap test taken by gynecologist at follow-up visit; no HPV 
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genotyping was performed on histological material. In total full HPV genotyping was 
performed on all 88 clinical samples of patients who revealed CIN and VAIN lesions in 
follow-up and on 20 external quality control samples (Quality Control in Molecular 
Diagnostics (QCMD) panels HPVDNA09 and HPVDNA10) by INNO-Lipa HPV Genotyping 
Extra (Innogenetics, Zwijnaarde, Belgium) and Full Spectrum PCR HPV Amplification and 
Detection/Genotyping System by Lab2Lab Diagnostic Service (GenoID Molecular 
Diagnostics Laboratory, Budapest, Hungary). Abbott RealTime High Risk HPV is multiplex 
realtime PCR for the detection of DNA from 14 HPV genotypes: 16, 18, 31, 33, 35, 39, 45, 
51, 52, 56, 58, 59, 66 and 68. As an additional feature, specific genotyping due to different 
probe labeling for HPV16 and HPV18 is possible. The assay is fully automated by use of 
m2000sp extraction and m2000rt amplification and detection instruments (Abbott, Madison, 
USA). INNO-Lipa HPV Genotyping Extra is based on the principle of reverse hybridization. 
Short fragment of HPV genome is amplified and biotinylated amplicons are hybridized with 
type-specific oligonucleotide probes that have been immobilized on the strip. After addition 
of streptavidin-conjugated alkaline phosphatase and consequent incubation with chromogen, 
colorimetric detection is performed automatically with the Auto-LiPA 30 instrument 
(Innogenetics, Zwijnaarde, Belgium). INNO-Lipa HPV Genotyping Extra recognized 15 
high-risk HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 and 82; 3 probable 
high-risk HPV types 26, 53, 66; 7 low-risk HPV types 6, 11, 40, 43, 44, 54 and 70 and 3 non-
classified HPV types 69, 71 and 74. Full Spectrum PCR HPV Amplification and 
Detection/Genotyping System by Lab2Lab Diagnostic Service (GenoID) is based on the HPV 
DNA amplification by PCR with consequent detection of PCR amplicons by solid phase 
hybridization. The results were provided for 13 high-risk HPV types 16, 18, 31, 33, 35, 39, 
45, 51, 52, 56, 58, 59, and 68; 2 probable high-risk HPV types 53 and 66 and 5 low-risk HPV 
types 6, 11, 42, 43 and 44. All 3 assays target conserved L1 region of HPV. All tests were 
performed according to the manufacturer’s instructions; GenoID results were available 
through Lab2Lab service. In case of limited HPV genotyping (HPV16, HPV18 and a pool of 
all other high risk HPV types included), concordance was considered to be present if 
HPV16/HPV18 result was matching of when at least one other high risk HPV genotype 
matched a positive pool in a limited genotyping test. Genotyping results only for genotypes 
present in both full HPV genotyping tests, INNO-Lipa and GenoID, were compared. 
Concordance in limited HPV genotyping was considered if the presence of HPV 16, HPV 18 
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or presence of any other common high risk HPV type were found. The follow-up data varied 
from 3 to 30 months (mean period of 14 months) post initial HPV genotyping. 
 
Results 
The comparison of genotyping methods on 214 initial samples revealed full concordance only 
for 49 (23%). Only 6 (12%) of these fully concordant samples presented multiple infections. 
Forty one (19%) of the initial samples showed non-concordance in limited genotyping and 27 
(13%) were discordant between 3 methods used regarding revealing presence of high risk 
HPV type. The detailed characteristics of the later group are presented in Table 1. For the 88 
patients cytological or histological data revealing CIN (CIN1 (n=38), CIN2 (n=28); CIN3 
(n=12)) or VAIN (VAIN3 (n=1)) lesion in follow-up were available. Full concordance in 
genotyping was present only in 19 (22%) samples. Nine (10%) of follow-up samples showed 
discordant results for the presence of high risk genotype between 3 tested genotyping methods 
either by negativity for high risk HPV by one of the methods (n=6) or by failure to genotype 
HPV (n=2) or by combination of both (n=1) (Table 2). Moreover, discordance for the 
detection of HPV16 or HPV18 was observed between 3 HPV DNA genotyping methods used 
in 9 (10%) follow-up samples (Table 3). Based on the results of external quality samples, 
HPV 16 was detected by Abbott and INNO-Lipa starting from 10 000 copies/4 ml; results for 
GenoID were less dependent on viral load. GenoID was not able to detect HPV 18 in the 
external quality sample with viral load of 10 000 copies/4 ml (Table 3). Patient’s age range 
was 16-65 years old, median: 32 years. Among the whole group, 20 (23%) patients positive 
for HSIL were younger that 30 years old. 
 
Discussion 
The clinical utility of HPV genotyping has recently gained more attention especially after the 
differences in oncogenic potential of high-risk HPV types has been observed as well as in the 
clinical setting of monitoring of women already treated for high grade CIN lesion or cervical 
cancer (Brink et al., 2007; de Sanjose et al., 2010). There is also a growing interest in the 
identification of multiple infections with various high-risk types due to their different 
infectious behaviour and carcinogenic potential (Liaw et al., 2001; Rousseau et al., 2001; 
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Woodman et al., 2007). However, the differences in performance of various available HPV 
genotyping methods have not been investigated in the clinical setting. There is a body of data 
available through the vaccine evaluation pointing out the need for continuous global 
proficiency studies due to the variation of performance of HPV genotyping methods (Quint et 
al., 2006; Eklund et al., 2010; Eklund et al., 2012; Eklund et al., 2014).
 
In the present study 
we observed marked differences in performance between INNO-Lipa HPV Genotyping Extra 
(INNO-Lipa) and HPV Full Spectrum PCR Amplification and Detection/Genotyping System 
(GenoID). Our finding that only minority of the samples (23% on initial samples and 12% at 
follow-up visit) were found fully concordant by genotyping methods accentuate the need for 
the constant efforts to the standardisation of these methods. The most concerning result of this 
study is the striking difference in the ability to detect the presence of high risk HPV types by 
these 3 CE-marked assays as 13% of samples were discordant regarding its high risk HPV 
presence on initial samples and 21% - on follow-up samples. The prognostic value of the 
detection of specific genotype as well as co-infection can become more important in the near 
future when more insights in the actual differences in the follow-up of co-infected women 
will be proposed. Recent IARC meta-analysis (Li et al., 2011) pointed out the variation 
according to the year of publication in HPV genotype distribution in invasive cervical cancers 
worldwide and the growing prevalence of detection of multiple HPV types. The main reasons 
to these observations are expected to be analytical methodological characteristics as increased 
sensitivity of the assays, increase in the types included in genotyping protocols as well as 
general rise in the quality and purification of biological reagents including DNA polymerases. 
The recent Danish study on 5064 samples using 4 different HPV assays (Rebolj et al., 2014) 
has also came to conclusion that assay design difference between the commercially applied 
tests is the most probable cause of considerable interassay disagreement. Also in our current 
study the samples with multiple infections presented the major challenge to the HPV 
genotyping methods used as only 12% of these samples were fully concordant. Other possible 
explanations for the differences between genotyping methods applied in the current study can 
be technical reasons, marked lot variations in commercial reagents used, accidental sampling 
error dividing LBC for HPV genotyping methods or high number of samples with low HPV 
viral load. However, it has been noted that the procedures were performed by the skilled and 
certified technical staff under the national accreditation procedures. Even if we focus on the 
most prevalent high-risk HPV types 16 and 18 in cervical cancer and on the differences in 
genotyping results for these types in our study, marked differences were observed. For HPV 
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16 the differences in genotyping results can be partly explained by various analytical 
sensitivity of the methods used; similar observation was achieved in typing of the external 
quality samples distributed by QCMD for HPV DNA testing in 2010: the concordance for 
genotyping results for samples containing high viral load (160 000 copies/4 ml) was 96.4% 
but declined to 42.9% for the external quality sample containing 1250 copies/4 ml 
(Schuuring, 2010). 
Guidelines for HPV DNA test requirements for primary cervical cancer screening in women 
of 30 years and older have been proposed and published by Meijer et al. in 2009. Briefly, 
these guidelines are based on the fullfillment for the candidate test of the non-inferiority 
criteria as compared to hybrid capture 2 assay regarding clinical sensitivity and clinical 
specificity for >=CIN2 as well as stringent requirements for inter- and intra-laboratory 
reproducibility. Detection of high-risk HPV is recommended in the available primary 
screening and triage algorithms while HPV genotyping is not currently proposed in either of 
the settings. Nevertheless, additional markers for the further stratification of risk of the 
developing of the invasive cervical cancer are being investigated and HPV genotyping, 
mainly for HPV16/HPV18, is one of the potential candidates. In the light of our findings there 
is a concern regarding poor comparability of HPV genotyping methods especially in the 
foresight of possible implementation of HPV genotyping as advanced triage of high-risk 
HPV-positive samples in primary screening for cervical cancer. Continous efforts on the 
standardisation of the methods used for HPV genotyping as well as ongoing inter-laboratory 
reproducibility assessments should be maintained. 
The study population was mainly represented by young women what once more emphasises 
the importance of HPV 16, 18 and 45 types as they are found more in the integrated state and 
in younger women suggesting faster progression to invasive cervical cancer (Vinokurova et 
al., 2008; Powell et al., 2013). 
Limitations of the present study are lack of extensive information about the study population, 
high number of lost to follow-up patients and different time to follow-up. These findings 
reflect the fact that the study population was presented by actual ambulant gynaecological 
population.  
The key message of our study is that irrespectively of the composition of the study population 
the genotyping results should be identical when various assays are used in order to make 
172 
 
comparable decisions in the management of the patient. From this point of view, the addition 
of African samples in order to enrich the Belgian pool of samples, can be considered as an 
added value of the current study. 
Therefore, as studies apply different HPV genotyping methods, it is mandatory to investigate 
the differences in their performance. The need for continuous global proficiency studies in 
and post vaccination era makes it obligatory to investigate the body of available data with 
comparable HPV genotyping methods. The use of international proficiency panels for the 
evaluation of HPV genotyping methods should be encouraged in the diagnostic laboratories 
prior to the effective utilisation of the test for the routine laboratory diagnosis. The concern of 
comparability of HPV genotyping methods is especially relevant in the foresight of the 
implementation of primary HPV screening for cervical cancer. 
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Table 1. Discordant initial results on limited
a
 genotyping between Abbott, INNO-Lipa and 
GenoID 
N
b
 
Abbott 
HPV16 
Abbott 
HV18 
Abbott 
Other 
HR 
HPV 
INNo-
Lipa 
HPV16 
INNo-
Lipa 
HPV18 
INNo-
Lipa 
Other HR 
HPV 
GenoID 
HPV16 
GenoID 
HPV18 
GenoID 
Other 
HR HPV 
12 negative negative positive negative negative positive negative negative negative 
8 negative negative positive negative negative positive negative negative X
c
 
6 negative positive positive negative positive positive negative negative positive 
3 positive negative positive positive negative positive negative negative positive 
2 negative negative positive negative positive positive negative negative positive 
2 negative negative positive negative negative negative negative negative X 
1 negative negative positive positive negative positive positive negative positive 
1 positive negative positive positive negative positive positive negative negative 
1 negative negative positive positive negative positive negative negative X 
1 positive negative positive negative negative positive positive negative positive 
1 negative negative negative negative negative negative negative negative positive 
1 positive negative negative positive negative negative negative negative negative 
1 negative negative negative negative negative X negative negative positive 
1 negative negative negative negative negative negative positive negative negative 
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Legend: 
a
limited genotyping: HPV 16, HPV 18 and presence of any other HR HP as detected 
by Abbott RealTime High Risk HPV test (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68);; 
b
N: number of discordant results; 
c
X: HPV present, further genotyping impossible. 
 
Table 2. Discordant results for the presence of high risk HPV samples between Abbott, 
INNO-Lipa and GenoID as compared to cytology or histology on follow-up 
Abbott INNO-Lipa GenoID Cytology/histology 
Other HR HPV
a
 69, 71, 51, 52  negative CIN1 (H
c
) 
Other HR HPV 45 negative CIN1 (H) 
Other HR HPV 52 X
b
 CIN1 (H) 
Other HR HPV negative 59 CIN1 (H) 
Other HR HPV 66 negative CIN2 (H) 
Other HR HPV 52,59 negative CIN2 (H) 
Other HR HPV 51,53,66,6,(52),HPV X X CIN2 (C
d
) 
Other HR HPV 39,51 negative CIN2 (C) 
Other HR HPV negative X CIN3 (C) 
 
Legend: 
a
Other HR HPV: other than HPV 16 or HPV 18 high risk HPV types included in Abbott 
RealTime High Risk HPV test (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68); 
b
X: HPV present, 
further genotyping impossible; 
c
H: histological result; 
d
C: cytological result. 
Table 3. Discordant results for the presence of HPV16 or HPV18 between Abbott, INNO-
Lipa and GenoID as compared to cytology or histology on follow-up 
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Abbott INNO-Lipa GenoID Cytology/histology 
Other HR HPV
a
 18, 33, 53, 59, (39)
b
, (52), (54) 59 CIN1 (C
c
) 
Other HR HPV 18, 45, (39), (68) 45 CIN1 (C ) 
Other HR HPV, HPV 16 16, 35 35 CIN1 (C ) 
Other HR HPV, HPV 16 16, 33, 35, 53, 74, (52), (54) 59 ,53, 33 CIN2 (H
d
) 
Other HR HPV 16, 51, 74, X
e
 51, 68, 16 CIN2 (H) 
Other HR HPV , HPV 18 18, 51, 53, 56, 66, (39), (52), (74) 51, 56, 59, 53, 66 CIN2 (H) 
Other HR HPV, HPV 18 18, (39) 39 CIN1 (C ) 
 
Legend: 
a
Other HR HPV: other than HPV 16 or HPV 18 high risk HPV types included in 
Abbott RealTime High Risk HPV test (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68); 
b
(HPV genotype): overlapping hybridisation pattern, HPV genotype between parentheses can 
not be excluded; 
c
C: cytological result;
 d
H: histological result;  
e
X: HPV present, further 
genotyping impossible. 
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Table 4. Results of QCMD Human Papillomavirus EQA Programme by Abbott, INNO-Lipa 
and GenoID 
Panel code 
Sample 
contents 
Sample 
concentration* Abbott INNO-Lipa GenoID 
HPVDNA09-01 HPV 16 20 000 HPV 16 HPV 16 HPV 16 
HPVDNA09-02 HPV 16 40 000 HPV 16 HPV 16 HPV 16 
HPVDNA09-04 HPV 16 5 000 HPV negative HPV negative HPV 16 
HPVDNA09-05 
HPV 
negative / HPV negative HPV negative HPV negative 
HPVDNA09-07 HPV 67 40 000 HPV negative HPV X
**
 HPV X 
HPVDNA09-09 HPV 16 10 000 HPV 16 HPV 16 HPV 16 
HPVDNA09-10 HPV 16 1 250 HPV negative HPV negative HPV negative 
HPVDNA10-02 
HPV 
negative / HPV negative HPV negative HPV negative 
HPVDNA10-03 HPV 16 160 000 HPV 16 HPV 16 HPV 16 
HPVDNA10-04 HPV 16 10 000 HPV 16 HPV 16 HPV 16 
HPVDNA10-05 HPV 67 20 000 HPV negative HPV X HPV X 
HPVDNA10-06 HPV 16 40 000 HPV 16 HPV 16 HPV 16 
HPVDNA10-07 HPV 16 2 500 HPV negative HPV negative HPV negative 
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HPVDNA10-08 HPV 18 10 000 HPV 18 HPV 18, (39)
***
 HPV negative 
HPVDNA10-09 HPV 16 80 000 HPV 16 HPV 16 HPV 16 
HPVDNA10-10 HPV 16 1 250 HPV negative HPV negative HPV negative 
HPVDNA10-11 HPV 16 20 000 HPV 16 HPV 16 HPV negative 
 
Legend: *:  copies/4 ml; 
**
HPV X: HPV present, further genotyping impossible; 
***
: (genotype): 
overlapping hybridisation pattern 
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Abstract 
Objective: Human papillomaviruses (HPV) are classified according to their potential for the 
development of cervical neoplasia. However, the carcinogenicity of HPV types forms an 
evolving continuum based on the newly available data especially regarding the role of 
probable and possible high-risk HPV types (pHR-HPV). The objective of the present work 
was to evaluate clinical significance of the pHR-HPV53.  
Study design: An observational cohort study of potential aetiological association between 
infection with HPV53 and development of high-grade cervical cytology was performed.  The 
study was conducted in two geographically remoted hospitals, in Belgium and Democratic 
Republic of Congo, as an attempt to collect data from regions with different geographical 
distribution of HPV genotypes. The samples were taken during routine gynaecological visit in 
outpatient clinics of both participating hospitals.  
Results: A total of 2283 liquid-Pap samples from were taken from 1465 women at Ghent 
University Hospital, Belgium, and from 660 women at General Hospital and Ngaliema 
Hospital of Kinshasa, DRC. “HPV53-only”-pattern as evaluated by full HPV genotyping was 
found in samples from only 34 (1.6%) samples. The initial cytology represented next to non-
dysplastic, undetermined and low-grade lesions also high-grade lesions (12%). For 26 
(76.5%) from the 34 women presented with “HPV53-only”-pattern follow-up results were 
available showing no progression to malignancy.  
Conclusion: Our findings support very low to lacking carcinogenic potential of HPV53. 
Recognising extreme rarity in cervical cancer next to high prevalence in general population of 
HPV53, further studies investigating progression to high-grade lesions are needed to elucidate 
the oncogenic potential of pHR-HPV53. 
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Introduction 
Epidemiological classification of human papillomaviruses (HPV) as high, low and probable 
high-risk is based on their association with cervical cancer. HPV types 26, 53 and 66 are 
within this classification determined as probable high-risk types based on their detection in 
few malignant cases and only in controls [1, 2]. According to the recent review of 
International Agency for Research on Cancer (IARC) assessing carcinogenicity of biological 
agents, HPV types 26, 53, 66, 67, 70, 73 and 82 as remaining types in mucosotropic alpha 
genus are classified as “possibly carcinogenic” based on limited evidence of their 
involvement in cervical cancer while HPV68 is classified as “probably carcinogenic” 
acknowledging its strong mechanistic evidence [3]. Recent studies have shown viral oncogene 
transcription of  possible high-risk HPV (pHR-HPV) types 26, 66, 70 and 82 in cervical 
cancer as well as detection of HPV73 in cancer specimens highlighting oncogenic potential of 
these pHR-HPV types and supporting reassessment of their carcinogenicity classification 
while HPV53 was shown to be lacking biological activity in cervical cancer [4, 5].  
Especially differences in carcinogenic potential between HPV53 and HPV66 are intriguing as 
they both belong phylogenetically to α-6 species, show almost similar prevalence in low-
grade squamous intraepithelial lesions (LSIL) as well as an comparable estimated potential 
for progression to malignancy and are both highly genetically diverse with distinct intratype 
variants [6-9]. There is currently no evidence that L1 polymorphisms are associated with 
cervical malignancy but the diversity of these types and their worldwide distribution are 
striking [10-13]. While the detection of HPV66 is currently included in the majority of 
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commercially available tests for cervical cancer screening, convincing data on the clinical 
significance and malignant potential of HPV53 are lacking [14, 15]. 
The objective of the present work was to evaluate clinical significance of the HPV53 on the 
follow-up data of cervical smears initially positive for HPV53 and not accompanied by 
presence of any tested high-risk HPV type (“HPV53-only”).  
Materials and Methods 
An observational cohort study of potential aetiological association between infection with 
HPV53 and development of high-grade cervical cytology was performed.  The study was 
conducted in geographically remoted hospitals, Ghent University Hospital, Belgium and 
General Hospital and Ngaliema Hospital of Kinshasa, Democratic Republic of Congo (DRC), 
as an attempt to collect data from regions with different geographical distribution of HPV 
genotypes. Recruitment in Ghent University Hospital took place from February 2008 till July 
2009 and in General Hospital and Ngaliema Hospital of Kinshasa from July 2009 till August 
2009. The samples were taken during routine gynaecological visit in outpatient clinics of both 
participating hospitals.  The samples were referred for HPV testing after an initial cytological 
screening of the liquid-based Pap test (PreserCyt Solution; Cytoc UK, Crawley, UK). The 
evaluation of cervical lesions was performed according to Bethesda classification of cervical 
cytology: Negative for squamous Intraepithelial lesion or malignancy (NILM), Atypical 
Squamous Cells of Undetermined Significance (ASC-US), Low-grade Squamous 
Intraepithelial Lesion (LSIL) and High-grade Squamous Intraepithelial Lesion (HSIL).  HPV 
DNA detection was performed using the HPV Full Spectrum PCR Amplification and 
Detection/Genotyping System (Lab2Lab Diagnostic Services; GenoID Molecular Diagnostics 
Laboratory, Budapest, Hungary), recognising HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 
56, 58, 59, 66, 68, 6, 11, 42, 43, 44 and 53 [16]. The subject was considered to be eligible for 
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the study if “HPV53-only”-pattern was observed considered when solely HPV53 without any 
of the above mentioned HPV types except 6, 11, 42, 43 or 44 was detected. No additional data 
on potential confounding factors as HIV status and previous of current history of other 
sexually transmitted infections has been collected. An estimation of follow-up visit in 24 
months after initial cytology and HPV genotyping result was proposed. 
Results 
A total of 2283 liquid-Pap samples from were taken from 1465 women at Ghent University 
Hospital, Belgium, and from 660 women at General Hospital and Ngaliema Hospital of 
Kinshasa, DRC. “HPV53-only”-pattern as evaluated by full HPV genotyping was found in 
samples from only 34 (1.6%) samples. The initial cytology of these study subjects comprised 
9 ASC-US  samples, 19 LSIL samples (corresponding to histological classification of cervical 
intraepithelial neoplasia (CIN)1), 4 HSIL samples (corresponding to histological classification 
of CIN2) and 2 samples revealed NILM. The data on initial cytology are presented in Table 1. 
HPV53 in association with any of HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 
68 was detected in 72 (3.2%) of total amount of samples. For 26 (76.5%) from the 34 women 
presented with “HPV53-only”-pattern follow-up results were available. The data on 
cytological and histological follow-up are presented in Table 2. Summarising, no evolution to 
high-grade lesions was found during the mean follow-up period of 26 months (range 2 – 48 
months).  
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Table 1. Initial cytological results of “HPV 53-only” positive women. 
Hospital 
“HPV 53-
only” 
NILM
a
 ASC-
US
b
 
LSIL
c
 HSIL
d
 
Ghent University Hospital, Belgium 33 2 8 19 4 
       
General Hospital and Ngaliema Hospital 
of Kinshasa, DRC 
1  1   
      
 
NILM
a
: negative for squamous intraepithelial lesion or malignancy; ASC-US
b
:  atypical 
squamous cells of undetermined significance; LSIL
c
: low-grade squamous intraepithelial 
lesion;  HSIL
d
: high-grade squamous intraepithelial lesion. 
 
Comments 
In the present study we could not find association between sole presence of HPV53 (“HPV53-
only”-pattern) as investigated at the time of initial cytological examination and progression to 
high-grade cervical lesion over the mean follow-up period of 26 months. Our findings do not 
support the evidence of the carcinogenic potential of HPV53 in cervical cancer and are 
consistent with the previously published reports showing lack of carcinogenic activity of this 
pHR-HPV type [4, 5, 17].  
The carcinogenicity of HPV types forms an evolving continuum with a permanent need of 
reclassification based on the newly available data. The data acquisition itself can be prone to 
variations based on the culturally different follow-up algorithms and end-point evaluations, 
quality of cytological specimens and biopsies taken next to the variety of HPV genotyping 
methods available with none of them as the reference standard [18, 19]. 
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Table 2. Follow-up cytological and histological data of “HPV 53-only” positive women. 
Initial cytology Follow-up cytology Follow-up histology 
ASC-US
a
 (5)
 b
 NILM
c
 (3)   
  LSIL
d
 (1)   
LSIL (16) NILM (14)   
    NILM (2) 
HSIL
e
 (4) LSIL (1)   
    NILM (3) 
NILM (1) NILM (1)   
 
ASC-US
a
: atypical squamous cells of undetermined significance; (5)
b
:  Numbers between 
parenthesis refer to absolute numbers of cases with corresponding cytology or histology; 
NILM
c
: negative for squamous intraepithelial lesion or malignancy; LSIL
d
: low-grade 
squamous intraepithelial lesion;  HSIL
e
: high-grade squamous intraepithelial lesion. 
 
The IARC Working Group has stated in its recent report that despite being relatively 
commonly present in population worldwide, HPV53 occurred extremely rare alone in 
invasive cervical cancer and in certain geographical regions (eg Oceania) and noted a concern 
regarding inclusion of this type, HPV70 as well as HPV66 in screening assays which would 
decrease the specificity and positive predictive value without substantial gain in sensitivity 
and negative predictive value of these methods [20, 21, 22, 23]. Especially recognising their 
extreme rarity in cervical cancer next to high general prevalence, studies as the current one 
investigating on relatively large initial cohort the progression to HSIL over time are of great 
value to gain more insight in the nature of pHR-HRV in general and HPV53 in particular. 
One of the limitations of the current study is a lack of the knowledge of the HIV serological 
status of the study subjects. In an HIV positive population, a higher prevalence of HPV 
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infections can be found, and often also a higher grade of co-infection with multiple HPV 
genotypes. Different distribution of HPV genotypes could be also noted in HIV-positive 
women with HSIL who were significantly more likely to be infected with HPV53 as found in 
the recent meta-analysis on this topic (24). Maranga et al. describe a significantly higher 
prevalence of HPV53 in the HIV positive part of the study population when compared to the 
HIV negative controls (91.7% of all HPV53 infections occurred in HIV positive women) [25]. 
However, even in the HIV positive population, there was a complete absence of HPV53 in the 
invasive cervical cancer cases.   
An important secondary role for HPV genotypes as HPV53 could be hypothesized. Mejhede 
et al. (2010), suggest that infections with certain HPV types might depend on the existence of 
certain other HPV types [26]. Based on this observation, a specific role for HPV53 could be 
suggested, inducing synergism between HPV53 and other HPV genotypes. To confirm this 
hypothesis, research efforts to identify commonly occurring HPV genotype pairs in multiple 
infections need to be performed to generate evidence for the synergistic relationship between 
different HPV genotypes. Important consequences would include that in the post-vaccine era, 
specific HPV genotypes will disappear from the population, leaving opportunity for 
phenomena as type replacement. It is unclear, with the selective removal of certain HPV  
genotypes, how the other, ‘less virulent’ genotypes will behave. 
Conflict of interest declaration: The authors declare that they have no conflict of interest. 
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General Discussion 
 
 
This study summarizes the results of investigations carried out in Kinshasa, the capital of the 
Democratic Republic of Congo (DRC). The purpose was to obtain knowledge about cervical 
cancer and to study the possibilities to develop a screening and treatment program in the 
future. The DRC is a low-income country with a gross domestic product (GDP) of about 680 
I$ per capita and a budget for health care of 3.5% of the GDP (WHO 2013, [1]).  
The set-up of a preventive network for cervical cancer, the most frequent cancer in women of 
Sub-Saharan Africa, encounters a number of substantial difficulties: absence of a national 
cancer program, lack of adequate equipment and expertise for cytology, HPV determination 
and preventive treatment and low awareness of the population about cancer. 
1. Knowledge, attitude and practices about cervical cancer in Kinshasa 
The KAP study explored the knowledge (K), attitude (A), and associated practices (P) of 
women in Kinshasa with regard to cancer of the uterine cervix. The results support the view 
that the awareness about cervical cancer among African women, and especially its prevention 
and treatment, is very limited. The lack of awareness is considered as one of the multiple 
factors that contribute to inefficient screening in low-income countries [2,3].   
In Sub-Saharan Africa, only a small percentage of women regularly participate in cervical 
cancer screening [4].  
Future sensibilization campaigns should take in account that several socio-demographic 
factors as the place of residence, level of education, occupation, marital status, and religion 
were found to affect the women’s knowledge, attitude, and/or practice (KAP), as 
demonstrated in our study. Knowledge of these factors can be used for designing and 
monitoring future screening programs. 
 
In the KAP paper we mentioned the shortcomings of the KAP analysis. Our study population 
did not include women who were not at home when the interviewers visited their houses, nor 
did it include women who did not want to participate. A second important concern is the 
KAP survey method itself. Launiala [5] summarized several limitations of the KAP method 
including the difficulty of expressing concepts of western medicine in a local African 
language, the possibility of social desiderability bias (i.e. the tendency of interviewers to 
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over-report what they believe to be “good behaviour”), and the fact that the KAP survey is 
not a good method to obtain in-depth information about sensitive issues. In spite of these 
limitations, this study represents a first attempt to systematically explore and document KAP 
about cervical cancer among women in the DRC. 
This KAP study revealed  that a large majority of women reported to have heard about 
cervical cancer confirming other studies in different African countries. In agreement with 
other reports there was also the low percentage of women who related cervical cancer to 
sexual  behavior. Although newspapers, radio and television are easily accessible in Kinshasa, 
word-of-mouth communication was the most important source of information. Although in 
some other African countries the media took the first place, oral communication remained 
important to exchange information on health issues. In rural areas without electricity, where 
most of the Congolese population (about 70 million) are living, it is the only way of 
communication. Marked differences are expected to exist between rural areas and the urban 
environment which is favoured by easy access to information. Even in Kinshasa, we found 
that the place of residence was associated with women’s knowledge about cervical cancer. 
The contribution of the media and oral communication may become increasingly important 
when the government and institutions might start a campaign of cancer prevention. 
Furthermore, because of the oral culture, churches may play an important role in the transfer 
of information on health care issues. 
Our study confirmed the low coverage rates for cervical cancer screening in developing 
countries: on average 19% compared to 63% in high-income countries [4]. Only 9% of the 
interviewed women in our study had ever had a Pap test. According to a recent review 
summarizing the situation in 15 developing countries as few as 4 % of the women aged 18-
69 years had undergone a pelvic examination or a Pap smear test in the last three years [6]. 
The mean reason for these low coverage rates for cervical cancer screening in developing 
countries is poor access to health care in general, and the lack of specific screening and 
treatment facilities. Another interesting result of the study is the willingness of women to 
participate in a screening program if it is free of costs. This suggests that the financial aspect 
will determine the success rate of a future screening program. Most women gaining 1-2 $ a 
day of hard work will be unable to pay the 30 to 50 $ for a Pap smear test. Furthermore, if 
screening is already an obstacle because of the high cost, it is difficult to motivate women to 
pay even more for preventive treatment such as loop electrical excision procedure (LEEP) or 
cryotherapy.  
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There was no correlation between knowledge and practice. The correlations between 
knowledge and attitude scores and between attitude and practice were significant but weak. 
That means that increased knowledge will not automatically lead to changes in attitude and 
practice. These findings fit with studies in which a high level of awareness, as encountered in 
medical students and physicians, was found to be associated with a low level of practice [7-
9]. 
Because of  the association between sexually transmitted HPV infection and cervical cancer, 
questions about sexual behaviour were included in the Practice section. A large majority of 
the respondents declared to have had sexuals contact with maximum one partner during the 
last year. In a comparative study on the number of sexual partners in Uganda, Zimbabwe and 
South-Africa men  above 35 years were reported to have had around 10 ‘lifetime’ sexual 
partners [10]. In the same study women were reported to have a much lower average of 2 or 3 
lifetime partners. In all age groups less than 5% of women reported more than one sexual 
partner in the past 12 months (see [11] for review).  
The discrepancy between knowledge and behavior also explains that even in high-income 
countries where information about cervical cancer is easily available, the effective coverage 
of screening was found to be only 63% [4]. We found that knowledge was associated with 
four socio-demographic factors: the place of residence within Kinshasa, level of education, 
occupation and marital status. Overall, the participants who were most likely to have a 
sufficient knowledge score were the married women with a degree of higher education. From 
the data available we could not find a good explanation for the association between the place 
of residence and the level of knowledge. Maybe it is the presence of the university of 
Kinshasa and higher biomedical institutes with more than 30.000 students living with local 
people in Mont-Ngafula that influences knowledge about health matters.  
Although the women from Mont-Ngafula scored well on knowledge, this was not reflected in 
the attitude score. This illustrates the poor correlation between knowledge and attitude. 
Adherents to the Catholic church had a better score than the category ‘other religions’ that 
included a series of small and diverse churches. Religion was not associated with a better 
practice. For practice, marital status and place of residence were independent predictors of a 
sufficient score.  
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We found no significant associations between parity and KAP suggesting that women did not 
learn about cervical cancer when they had contact with health services. The fact that only 4% 
of the women mentioned doctors or health services as a source of information about cervical 
cancer is an additional illustration of a missed opportunity  
Our study illustrates that women want to participate in screening initiatives. But this 
willingness has to be associated with the availability of an effective treatment at a reasonable 
and low cost. 
 
2. Prevalence and co-factors of precancerous lesions 
The high prevalence of precancerous lesions reported in Sub-Saharan countries explain the 
high age-standardized incidence rate of cervical cancer in low-income countries amounting to 
about 30-35 per 100.000 women per year year [12-16]. In contrast, in high-income countries 
as the US and Europe the age-standardized incidence rate is about 6-10 per 100.000 women 
per year year [12-15]. But differences are even higher for the number of  deaths from cervical 
cancer: this is nearly 10 times lower in high-income countries [17,18]. 
Variations between low- and high-income countries have been related to differences in 
exposure to risk factors and adequacy of screening. Several co-factors have been found to 
increase the risk of cervical cancer:  the number of sexual partners, early sexual activity 
activity [19], parity [20], long-term use of oral contraceptives [21-23], cigarette smoking [24] 
and HIV/AIDS as the main risk factor [25-27]. Most of these co-factors have been related to 
the risk of HIV and HPV infection.  
Since little data are available on the prevalence of the different HR HPV types and the 
occurrence of precursor lesions in the DRC we conducted a cross–sectional study in different 
groups of women in Kinshasa. The cut-off of precancerous lesions was set at the level of the 
Bethesda category LSIL. The study was conducted with a sample of 1018 women. Pap smears 
were collected and treated for LBC from women with an unknown HIV serology (groups 1 
and 2) and from women with a HIV-negative (group 3) and HIV-positive (group 4) serology.  
The prevalence of (pre)cancerous lesions ranges from about 4% in groups with unknown or 
negative HIV status (groups 1-3) to 31% in the group of HIV-positive women (group 4). The 
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percentages were similar in the three groups of women recruited in different ways (3.9% in 
group 1, 4.1%  in group 2, and 3.9% in group 3).  
Comparable findings have been reported for women with a seronegative or unknown status 
for HIV in other Sub-Saharan countries with a mean value of 7.4% in 12 studies (range 3.8% 
- 16.4%). The prevalence is also comparable with previous studies performed in Kinshasa 
[28,29] and in Bukavu in the eastern part of the country [30]. In these studies, prevalences of 
4.9 % (Kinhsasa) and 7 % (Bukavu) have been reported. For HIV-seronegative commercial 
sex workers in Kinshasa, a prevalence of 3 % has been published [28].  
Cervical cancer is known to be more frequent among HIV-positive women. The high 
percentage of 31% of  LSIL and HSIL in HIV-positive women   confirms earlier findings (27 
%) in a small group of seropositive women in Kinshasa [28]. These values for HIV-positive 
women in the DRC are comparable with those found in other Sub-Saharan countries (for 
details see paper in chapter 5 and 6): (mean 30%, range 10.9% – 73% in 9 studies). The 
prevalences in these countries are about 5 times higher in HIV-positive women than in 
seronegative women or in women with unknown serology. Several reports have demonstrated 
that HIV-positive women are more likely to have persistent HPV infections than HIV-
negative women [31-33].  
We found that in the group with HIV-positive serology, infection by  HIV markedly increased 
the risk for development of suspect cervical lesions. On bivariate analysis, four independent 
variables other than HIV infection were significantly associated with the presence of a suspect 
lesion: age, number of childbirths, a history of abortion, and marital status. Two of these 
variables (multiparity and marital status) were confounders for the association between HIV 
infection and the presence of a suspect lesion. But the association between a positive HIV 
serology and the presence of a suspect lesion remained siginificantly strong. In HIV-positive 
women the CD4+ count was significantly lower in those with suspect lesions. This finding 
indicates that the factor immunity plays an additional role in increasing the risk of a persisting 
HPV infection.  
In the groups 3 and 4 with unknown HIV serology, we found that the intravaginal application 
of plants increased the risk of precursor lesions. Although the number of sex partners could be 
a confounding factor in this association, it was not. There was no significant association 
between use of plants for vaginal care and having three or more lifetime sex partners. This 
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effect was not seen for intravaginal application of chemical or pharmaceutical products. It is a 
frequent practice in Sub-Saharan Africa to use herbs and leaves to reduce vaginal lubrication 
and to increase friction during sexual intercourse (dry sex); this practice has been reported in 
the DRC, Zimbabwe, Malawi, Zambia, Kenya, South Africa, KwaZulu-Natal. One study 
conducted in the current territory of the DRC revealed that one-third of the women had used 
intra-vaginal or tightening substances at some time [34]. Most of these studies have been 
performed in relation to the risk of HIV, less extensively in relation to cervical cancer. 
Increased friction during sexual intercourse may cause traumatic lesions and inflammation in 
the vaginal wall facilitating the entry of the HPV virus. In addition, insertion of herbs may 
alter the vaginal microflora and may lead to bacterial vaginosis. It has been shown that there 
is an increased risk for women with bacterial vaginosis to be infected with HPV [35] and to 
develop HPV-related lesions [36].  
Although the insertion of plants to reduce lubrication is a widely applied practice in Sub-
Saharan Africa, it cannot be generalized. Studies on the acceptability of microbicidal vaginal 
gels indicated that, at least in some regions, dry sex seemed not to be a common practice [37].   
3. Typing of HR HPV 
There is no doubt about the causal link between cervical cancer and HPV infection [33,38-
40].  All known HPV types are currently classified into five genera (alpha, beta, gamma, mu 
and nu). About 40 different HPV types from the genus alpha are known to infect the mucosal 
epithelium.  Ten to fifteen HPV types have been associated with lesions that can progress to 
cancer in humans [41-43]. These are the high-risk HPV (HR-HPV) types from which types 
HPV16 and HPV18 are the most frequently found [44]. There is some uncertainty about the 
categorization of alpha-HPV in different risk categories (high-risk, possibly carcinogenic, 
probably carcinogenic, low-risk), and certain HPV types have been moved from one category 
to the other. The following HPV types are considered to be carcinogenic: HPV16, HPV18, 
HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52, HPV56, HPV58 and HPV59 (for 
review see [40,45]). HPV26, HPV53, HPV66, HPV67, HPV70, HPV73 and HPV82 are 
currently classified as possibly carcinogenics, with HPV68 as probably carcinogenic.  
The IARC Working Group concluded in its recent report [46] that despite relatively common 
worldwide, HPV53 occurred extremely rare alone in cervical cancer. We found a frequency 
of HPV53 (2.2%) in a cohort of 1.465 women. During a follow-up of 26 months no 
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progression to malignancy could be found underlining the very low or lacking carcinogenic 
potential of HPV53. Although the potential of HPV53 to induce cancer may be very low, it is 
not excluded that it may induce synergy or competition with other HPV types [47]. According 
to these authors some less carcinogenic HPV types (as HPV53) might play a secondary role: 
infections with certain HPV types might depend on the co-existence with other HPV types. If, 
in addition to co-existence, an interaction exists between these HPV types such interaction 
may either positively or negatively influence the rate of progression to cervical cancer [48] 
and decrease or increase the efficacy of of current HPV vaccines that offer mainly type-
specific protection [47,49]. Cervical infection with multiple HPV types is common finding 
among women in all age groups (see [49]), and is even more pronounced in HIV-positive 
women [48]. 
The prevalence of HR HPV infection has been found to be highest in Sub-Saharan Africa 
[50]. Although type 16 seems to be the most frequently found in Sub-Saharan Africa, other 
oncogenic types may be important as well, and their relative proportion may differ from one 
country to the other [33,48,51,52]. In a comparative study on HPV type distribution in Ghana, 
Nigeria and South Africa, about 90 % of samples were HPV positive and HPV 16, 18, 45 and 
35 were the most common types [33]. Other studies in Sub-Saharan Africa confirm the 
relative importance of HPV 16 and/or 18 [53-55]. In other Sub-Saharan countries, other types 
were more frequently found  [31,48,56-58] and HIV infection appears to alter the spectrum of 
HPV types found in cervical smears and invasive carcinomas [48].  
In our study HR HPV DNA was detected in 96% of the samples of HIV-positive women in 
the Bethesda categories ASCUS+, and in 79% of the samples from the women with unknown 
and HIV-negative serology. In the HIV-positive group HPV16 was found in 20% of samples, 
and HPV18 in 5%. Other frequently found genotypes were: HPV35 (24%), HPV52 (24%), 
HPV68 (24%), HPV51 (20%), and HPV31 (18%).  The most frequently detected genotypes in 
women with unknown and negative HIV serology were: HPV52 (n=24%), HPV35 (12%), 
HPV16 (6%), HPV18 (10%), HPV51(10%), and HPV54 (10%). When we add the three 
samples in which HPV16 was found with the Abbot Real Time and the GenoID tests to the 
INNO-LiPA results, the frequency of HPV16 amounted to 12%. While in the seronegative 
and HIV-unknown group the majority (55%) of HPV-DNA-positive samples contained a 
single HPV type, the presence of one single HPV type was rather exceptional (20%) in the 
HIV-positive group of women.  
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These results on HR HPV typing illustrate the variation in the relative frequency of HR HPV 
types between different studies depending on region, cytology and HIV status. In agreement 
with recent findings in different geographic regions [48,59] we found a differend spectum of 
HPV types in HIV-negative and HIV-positive women. Previous to our study, a few data on a 
small number of women had been published for the DRC. HR HPV DNA was found in 9 of 
11 HIV-positive women, three of which were identified as HPV 16; HPV 18, 31, 33 and 56 
were present in each of the other samples that were sequenced [60]. In 58 HR HPV-positive 
samples of women with unknown HIV serology in Bukavu, the most frequent HR HPV type 
was 35, followed by 45 and 16 [30]. The differences in HPV types in HIV-infected women 
are particularly interesting because some reports indicate that less virulent HPV types may 
cause malignant transformation in HIV-positive women [59].  
We found that HPV53 classified as “possibly carcinogenic” [46] occurred as the ‘only HPV 
virus’ in 2.2% of Belgian women with ASCUS+ lesions. It was found in 1 on 50 women in 
Kinshasa. Follow-up during 26 months of the Belgian women infected with HPV53 showed 
no progression to malignancy. There was no follow-up information of the Congolese woman. 
Therefore, our results support the classification of HPV53 as a weak carcinogenic.  
Over the years, increasing importance has been spent on the issue of primary screening 
applying molecular techniques based on the presence of HR HPV DNA. This application in a 
primary screening setting or as a triage for cytological abnormalities is now under 
investigation in low-income countries. In this respect, future tests have to be accurate, simple, 
rapid, stable in humid and hot conditions, and importantly: to be successful as a screening test 
it has to be at low cost.  
In our comparative study on different techniques for genotyping HR HPV (Abbott, GenoID, 
INNO-Lipa) we found major differences in the ability to detect HR HPV types. Full 
concordance was only found in 23% of samples. The (dis)concordance was highly dependent 
on the viral load with increasing discordance with decreasing load. Discordance even 
persisted when genotyping was performed on external quality samples with a low viral load. 
An underestimation of the presence of certain HR HPV genotypes present at relatively low 
concentrations in multiple HPV infections has been recently described for the evaluation of 
vaccine efficacy [61].  
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Our findings accentuate the importance of careful interpretation of data from studies using 
different HPV genotyping methods and underline the need for standardisation by method 
validation in clinical laboratories especially in the foresight of primary HPV screening. 
These findings may have also important consequences regarding the generalization of 
vaccination with types 16 and 18 in Sub-Saharan countries. Fortunately, cross-protection 
against non-vaccine HR HPV types broadens the range of efficacity of Cervarix (HPV 16/18)  
and Gardasil (HPV 6/11/16/18) which are partially effective against the additional HPV types 
included in the nonavalent vaccine Gardasil 9 (HPV 6/11/16/18/31/33/45/52/58).  In a recent 
comparative study on the efficacity of Gardasil and Gardasil the nonavalent HPV vaccine 
showed significant increased potential impact compared to the quadrivalent vaccine [62]. In 
view of our findings and data from the literature on HR HPV types in Sub-Saharan Africa 
polyvalent vaccines may be a better option.  
 
4. Conventional versus Liquid-Based Cytology (LBC) in a low-income setting 
 
 
We evaluated the accuracy of the conventional smear (CS) test in comparison with results 
obtained with LBC in the setting of Kinshasa. We analyzed smears of 128 HIV- and 132 
HIV+ women with  the CS test and with LBC. We found that high grade dysplastic lesions 
(CIN2/3 and CIS/invasive cancer) were about 8 times more frequent in HIV+ women. A good 
concordance could be found between the results based on the CS test and LBC in HIV-
negative women, although a tendency towards a lower sensitivity with the Pap test could be 
observed. This tendency was even more pronounced in HIV-positive women. The lower 
sensitivities and lower negative predictive values were caused by a higher number of false 
negative cases. Although we could not find a direct explanation, the lack of accuracy could be 
caused by the severe inflammatory and reactive change of the epithelium in HIV+ women 
complicating correct interpretation of the slides.  
Based on these findings, and referring to the extensive literature on cervical cancer screening, 
what would be our policy concerning the most suitable screening test for cervical cancer in 
the Congolese context in the future?  
The CS test has been proven to be highly efficient to reduce the prevalence and mortality of 
cervical cancer in countries where it has been applied as the primary screening test for 
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cervical cancer. In most Sub-Saharan countries the most widely used test remains the CS test. 
Even with its limitation, in the hands of a skilled pathologist the CS test remains a valuable 
screening tool. The accuracy of LBC is not significantly different from conventional cytology 
for detection of CIN of grade 2 or more [63-66] or may be even lower [67]. Special attention 
has to be given to HIV-positive women because precancerous lesions can be easily missed 
with the CS test. 
The few reports that exist on the prevalence of cervical cancer in the DRC are based on 
conventional cytology. Because of the absence of a national registration system the 
prevalence of cervical cancer based on histopathological data is largely unknown. Therefore, 
information on cervical cancer in the DRC is based on extrapolations of surrounding Sub-
Saharan countries. Direct cytological data are only available for Kinshasa and Bukavu. There 
is no information on the situation in rural areas where the majority of Congolese women lives, 
nor is there information on the follow-up of the few studies that have been performed in both 
cities.  
As to the choice between the CS and LBC, there is no option in low-income settings: the LBC 
technique is too expensive and difficult to apply because of the too small number of 
pathologists and qualified cytotechnicians. In the DRC about 14 pathologists (October 2015) 
are active for a population of about 70 million people; about 10 of them are working in 
Kinshasa. Apart from the screening problem, there is also the lack of preventive therapy 
halting the progression of precancerous lesions into cancer; 
Another approach is the ‘see-and-treat’ method which is based on the visual inspection of the 
cervix after it has been stained with acetic acid (visual inspection with acetic acid, VIA) 
or/and Lugol’s Iodine (VILI). This is a low-cost screening method that has the advantage that 
suspect lesions can be treated immediately with cryotherapy or LEEP. It has been extensively 
applied in some low-resource settings as a useful alternative for cytological screening [68-72] 
as a useful alternative. The ‘see-and-treat’ approach is practically totally lacking in Kinshasa. 
Cryotherapy cannot be currently applied because the freezing gazes CO2 and N2O are not 
regularly imported. The sensitivity and specificity markedly varies between different studies 
indicating that individual expertise may play an important role in the final result. 
Whether a strategy will be successful or not finally depends on the cost. How to participate in 
a screening program if the cost of a smear ranges between 30-50 $, and the cost of a LEEP 
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about 150 $. Women have to make a choice between paying the school of their children and 
preventive treatment of a disease that may become a risk 10 years later. Only when screening 
will be without payment and supported by the governement, screening can have a chance of 
being successful. Even in countries where the cost of screening does not play a major role, 
coverage of screening is below 80% ranging between 10% and 79% % [73]. In Belgium the 
screening recoverage is about 60% and depends on the age group studied (from 70% in the 
age group 25-34 years to 44% in the age group 60-64 years) [74]. A recent study in Sweden 
on compliance with clinic-based cervical cancer screening [75] illustrates that even in high-
income countries time, travel costs and other direct non-medical costs may constitute barriers 
to screening while knowledge on HPV may facilitate compliance with screening. Because of 
unsatisfactory screening coverage new procedures have been developed in high- as well as in 
low-income countries to recruit nonscreened women, particularly those at increased risk for 
cervical (pre)cancer. One of these is self-sampling. Several studies have shown that self-
sampling for HPV testing and educational efforts to increase knowledge about HPV and 
cancer, increased the rate of compliance in low-resource settings [76-78]. 
Several cost-effectiveness studies have been published to determine the most effective way to 
prevent cervical cancer. Although most of these studies are done in high-income countries, a 
few deal with low- and middle-income countries (vaccine implementation [79-82] in Kenya, 
Mozambique, Sout-Africa, Uganda, Tanzania, Zimbabwe; cancer screening [83,84] in Kenya 
and South-Africa). Models predict that vaccination of females before sexual onset is the most 
cost-effective strategy [80]. But some authors warn not to generalize the cost-effectiveness 
analyses across countries and settings [85] because there is no ‘golden standard’ vaccination 
program applicable on a global or even national scale. Therefore, cost-effectiveness results 
may differ from those of another country because the costs as well as the outcomes are 
country-specific. This is illustrated by the differences in the Incremental Cost-Effectiveness 
Ratios (ICER) in some African countries: the ICER is the additional cost (in international 
dollars, I$) of introducing a new intervention over the additional health benefit (in Quality 
Adjusted Life Years (QALY’s) added, or Years of Life Saved, YLS).  Exemples: Tanzania 90 
I$/Years of Life Saved (YLS), Uganda 130 I$/YLS, Mozambique 250 I$/YLS, Kenya 470 
I$/YLS. At the moment most elements that are needed to make a cost-effectiveness analysis 
are missing in the DRC.  
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Although screening in low-income countries will still be largely based on conventional Pap 
screening in a limited numbers of women, this situation may change quickly when more 
attention will be given to cancer prevention in general, and cervical cancer in particular. It is 
important that women become aware of their own fate and health and their crucial place in the 
community and family. In emerging countries with an increasing middle-class the demand for 
improvement of the health care system with better care and attention for prevention of 
diseases will augment and put pressure on the political system. Because of the implication of 
women as the main advocates for better health for their families the focus on gynecological 
cancers, including breast cancer and cervical cancer, may stimulate awareness about health 
matters. Now today, cancer is still considered as a malediction that only can be healed by 
witchcraft and praying. Therefore, so many women with cancer are arriving in medical 
centers and reference hospitals in a late stage of the disease desperately seeking for help, too 
late. Cancer is considered just a bad fate. 
 
Conclusions 
 
1. Despite the high incidence and mortality caused by cervical cancer among women in 
Kinshasa the sufficient score for knowledge, attitude and practice was low. Awakening the 
women’s awareness is considered as the first step in the long list of conditions to lower the  
incidence and mortality of cervical cancer. In parallel with an increased awareness, the 
national health care system should facilitate and encourage early diagnosis and therapy. The 
general structure of the health care system in the DRC with a dense network of medical 
centers and reference hospitals over the country can create the base for screening on the 
national level.  
 
2. Our work shows that the prevalence of precancerous and cancerous lesions in women from 
different districts in Kinshasa is in the order of 4%. In HIV-positive women, the prevalence is 
about 8 times higher. The traditional practice of phytovaginal care appears to be an 
independent risk factor that merits further evaluation. 
3. The sequence of the most common HR HPV types in women with ASCUS+ confirms that 
marked differences in the relative frequency of different HPV types may occur in Sub-
Saharan countries. Whereas the types HPV 16 and HPV 18 are the most commonly found 
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types in Europe and the US, other types may be more important in Sub-Saharan countries. We 
found that HPV53 has a weak carcinogenic potential. 
4. The conventional smear test remains a valuable test and is the test of choice in low-income 
countries if cytological knowledge is available. We could show that in women with a HIV-
positive serology the accuracy of the test may decrease in comparison with the Liquid Based 
Cytology, most probably because of the higher degree of inflammation.  
5. Discordance has been found between three different tests that are currently used for 
detecting HR- HPV DNA. The degree of discordance increased with decreasing viral load. 
This finding urgently necessitates standardisation and validation of the multiple tests that 
actually exist.  
 
Perspectives 
 
As everywhere in the world governments are worrying about the cost-effectiveness of their 
interventions in health care. Infectious and parasitic diseases are still the major cause of death 
and disability in low-income countries. Therefore, the interest is focused on, and money is 
mostly spent in infection control leaving oncology still at the horizon. But as countries are 
leaving extreme poverty and are better controlling infant mortality, non-communicable 
diseases (diabetes, hypertension, cancer, rheumatic diseases…) will recieve more attention. In 
some African countries this process is already going on. Cancer of the uterine cervix is a 
preventable cancer, classified as a non-communicable disease, but preventable by infection 
control. Vaccination may be part of its prevention. In addition, new diagnostics are underway 
to facilitate screening.  The DRC is not a poor country but not yet ready to consider oncology 
as a priority in health care. Cancer of the uterine cervix may be one of the first cancers that 
can recieve large-scale concern in low- and middle-income countries because its association 
with HPV and new preventive techniques.  
The few data that exist on the prevalence of precancerous lesions of the uterine cervix in the 
DRC indicate that cervical cancer is as frequent as it is in other Sub-Saharan countries most 
probably with the same high mortality rate. With one pathologist per 6 à 7 million inhabitants 
it is difficult to develop a screening system based on cytology that covers the whole nation. 
But hopefully the DRC will not stay behind in the evolution to protect its women from a fatal, 
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but preventable disease. With its medical centers and reference hospitals over the country 
samples for screening can be easily obtained. Self-sampling may further decrease the 
threshold for large-scale participation of women.   
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The government is advised to start a national program on cancer prevention and medical 
faculties will be asked to train more pathologists than they do today. Even if new molecular 
screening techniques will become available the need for a cytologist remains mandatory for 
triage of suspect lesions.  Gynecologists and general practicioners working in reference 
hospitals have to be trained to apply LEEP in case of suspect lesions and/or persistent HR 
HPV infection. We learned that women are prepared to participate in a screening program but 
the majority will not pay for it. The cost is one of the main obstacles. The actual price for a 
Pap smear test is too high for most people, and even the subsequent therapy in case of a 
precancerous lesion is not guaranteed to be carried out. Therefore, the most frequently applied 
therapy is hysterectomy, mostly in a late stage, too late.  At least initiatives can be started in 
some pilote centers over the country with implication of women’s organizations, medical 
doctors, pathologists, and nurses.  
The final goal is that also low-income countries may profit from vaccination that is already 
introduced on a low scale in a few African countries. To be efficient new, more polyvalent 
vaccines have to be developed.  
An algorithm approach should be taught in medical centers for which gynecologists, 
cytopathologists and general practicioners have to be trained in this perspective. A triage 
applying the determination of HR HPV would be most helpful in order to decrease the 
number of conventional smears to be read. To realize this, a performant, low-cost HPV 
determination test should be available. In addition to better screening, a follow-up strategy 
should be developed in parallel to treat abnormal cytology by LEEP, conisation or 
cryotherapy.  
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RECOMMENDATIONS: A BLUE-PRINT FOR A SCREENING PROJECT 
1. Role of policy makers 
 
Development of a platform for cervical cancer screening and follow-up. 
By: 
 
 Organisation of a national cancer registration system 
 Installing a task force that studies all aspects of preventive screening with promotion campaigns on 
television for cervical and breastcancer.   
 This task force should provide  information on cost-effectiveness of HPV screening and vaccination 
where the outcomes are measured in terms of Disability Adjusted Life Years (DALY’s) prevented.  
 Start up of a screening and follow-up system, starting in the big cities, and later in rural areas using 
existing health care network. Several international examples, inclusive low-income countries, illustrate 
how to install an effective screening system. Active promotion of self-sampling to increase the 
screening coverage. 
 Organisation of (reference) laboratories with quality assurance in  collaboration with international 
organisations and NGO’s working in the field of cancer prevention 
 Application of validated  molecular techniques for high-risk HPV detection  
 Control of the cost of screening, vaccination and  preventive treatment: without low cost of all three 
interventions,  any action will be doomed to fail 
 
2. Role of medical faculties and higher institutions  
By: 
 Training of more cyto-pathologists, virologists and laboratory technicians able to perform tests and to 
interprete the results 
 Installing an  active collaboration between Congolese and universities abroad for surveillance of 
quality control and second opinion via internet 
 Formation of gynecologists in colposcopy, cryotherapy and LEEP 
3. Role of the biomedical industry 
By:  
 Development of new, low cost diagnostics with validated high sensitivity and specificity for detection 
of HR-HPV types and/or HPV-dependent cell proliferation  
 By developing vaccins that are  designed in function of the HR-HPV types prevailing in Sub-Saharan 
Africa 
 
4. Role of churches and women’s organizations 
By:  
 Informing women and husbands about prevention of cervical cancer by early detection, preventive 
treatment of precancerous lesions, and vaccination 
 Convincing women that cervical cancer is not an inevitable bad fate but a highly preventable disease 
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The aim of this doctoral dissertation was to investigate different aspects of cervical cancer in 
the Democratic Republic of Congo. Although cervical cancer is the most frequent cancer of 
women  in Sub-Saharan Africa, and most probably also in the DR Congo, little is known 
about the awareness of women about this cancer, its prevalence, co-factors of risk and its 
relation with high-risk Human Papillomaviruses.  
To estimate women’s awareness about cervical cancer a cross-sectional study was conducted 
in Kinshasa, including 524 women who were interviewed at home by trained field workers 
using a standardized questionnaire. The women’s score on knowledge (K), attitude (A) and 
practice (P) were dichotomized as sufficient or insufficient. KAP scores were related to a 
series of socio-demographic factors. The women’s score on knowledge was not significantly 
correlated with their score on practice. The results support the view that the awareness about 
cervical cancer among African women is very limited. The lack of awareness is considered as 
one of the multiple factors that contribute to inefficient screening in low-income countries.  
Although newspapers, radio and television are easily accessible in Kinshasa, word-of-mouth 
communication was the most important source of information. We found no significant 
associations between parity and KAP suggesting that women did not learn about cervical 
cancer when they had contact with health services. Only 4% of the women  mentioned doctors 
or health services as a source of information about cervical. Our study illustrates that women 
want to participate in screening initiatives. But this willingness has to be associated with the 
availability of an  effective treatment at a low cost related to their income. 
We found a lower sensitivity and an almost similar specificity with the conventional Pap test 
in comparison with Liquid Based Cytology (LBC); this difference in sensitivity was most 
pronounced in HIV-positive women. Because of the increase in false negative results, HIV-
positive women have to be more frequently screened and more closely followed than HIV-
negative ones.  
 
In total 1.018 women were examined with LBC. They were recruited in different districts of 
Kinshasa.  The prevalence of precancerous lesions was about 4% in women with unknown or 
HIV-seronegative status.  The prevalence was eight times higher in HIV-seropositive women.  
Five independent variables were significantly associated with the presence of suspect lesions: 
age, number of childbirths, a history of abortion, and marital status. Two of these variables 
(the number of childbirths and marital status) were confounders for the association between 
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HIV infection and suspect lesions. HIV infection was the only independent variable for which 
the association with the presence of a suspect lesion remained significant. The CD4+ count 
was significantly lower in HIV-positive women with suspect lesions.   
In the seronegative group, or in women with unknown HIV serology the only risk factor that 
remained after application of multivariate analysis was the practice of intravaginal application 
of plants (dry sex). This is a frequent practice in Sub-Saharan practice. Insertion of herbs with 
the intention to increase friction may cause microtraumata and inflammation of the vaginal 
wall facilitating the entry of the HPV and HIV virus.  
 
HR HPV DNA was detected in 79 % of women with unknown or HIV-seronegative serology; 
in the seropositive group the percentage was 96%. The most frequently found types in the 
seronegative group were HPV52, HPV35 and HPV18, in the seropositive group HPV68, 
HPV35, HPV52 and HPV16. These findings agree with other reports in Sub-Saharan Africa 
describing the contribution of other types of HR HPVs than those found elsewhere. We found 
that HPV53 has weak carcinogenic properties. 
 
We found major differences in genotyping HPV according to the HPV DNA method used. 
These findings accentuate the need for standardisatiion in clinical laboratories especially in 
the foresight of primary HPV screening  in the future.  
 
In conclusion:  the prevalence of precancerous lesions of the uterine cervix is high in the 
DRC. The frequency of  HR HPVs  contributing to the disease may be different in Sub-
Saharan Africa. There is a need to change strategy at different levels to introduce a successful 
management of prevention of cervical cancer. An increase in the awareness of women about 
cervical cancer is the first step in this process.  
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Het doel van dit doctoraal werk was verschillende aspecten van baarmoederhalskanker in de 
Democratische Republiek Congo in kaart te brengen. Alhoewel baarmoederhalskanker de 
meest frequente kanker bij vrouwen is in Afrika, en waarschijnlijk ook in de DRC, is er 
weinig geweten over de perceptie van vrouwen over deze kanker, over de prevalentie ervan, 
risicofactoren en de relatie met het Humaan Papillomavirus (HPV).  
Om meer te weten over de kennis en houding van vrouwen in Kinshasa in verband met  
baarmoederhalskanker werd een cross-sectionele studie uitgevoerd waaraan 524 vrouwen 
deelnamen. Interviews werden in de woonplaats afgenomen door personen die hiervoor 
special opgeleid werden en een voorafbepaalde vragenlijst hanteerden. De vragen werden 
ondergebracht in drie categorieën: kennis, attitude en praktisch handelen (KAP). Elk 
antwoord kreeg een score voldoende of onvoldoende. De scores werden gerelateerd aan een 
reeks sociodemografische factoren. De score kennis was niet significant gecorreleerd met 
praktisch handelen. De resultaten toonden aan dat de perceptie over baarmoederhalskanker 
zeer beperkt is. Het is één van de vele factoren die maken  dat screening in 
ontwikkelingslanden zo moeilijk van de grond komt.  Alhoewel kranten, radio en televisie 
gemakkelijk toegankelijk zijn in Kinshasa, blijft de mond-aan-mond overdracht de 
belangrijkste bron van informatie. We vonden geen associatie tussen KAP en het aantal 
zwangerschappen wat aantoont dat contacten met de gezondheidsdiensten geen 
kennisoverdracht bewerkstelligden. Slechts 4% van de vrouwen beweerden dat hun 
informatie over baarmoederhalskanker gekregen hadden van een arts of iemand van de 
gezondheidsdiensten. Onze studie toonde ook aan dat vrouwen bereid zijn deel te nemen aan 
screeningsactiviteiten. Maar diagnostiek moet dan wel  gerelateerd zijn aan een follow-up en 
preventieve behandeling aan een betaalbare kostprijs.  
De conventionele Pap test was minder gevoelig dan Liquid Based Cytologie; de specificiteit 
was ongeveer gelijk.  Dit was vooral uitgesproken bij HIV-positieve vrouwen. Daarom is het 
aangewezen om bij HIV-positieve vrouwen meer frequent te screenen en van dichtbij te 
volgen.  
 
In totaal werden 1.018 vrouwen onderzocht met de LBC methode. Zij kwamen uit 
verschillende districten van Kinshasa. De prevalentie van precancereuze letsels was ongeveer 
4% bij vrouwen met een ongekende of met een negative HIV serologie. De prevalentie was 
acht maal hoger bij HIV-positieve vrouwen.  Vijf variabelen bleken significant geassocieerd 
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te zijn met de aanwezigheid van verdachte letsels: leeftijd, aantal kinderen, een 
voorgeschiedenis van abortus en burgelijke stand. Twee van deze variabelen beïnvloedden de 
associatie tussen HIV en het risico van een suspect letsel. Alhoewel de kracht van de 
associatie lichtjes verminderde in het multivariaat model onder invloed van deze factoren, 
bleef  een sterke associatie bestaan tussen een positieve HIV serologie en verdachte letsels.  
Bij HIV-positieve vrouwen met verdachte letsels was de concentratie CD4+ cellen significant 
lager. In de HIV-seronegatieve groep bleek na multivariatieanalyse enkel intravaginale 
applicatie van planten en kruiden een significant verhoogd risico te betekenen. Dit is een 
algemeen verspreid gebruik in Sub-Saharisch Afrika, en is bekend als ‘dry sex’.  Door 
verhoogde wrijving met de vaginale wand ontstaan waarschijnlijk microtrauma die de 
ingangspoort vormen voor HPV en HIV.  
 
In 79 % van de vrouwen  met ongekende of negatieve HIV serologie werd DNA gevonden 
van hoog-risico HPVs; in de HIV-positieve groep was dit percentage 96%. De meest frequent 
teruggevonden types in de HIV-negatieve groep waren: HPV52, HPV35 en HPV18, in de 
seropositieve group: HPV68, HPV35, HPV52 en HPV16. Deze bevindingen komen overeen 
met andere publicaties Sub-Saharisch Afrika waar andere types HPV de lijst aanvoeren van 
de meest frequente HPVs. We konden aantonen dat HPV53 kan geklassifieerd worden in de 
groep van “mogelijks carcinogeen” als een eerder zwak carcinogeen.  
 
Wij vonden belangrijke verschillen in het typeren van HPV DNA volgens de gebruikte 
methode.  Deze bevindingen onderlijnen de noodzaak tot standaardisatie van verschillende 
testen in klinische laboratoria, zeker in het vooruitzicht van een veralgemeende screening op 
basis van HPV DNA.  
 
Als besluit: de prevalentie van  precancereuze  letsels is hoog in de DRC. De frequentie van 
meest teruggevonden  types HPV  is in Sub-Saharisch Afrika verschillend van de rest van de 
wereld. Op verschillende niveaus is er nood aan een andere aanpak om  te komen  tot een 
succesvol screeningsbeleid. Een hogere graad van  bewustwording van  het probleem van  
baarmoederhalskanker bij vrouwen is een eerste stap in de goede richting. 
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Le but de ce travail doctoral était d’étudier les différents aspects du cancer du col utérin 
(CCU) dans la République Démocratique de Congo (DRC). Malgré que le CCU est le cancer 
le plus fréquent chez la femme Africaine, et très probablement aussi en DRC, la connaissance 
par rapport à sa prévalence, aux facteurs de risque et sa relation avec l’infection du 
Papillomavirus Humain (HPV) reste faible.  
Pour combler cette lacune sur la connaissance et l’attitude sur le CCU parmi les femmes de 
Kinshasa une étude cross-sectionelle a été accomplie avec la participation de 524 femmes de 
Kinshasa. Les femmes étaient interviewées dans leurs maisons par des enquêteurs entraînés 
pour ce but en utilisant un questionnaire écrit.  Les questions étaient classifiées selon trois 
catégories: la connaissances, l’attitude et les pratiques par rapport au CCU (CAP). Chaque 
réponse obtenait un score suffisant ou insuffisant. Les scores ont été relatés à une série de 
facteurs sociodémographiques.  Le score connaissance n’était pas corrélé de façon 
significative avec la pratique. Les résultats démontraient que la perception du CCU est très 
limitée. C’est un des facteurs multiples qui freine le développement d’un système de 
dépistage efficace dans les pays en voie de développement. Malgré que les journaux, le radio 
et la télévision sont facilement accessibles à Kinshasa, la communication orale est la source la 
plus importante pour l’échange d’information, aussi sur la santé.  Nous n’avons pas trouvé un 
association entre CAP et le nombre de grossesses ce que démontre que les contacts avec les 
services de santé ne sont pas à la base de tranfert d’information sur le cancer le plus fréquent 
chez la femme.  Notre étude démontre aussi que les femmes sont motivées à participer à des 
activités de dépistage si le diagnostic est relaté à un poursuivi et un traitement préventif à un 
coût abordable.  
Le test Pap conventionel était moins sensible que la Cytologie à Couche Mince (CCM); la 
spécificité était à peu près la même. La différence était plus remarquée chez les femmes avec 
HIV sérologie positive. Sur base de cette donnée les femmes HIV-positives seront dépistées 
plus fréquemment.  
 
En total, 1.018 femmes étaient dépistées avec la méthode CCM. Elles originaient de différents 
districts de Kinshasa.  La prévalence des lésions précancéreuses était environ 4% parmi les 
femmes avec une sérologie VIH-négatives ou une sérologie inconnue. La prévalence était huit 
fois plus élevée chez des femmes VIH-positives.  Cinq variables étaient associés avec la 
présence de lésions suspectes: l’age, le nombre d’enfants, un pré-histoire d’avortement et 
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l’état civil. Deux de ces variables influencent l’association entre VIH et le risque d’avoir une 
lésion suspecte. Malgré que le degré de l’association diminuait légèrement dans le modèle 
multivariable, l’association entre l’infection de VIH et la présence d’une lésion précancéreuse 
restait très significative.  Dans le groupe de femmes VIH-positives avec des lésions suspectes 
la concentrations de cellules CD4+ était plus basse.  Dans le groupe VIH-négatif l’application 
intravaginale d’herbes était un facteur de risque. C’est une habitude très fréquent en Afrique 
Sub-Saharienne, connu comme ‘dry sex’.  Probablement c’est la friction augmentée de la 
paroi vaginale qui est à la base de microtraumatismes qui présents une porte d’entrée pour le 
HPV ainsi que le HIV.  
 
Pour 79% de femmes avec VIH serologie inconnue ou negative, l’ADN des HPV à haute 
risque (HPV-HR) a été retrouvé. Dans le group VIH-positif ce percentage était 96%. Les 
types les plus retrouvés dans le groupe VIH-négatif étaient HPV52, HPV51 et  HPV35; dans 
le groupe HIV-positif HPV68, HPV35 et HPV52. Dans les deux groups le HPV 16 venait à la 
4
e
 place. Ces résultats correspondent avec d’autres observations en Afrique Sub-Saharienne 
où d’autres types de HPV sont plus fréquents que ceux trouvés en Europe et les Etats-Unis. 
Nous avons trouvé que HPV53 peut être classifié plutôt comme un carcinogène faible dans le 
groupe de ‘carcinogène possible’.  
 
Nous avons trouvé des différences importantes entre les méthodes de détermination de l’ADN 
de HPV.  Ces résultats soulignent la nécessité pour standardiser les différents test dans les 
laboratoires cliniques, et surtout en vue d’un dépistage généralisé basé sur la présence de 
l’ADN viral.  
 
En conclusion: la prévalence des lésions précancéreuses est élevée en RDC. La fréquence des 
types les plus retrouvés en Afrique Sub-Saharienne est différente de celle publiée pour 
l’Europe et les Etats-Unis.  Une autre approche est nécessaire pour installer une gestion 
efficace du dépistage du CCU. Une meilleure prise de conscience par rapport au CCU parmi 
les femmes elles-mêmes sera la première étappe qui peut garantir du succès.  
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